bioc-10q_20170630.htm

Large accelerated filer

Accelerated filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

0001564590-17-017529.txt : 20170814 0001564590-17-017529.hdr.sgml : 20170814 20170814083122 ACCESSION NUMBER: 0001564590-17-017529 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 71 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170814 DATE AS OF CHANGE: 20170814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCEPT INC CENTRAL INDEX KEY: 0001044378 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 330757995 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36284 FILM NUMBER: 171027354 BUSINESS ADDRESS: STREET 1: 5810 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-320-8200 MAIL ADDRESS: STREET 1: 5810 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 10-Q 1 bioc-10q_20170630.htm BIOC-Q2-20170630 bioc-10q_20170630.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission file number: 001-36284

Biocept, Inc.

(Exact name of registrant as specified in its charter)

Delaware

80-0943522

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

5810 Nancy Ridge Drive, San Diego, California

(Address of principal executive offices)

92121

(Zip Code)

(858) 320-8200

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 10, 2017, there were 30,253,743 shares of the Registrant’s common stock outstanding.

BIOCEPT, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED

June 30, 2017

INDEX

		Page

IMPORTANT NOTE REGARDING FORWARD-LOOKING STATEMENTS		3

PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements	4

	Condensed Balance Sheets as of December 31, 2016 and June 30, 2017 (unaudited)	4

	Condensed Statements of Operations and Comprehensive Loss for the three and six-months ended June 30, 2016 and 2017 (unaudited)	5

	Condensed Statements of Cash Flows for the six months ended June 30, 2016 and 2017 (unaudited)	6

	Notes to Condensed Financial Statements (unaudited)	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	33

Item 4.	Controls and Procedures	33

PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings	34

Item 1A.	Risk Factors	34

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	34

Item 3.	Defaults Upon Senior Securities	34

Item 4.	Mine Safety Disclosures	34

Item 5.	Other Information	34

Item 6.	Exhibits	34

IMPORTANT NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included or incorporated by reference in this Quarterly Report other than statements of historical fact, are forward-looking statements. You can identify these and other forward-looking statements by the use of words such as “may,” “will,” “could,” “anticipate,” “expect,” “intend,” “believe,” “continue” or the negative of such terms, or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to such statements.

Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in our other filings with the Securities and Exchange Commission, or the SEC. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements speak only as of the date on which they are made and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made except as required by law. Readers should, however, review the factors and risks we describe in the reports and registration statements we file from time to time with the SEC.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Biocept, Inc.

Condensed Balance Sheets

	December 31,			June 30,
	2016			2017
				(unaudited)
Current assets:
Cash	$	4,609,332		$	10,000,155
Accounts receivable, net		128,969			994,746
Inventories, net		549,045			631,210
Prepaid expenses and other current assets		484,649			624,827
Total current assets		5,771,995			12,250,938
Fixed assets, net		1,806,331			2,402,255
Total assets	$	7,578,326		$	14,653,193
Current liabilities:
Accounts payable	$	960,486		$	1,777,409
Accrued liabilities		1,160,036			1,387,767
Supplier financings		75,691			240,913
Current portion of equipment financings		262,674			362,777
Current portion of credit facility, net		1,934,665			1,980,550
Total current liabilities		4,393,552			5,749,416
Non-current portion of equipment financings		778,643			794,320
Non-current portion of credit facility, net		1,123,001			135,848
Non-current portion of interest payable		227,177			298,093
Non-current portion of deferred rent		397,292			333,259
Total liabilities		6,919,665			7,310,936
Commitments and contingencies (see Note 11)
Shareholders’ equity:
Preferred stock, $0.0001 par value, 5,000,000 authorized; no shares issued and outstanding at December 31, 2016 and June 30, 2017.		—			—
Common stock, $0.0001 par value, 150,000,000 authorized; 17,499,397 issued and outstanding at December 31, 2016; 28,697,078 issued and outstanding at June 30, 2017.		1,750			2,870
Additional paid-in capital		174,292,781			191,101,115
Accumulated deficit		(173,635,870	)		(183,761,728	)
Total shareholders’ equity		658,661			7,342,257
Total liabilities and shareholders’ equity	$	7,578,326		$	14,653,193

The accompanying notes are an integral part of these unaudited condensed financial statements.

Biocept, Inc.

Condensed Statements of Operations and Comprehensive Loss

(Unaudited)

	For the three months ended June 30,						For the six months ended June 30,
	2016			2017			2016			2017
Net revenues	$	662,860		$	1,278,961		$	884,229		$	2,962,026
Costs and expenses:
Cost of revenues		1,669,571			2,368,705			3,144,361			4,498,159
Research and development expenses		716,279			841,991			1,444,355			1,599,249
General and administrative expenses		1,517,664			1,798,026			3,004,888			3,704,661
Sales and marketing expenses		1,291,709			1,746,867			2,596,608			3,025,178
Total costs and expenses		5,195,223			6,755,589			10,190,212			12,827,247
Loss from operations		(4,532,363	)		(5,476,628	)		(9,305,983	)		(9,865,221	)
Other income/ (expense):
Interest expense		(99,720	)		(214,377	)		(238,160	)		(296,903	)
Other income		38,412			—			76,824			38,412
Total other income/ (expense):		(61,308	)		(214,377	)		(161,336	)		(258,491	)
Loss before income taxes		(4,593,671	)		(5,691,005	)		(9,467,319	)		(10,123,712	)
Income tax expense		(503	)		(2,146	)		(2,053	)		(2,146	)
Net loss and comprehensive loss	$	(4,594,174	)	$	(5,693,151	)	$	(9,469,372	)	$	(10,125,858	)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic		7,702,286			26,778,549			7,134,639			23,889,888
Diluted		7,702,286			26,778,549			7,134,639			23,889,888
Net loss per common share:
Basic	$	(0.60	)	$	(0.21	)	$	(1.33	)	$	(0.42	)
Diluted	$	(0.60	)	$	(0.21	)	$	(1.33	)	$	(0.42	)

The accompanying notes are an integral part of these unaudited condensed financial statements.

Biocept, Inc.

Condensed Statements of Cash Flows

(Unaudited)

	For the six months ended June 30,
	2016			2017
Cash Flows from Operating Activities
Net loss	$	(9,469,372	)	$	(10,125,858	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		157,979			226,015
Inventory reserve		(37,662	)		(28,997	)
Stock-based compensation		699,710			756,461
Non-cash interest expense related to credit facility and other financing activities		32,919			6,886
Increase/ (decrease) in cash resulting from changes in:
Accounts receivable, net		(52,453	)		(865,777	)
Inventory		(109,114	)		(53,168	)
Prepaid expenses and other current assets		264,071			219,444
Accounts payable		362,648			665,882
Accrued liabilities		(163,377	)		204,760
Accrued interest		36,087			81,960
Deferred rent		(15,226	)		(34,762	)
Net cash used in operating activities		(8,293,790	)		(8,947,154	)
Cash Flows from Investing Activities:
Purchases of fixed assets		(323,923	)		(527,431	)
Net cash used in investing activities		(323,923	)		(527,431	)
Cash Flows from Financing Activities:
Net proceeds from issuance of common stock and warrants		4,657,525			8,559,958
Proceeds from exercise of common stock warrants		—			7,493,035
Payments on equipment financings		(49,061	)		(45,012	)
Payments on supplier and other third-party financings		(282,207	)		(194,400	)
Payments on credit facility		(778,303	)		(948,173	)
Net cash provided by financing activities		3,547,954			14,865,408
Net increase/ (decrease) in Cash		(5,069,759	)		5,390,823
Cash at Beginning of Period		8,821,329			4,609,332
Cash at End of Period	$	3,751,570		$	10,000,155
Supplemental Disclosures of Cash Flow Information:
Cash paid during the period for:
Interest	$	187,319		$	225,207
Income taxes	$	2,053		$	2,146

Non-cash Investing and Financing Activities:

A public offering of Biocept, Inc.’s, or the Company’s, common stock and warrants to purchase its common stock closed on May 4, 2016 (see Note 3). In connection with the closing of this offering, warrants were issued to purchase up to an aggregate of 1,163,526 shares of common stock at an exercise price of $3.90 per share with a term of five years and an estimated grant date fair value of approximately $2.0 million, which was recorded as an offset to additional paid-in capital.

During the six months ended June 30, 2016 and 2017, the Company financed insurance premiums of $434,475 and $359,622, respectively, through third-party financings.

Fixed assets purchased totaling $445,386 and $165,516 during the six months ended June 30, 2016 and 2017, respectively, were recorded as equipment financing obligations and were excluded from cash purchases in the Company’s unaudited condensed statements of cash flows. During the six months ended June 30, 2016, fixed assets with an aggregate net book value of $270,377,

which had previously been recorded as equipment financings with remaining outstanding balances owed totaling $239,994, were effectively disposed of and replaced with upgraded equipment recorded as equipment financings.

The amount of unpaid fixed asset purchases excluded from cash purchases in the Company’s unaudited condensed statements of cash flows decreased from $64,300 at December 31, 2015 to $14,032 at June 30, 2016, and increased from $58,066 at December 31, 2016 to $209,107 at June 30, 2017.

An offering of the Company’s common stock and warrants to purchase its common stock occurred on March 31, 2017 (see Note 3). In the offering, warrants were issued to buy (in the aggregate) up to 2,160,000 shares of common stock at an exercise price of $2.50 per share with a term of five years and an estimated grant date fair value of approximately $2.8 million, which was recorded as an offset to additional paid-in capital (see Note 4). Additionally, approximately $728,000 of fees and costs directly associated with the offering were recorded as an offset to additional paid-in capital within common stock issuance costs in accordance with applicable accounting guidance.

The accompanying notes are an integral part of these unaudited condensed financial statements.

BIOCEPT, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

1. The Company, Business Activities and Basis of Presentation

The Company and Business Activities

The Company was founded in California in May 1997 and is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Often, traditional methodologies such as tissue biopsies are insufficient or unavailable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays have the potential to provide more contemporaneous information on the characteristics of a patient’s disease compared with traditional methodologies such as tissue biopsy and radiographic imaging. Additionally, the Company’s proprietary blood collection tubes, which allow for the intact transport of research use only liquid biopsy samples from regions around the world, are anticipated to be sold to laboratory supply distributor(s) commencing in the six months ending December 31, 2017.

The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations.

In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.

Basis of Presentation

The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America.

The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2016 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2016, filed with the SEC with our Annual Report on Form 10-K on March 28, 2017 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.

Reverse Stock Split

On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares. The one-for-three reverse stock split was effected September 29, 2016. As such, all references to share and per share amounts in the unaudited condensed financial statements and accompanying notes to the unaudited condensed financial statements have been retroactively restated to reflect the one-for-three reverse stock split, except for the authorized number of shares of the Company’s common stock of 150,000,000 shares, which was not affected by the one-for-three reverse stock split.

Revenue Recognition and Related Reserves

arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. Commencing on March 31, 2017, the Company recognizes commercial revenue related to billings for assays delivered and billed to Medicare and other third-party payers on an accrual basis when amounts that will ultimately be realized can be estimated upon delivery, whereby prior to March 31, 2017, the Company recognized revenues for its commercial diagnostic services on a cash basis as collected because the amounts ultimately expected to be received could not be estimated upon delivery due to insufficient collection history experience.

The Company bills third-party payers on a fee-for-service basis at the Company’s list price and third-party commercial revenue is recorded net of contractual discounts, payer-specific allowances and other reserves. The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, as well as certain other diagnostic services provided to physicians. Diagnostic services are completed upon the delivery of assay results to the prescribing physician, at which time the Company bills for the service.

The Company’s gross commercial revenues billed are subject to estimated deductions for such contractual discounts, payer-specific allowances and other reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected. These third-party payer discounts and sales allowances are estimated based on a number of assumptions and factors, including historical payment trends, seasonality associated with the annual reset of patient deductible limits on January 1 of each year, and current and estimated future payments. Specifically, the Company maintains four such reserves: the reserve for contractual discounts, the reserve for aged non-patient receivables, the reserve for estimated patient receivables, and the reserve for other payer-specific sales allowances. The reserve for contractual discounts relates to discounts to gross amounts billed to Medicare and contracted third-party payers to arrive at the deemed “allowed expense" amount covered by that payer. The Company’s contracted third-party commercial sales are recorded using an actual or contracted fee schedule at the time of sale, while estimated fee schedules are maintained for each non-contracted payer separately as part of other payer-specific sales allowances. Contractual discounts are recorded at the transaction level at the time of sale based on a fee schedule that is maintained for each contracted third-party payer. The Company periodically adjusts fee schedules for both contracted and non-contracted third-party payers based upon historical payment trends. The reserve for aged non-patient receivables reduces gross amounts billed to non-contracted third-party payers for amounts estimated to be collected according to the age of the outstanding balance. The reserve for estimated patient receivables reduces gross amounts billed to third-party payers for amounts estimated to be collected directly from individual patients, such as copayments, deductibles, or amounts otherwise designated as patient responsibility. The reserve for other payer-specific sales allowances relates to the amounts billed to non-contracted third-party payers that are estimated to not be covered by that specific payer’s coverage policies, as well as estimated necessary adjustments to gross amounts billed based on historical collection experience for a particular third-party payer unrelated to the age of outstanding balances.

The estimates of amounts that will ultimately be realized from commercial diagnostic services require significant judgment by management. Patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that they have not met their annual deductible limit under their insurance policy, if any, or if their insurance otherwise declines to reimburse the Company. Adjustments to the estimated payment amounts are recorded at the time of final collection and settlement of each transaction as an adjustment to commercial revenue. The estimation process used to determine third-party payer discounts and sales allowance has been applied on a consistent basis since March 31, 2017, and no subsequent significant adjustments have been necessary to increase or decrease these discounts and allowances as a result of changes in underlying estimates.

The composition of the Company’s gross and net revenues recognized during the three and six-months ended June 30, 2016 and 2017 is as follows:

	For the three months ended June 30,					For the six months ended June 30,
	2016		2017			2016		2017
Commercial revenues recognized upon delivery	$ —		$	3,970,630		$ —		$	8,696,596
Development services revenues recognized upon delivery		66,481		83,553			98,329		144,342
Commercial revenues recognized upon cash collection		596,379		159,457			785,900		1,056,043
Total gross revenues		662,860		4,213,640			884,229		9,896,981
Provisions for contractual discounts		—		(1,489,527	)		—		(2,815,323	)
Provisions for aged non-patient receivables		—		(129,091	)		—		(445,643	)
Provisions for estimated patient receivables		—		(15,500	)		—		(118,840	)
Provisions for other payer-specific sales allowances		—		(1,300,561	)		—		(3,555,149	)
Net revenues	$	662,860	$	1,278,961		$	884,229	$	2,962,026

and $0.04, respectively. The incremental net revenue and decrease in loss from operations as a result of recognizing revenue on an accrual basis commencing on March 31, 2017, or the total amount of net revenue recorded in excess of the amount of commercial cash collections, was $191,193 and $916,883 during the three and six-months ended June 30, 2017, respectively, and the corresponding decrease in net loss per common share was $0.01 and $0.04, respectively.

A summary of activity in the Company’s gross and net accounts receivable balances, as well as corresponding reserves, during the six months ended June 30, 2017 is as follows:

	Balance at		Amounts			Settlements			Balance at
	December 31,		Recognized			Upon			June 30,
	2016		Upon Delivery			Adjudication			2017
Accounts receivable, gross	$	128,969	$	8,840,938		$	(2,773,573	)	$	6,196,334
Reserve for contractual discounts		—		(2,815,323	)		956,314			(1,859,009	)
Reserve for aged non-patient receivables		—		(445,643	)		14,270			(431,373	)
Reserve for estimated patient receivables		—		(118,840	)		13,741			(105,099	)
Reserve for other payer-specific sales allowances		—		(3,555,149	)		749,042			(2,806,107	)
Accounts receivable, net	$	128,969	$	1,905,983		$	(1,040,206	)	$	994,746

Concentration of Risk

Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types.

The Company's third-party payers that represent more than 10% of total net revenues in any period presented, and their related net revenue amount as a percentage of total net revenues, during the three and six-months ended June 30, 2016 and 2017 were as follows:

	For the three months ended June 30,						For the six months ended June 30,
	2016			2017			2016			2017
Medicare and Medicare Advantage		47	%		45	%		44	%		39	%
Blue Cross Blue Shield		8	%		15	%		9	%		18	%
United Healthcare		18	%		9	%		18	%		11	%

The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at June 30, 2017 were as follows:

Medicare and Medicare Advantage	26	%
Blue Cross Blue Shield	24	%
United Healthcare	12	%

Recent Accounting Pronouncements

In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or the FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, and may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. As the Company has not yet completed its final review of the impact of the new guidance but expects to during 2017, the Company has not determined whether the adoption of this guidance will have a material impact on its financial statements or disclosures. The Company is still evaluating disclosure requirements under the new guidance, and will continue to evaluate additional changes, modifications or interpretations to the guidance which may impact the current conclusions. The Company expects to adopt the new standard for the fiscal year beginning January 1, 2018 and has not yet determined whether the full or modified retrospective application method will be applied.

estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures.

In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company expects to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently have any equity method investments.

In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company anticipates that the adoption of this guidance will materially affect its statement of financial position and will require changes to its processes. The Company has not yet made any decision on the timing of adopting this guidance or the method of adoption with respect to the optional practical expedients, but expects to during 2018.

In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require de-designation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures.

In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures.

In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures.

In August 2016, the FASB issued authoritative guidance clarifying the classification of certain cash receipts and cash payments in the statement of cash flows. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, on a retrospective transition method to each period presented. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company has not historically engaged in the transactions encompassed by the proposed guidance.

In January 2017, the FASB issued authoritative guidance clarifying the definition of a business when evaluating transactions involving acquisitions or disposals of assets or businesses. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Certain applications of this guidance are permitted for early adoption. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the

adoption of this guidance will have a material impact on its financial statements or disclosures because the Company has not historically acquired or disposed of material assets or businesses.

In January 2017, the FASB issued authoritative guidance eliminating the “Step 2” requirement for an entity to determine the fair value of its assets and liabilities for goodwill impairment testing in the same manner that would be required for those assumed in a business combination. Instead, the amended guidance allows an entity to perform goodwill impairment testing by comparing the fair value of a reporting unit with its carrying amount. This guidance is effective for any goodwill impairment tests in fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning January 1, 2020, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently have any recorded goodwill.

In February 2017, the FASB issued authoritative guidance clarifying the definition of the term “in substance nonfinancial asset” when accounting for transfers of financial and nonfinancial assets, and other matters concerning the transfer, sale and partial sale of nonfinancial assets to both consolidated entities and non-consolidated counterparties. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company has not historically engaged in transfers, sales or partial sales of nonfinancial assets.

In March 2017, the FASB issued authoritative guidance shortening the amortization period to the earliest call date for certain purchased callable debt securities held at a premium. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2019, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently hold any callable debt securities.

In May 2017, the FASB issued authoritative guidance clarifying what modifications to a share-based payment award may be considered substantive, and therefore requiring the application of modification accounting. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently expect any significant modifications to outstanding share-based payment awards.

In July 2017, the FASB issued authoritative guidance changing the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features, whereby a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock, and also clarifying existing disclosure requirements for equity-classified instruments. This guidance is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2020, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently hold any significant financial instruments with down round features.

2. Liquidity and Going Concern Uncertainty

As of June 30, 2017, cash totaled $10.0 million and the Company had an accumulated deficit of $183.8 million. For the year and six-month periods ended December 31, 2016 and June 30, 2017, the Company incurred net losses of $18.4 million and $10.1 million, respectively. At June 30, 2017, the Company had aggregate net interest-bearing indebtedness of $3.8 million, of which $2.6 million was due within one year in the absence of subjective acceleration of amounts due under a credit facility entered into in April 2014 with Oxford Finance LLC, or the April 2014 Credit Facility, in addition to $3.2 million of other non-interest bearing current liabilities. Additionally, in February 2016, the Company signed a firm, non-cancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly installments of $62,500 through May 2020, under which $628,760 remained outstanding at June 30, 2017 (see Note 11). These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these unaudited condensed financial statements were issued. The accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern. The unaudited condensed financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses for the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have

included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations.

In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. A public offering of the Company’s common stock and warrants to purchase its common stock closed on May 4, 2016, pursuant to which the Company received net cash proceeds of approximately $4.3 million (see Note 3). Subsequent to the closing of this offering on May 4, 2016, no warrants sold in this offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. A second offering of the Company’s common stock was effected under this shelf registration statement on March 28, 2017, the closing of which occurred on March 31, 2017, pursuant to which the Company received net cash proceeds of approximately $8.6 million (see Note 3). In a concurrent private placement, the Company sold unregistered warrants to purchase up to 2,160,000 shares of the Company’s common stock that closed concurrently with the March 31, 2017 offering of common stock sold pursuant to this shelf registration statement. Subsequent to the closing of the sales of these unregistered warrants, no warrants sold have been exercised, with $5.4 million in gross warrant proceeds remaining outstanding and available to be exercised at $2.50 per share commencing on the six month anniversary of the closing of the offering, or September 30, 2017, until their expiration in March 2022. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. A public offering of the Company’s common stock and warrants to purchase its common stock was effected under an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, the closing of which occurred on October 19, 2016, pursuant to which the Company received net cash proceeds of approximately $9.0 million (see Note 3). Subsequent to the closing of this offering, cash proceeds of approximately $7.5 million have been received from the exercise of warrants sold in this offering, while approximately $3.2 million in gross warrant proceeds remain outstanding and available to be exercised at $1.10 per share until their expiration in October 2021. Pursuant to a common stock and warrant purchase agreement dated August 9, 2017 between the Company and Ally Bridge, the Company received net cash proceeds of approximately $2.0 million as a result of the sale of its common stock and warrants. Subsequent to August 9, 2017, no additional cash proceeds had been received from the exercise of warrants sold in this offering, with approximately $2.2 million in gross warrant proceeds remaining outstanding and available to be exercised at $1.50 per share until their expiration in August 2022.

Management’s Plan to Continue as a Going Concern

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all.

3. Sales of Equity Securities

On December 21, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC, or Aspire Capital, which committed to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock over the 30-month term of the common stock purchase agreement. On November 4, 2016, the Company voluntarily terminated this common stock purchase agreement. Upon execution of the common stock purchase agreement, the Company sold to Aspire Capital 208,334 shares of common stock at $4.80 per share for proceeds of $1,000,000, and concurrently also entered into a registration rights agreement with Aspire Capital, pursuant to which the Company filed a registration statement registering the sale of the shares of the Company’s common stock that were issued to Aspire Capital under the common stock purchase agreement. In consideration for entering into, and concurrently with the execution of, the common stock purchase agreement, the Company issued to Aspire Capital 55,000 shares of its common stock. The proceeds received by the Company under the common stock purchase agreement were used for working capital and general corporate purposes. During the year ended December 31, 2016, the Company submitted purchase notices to Aspire Capital for an aggregate of 173,145 shares of common stock for gross proceeds of $544,051. Costs associated with this offering of approximately $42,000 and $79,000 during the years ended December 31, 2015 and 2016, respectively, were also recorded to common stock issuance costs under applicable accounting guidance, and as such, the total net increase in capital related to these transactions was approximately $1.4 million.

$75 million. Pursuant to an exclusive placement agent agreement dated April 25, 2016 between the Company and H.C. Wainwright & Co., LLC, and a securities purchase agreement dated April 29, 2016 between the Company and the purchasers signatory thereto, a public offering of 1,662,191 shares of the Company’s common stock and warrants to purchase up to an aggregate of 1,163,526 shares of common stock was effected under this registration statement at a combined offering price of $3.00. All warrants sold in this offering have a per share exercise price of $3.90, are exercisable immediately and expire five years from the date of issuance. The estimated grant date fair value of these warrants of approximately $2.0 million was recorded as an offset to additional paid-in capital upon the closing of this offering. The closing of the sale of these securities to the purchasers occurred on May 4, 2016, pursuant to which the Company received, after deducting $0.7 million of costs directly associated with the offering that were recorded as an offset to additional paid-in capital under applicable accounting guidance, approximately $4.3 million of net cash proceeds. Subsequent to the closing of this offering on May 4, 2016, no warrants sold in this offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. Pursuant to an exclusive placement agent agreement dated March 28, 2017 between the Company and Roth Capital Partners, LLC as lead placement agent, and WestPark Capital and Chardan Capital as co-placement agents, a securities purchase agreement for a second offering of 4,320,000 shares of the Company’s common stock was effected under this registration statement at per share price of $2.15, which closed on March 31, 2017. In a concurrent private placement, the Company sold unregistered warrants to purchase up to an aggregate of 2,160,000 shares of the Company’s common stock that closed concurrently with the March 2017 offering of common stock sold pursuant the shelf registration statement. All warrants sold in this offering have a per share exercise price of $2.50, are exercisable beginning on the six-month anniversary of the date of issuance, and expire five years from the date first exercisable. The estimated grant date fair value of these warrants of approximately $2.8 million was recorded as an offset to additional paid-in capital upon the closing of this offering (see Note 4). At the closing of these sales on March 31, 2017, the Company received, after deducting $0.7 million of costs directly associated with the offering that were recorded as an offset to additional paid-in capital under applicable accounting guidance, approximately $8.6 million of net cash proceeds. In connection with the closing of the offering, the Company has agreed to certain contractual terms that limit its ability to issue variable rate securities for a period of one year following the closing of the offering, with certain exceptions. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings.

Pursuant to an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, a public offering of 9,100,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,100,000 shares of common stock was effected at a combined offering price of $1.10. The estimated grant date fair value of these warrants of approximately $5.2 million was recorded as an offset to additional paid-in capital upon the closing of this offering. Additionally, the underwriters were granted a 30-day option to purchase up to 1,365,000 additional shares of common stock at a price of $1.0331 per share, net of the underwriting discount, and/or additional warrants to purchase up to 1,365,000 shares of common stock at a price of $0.0009 per warrant to cover overallotments, if any, of which the underwriters exercised their overallotment option to purchase 627,131 option warrants for total proceeds to the Company of $564. The estimated aggregate grant date fair value of the overallotment options and warrants of approximately $0.8 million was recorded as an offset to additional paid-in capital upon the closing of this offering. All warrants sold in this offering have a per share exercise price of $1.10, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the underwriters occurred on October 19, 2016, when the Company received, after deducting $1.0 million of costs directly associated with the offering that were recorded as an offset to additional paid-in capital under applicable accounting guidance, $9.0 million of net cash proceeds. Subsequent to the closing of this offering, approximately $7.5 million of additional cash proceeds had been received from the exercise of warrants sold in this offering. As such, the total net increase in capital as a result of the sale of these shares and warrants has been $16.5 million.

4. Fair Value Measurement

The estimated fair value of the April 2014 Credit Facility at June 30, 2017 approximated carrying value, which was determined using a discounted cash flow analysis. The analysis considered interest rates of instruments with similar maturity dates, which involved the use of significant unobservable Level 3 inputs.

Other Fair Value Measurements

As of the closing of the Company’s March 31, 2017 offering, the estimated grant date fair value of $1.31 per share associated with the warrants to purchase 2,160,000 shares of common stock issued in this offering, or a total of approximately $2.8 million, was recorded as an offset to additional paid-in capital, and was estimated using a Black-Scholes valuation model with the following assumptions:

Stock price	$	2.13
Exercise price	$	2.50
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		1.93	%
Expected life (in years)		5.00
Expected volatility		80.0	%

5. Balance Sheet Details

The following provides certain balance sheet details:

	December 31,			June 30,
	2016			2017
Fixed Assets
Machinery and equipment	$	2,728,468		$	3,012,178
Furniture and office equipment		143,726			147,976
Computer equipment and software		620,582			925,206
Leasehold improvements		517,968			523,665
Financed equipment		1,559,690			1,725,205
Construction in process		169,896			236,474
Total fixed assets, gross		5,740,330			6,570,704
Less accumulated depreciation and amortization		(3,933,999	)		(4,168,449	)
Total fixed assets, net	$	1,806,331		$	2,402,255
Accrued Liabilities
Accrued interest	$	20,776		$	14,495
Accrued payroll		168,727			199,024
Accrued vacation		364,953			498,676
Accrued bonuses		422,868			448,380
Accrued sales commissions		77,844			67,354
Current portion of deferred rent		67,085			96,356
Accrued other		37,783			63,482
Total accrued liabilities	$	1,160,036		$	1,387,767

6. April 2014 Credit Facility

On April 30, 2014, the Company received net cash proceeds of approximately $4,898,000 pursuant to the execution of the April 2014 Credit Facility with Oxford Finance LLC. Upon the entry into the April 2014 Credit Facility, the Company was required to pay the lender a facility fee of $50,000 in conjunction with the funding of the term loan. The April 2014 Credit Facility is secured by substantially all of the Company’s personal property other than its intellectual property. Amounts due to Oxford Finance LLC under the April 2014 Credit Facility are callable before maturity by the lender under certain subjective acceleration clauses of the underlying agreement, including changes deemed to be materially adverse by the lender. The term loan under the April 2014 Credit Facility bears interest at an annual rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the term loan, plus (b) 7.71%. The term loan bears interest at an annual rate of 7.95%. The Company was required to make interest-only payments on the term loan through August 1, 2015. The outstanding term loan under the April 2014 Credit Facility began amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lender in consecutive monthly installments following such interest-only period. The term loan under the April 2014 Credit Facility matures on July 1, 2018. Under the original terms of the underlying agreement, the Company is also required to make a final payment to the lender equal to 5.5% of the original principal amount of the term loan funded. At its option, the Company may prepay the outstanding principal balance of the term loan in whole but not in part, subject to a prepayment fee of 1% of any amount prepaid.

On June 30, 2016, the Company entered into an amendment of the April 2014 Credit Facility. This amendment required the Company to make interest-only payments on the term loan from July 1, 2016 through September 30, 2016, and also requires an additional final

payment of $50,000 to the lender. The terms of the amendment require the amortization of the outstanding amount due under the term loan to commence at the end of the applicable interest-only period, with monthly payments of principal and interest, in arrears, being made by the Company to the lender in consecutive monthly installments following such interest-only period. Additionally, pursuant to the amendment the aggregate outstanding principal amount of the Company’s permitted indebtedness, consisting of capitalized lease obligations and purchase money indebtedness outstanding at any time, was increased to $1.2 million. The June 30, 2016 amendment of the April 2014 Credit Facility was accounted for as a modification of debt under applicable accounting guidance. On June 28, 2017, the Company entered into an amendment of the April 2014 Credit Facility whereby the aggregate outstanding principal amount of the Company’s permitted indebtedness was increased to $3.0 million.

The April 2014 Credit Facility includes affirmative and negative covenants applicable to the Company and any subsidiaries created in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports and maintain insurance coverage. The negative covenants include, among others, restrictions on transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets, and suffering a change in control, in each case subject to certain exceptions. The April 2014 Credit Facility also includes events of default, the occurrence and continuation of which provide Oxford Finance LLC, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the term loan under the April 2014 Credit Facility, including foreclosure against the Company’s properties securing the April 2014 Credit Facility, including its cash. These events of default include, among other things, the Company’s failure to pay any amounts due under the April 2014 Credit Facility, a breach of covenants under the April 2014 Credit Facility, insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $250,000, and a final judgment against the Company in an amount greater than $250,000.

A warrant to purchase up to 17,655 shares of the Company’s common stock at an exercise price of $14.16 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. Issuance costs of $102,498 associated with the term loan under the April 2014 Credit Facility were recorded as a discount to outstanding debt as of the closing date, resulting in net proceeds of $4,897,502. The estimated fair value of the warrant issued of $233,107 was also recorded as a discount to outstanding debt as of the closing date. The discounts and other issuance costs are amortized to interest expense utilizing the effective interest method over the underlying term of the loan, with total unamortized discounts of $78,408 and $71,503 remaining at December 31, 2016 and June 30, 2017, respectively. The effective annual interest rate associated with the April 2014 Credit Facility was 13.87% at both December 31, 2016 and June 30, 2017. As of June 30, 2017, total remaining principal payments of $986,492 and $1,201,409 were due under the April 2014 Credit Facility during the fiscal years ending December 31, 2017 and 2018, respectively.

7. Equipment Financings

The Company leases certain laboratory equipment under arrangements accounted for as capital leases and classified as equipment financings. The financed equipment is depreciated on a straight-line basis over periods ranging from 5 to 7 years. The total gross value of fixed assets capitalized under such financing arrangements was $1,559,690 and $1,725,205 at December 31, 2016 and June 30, 2017, respectively. Total accumulated depreciation related to financed equipment was approximately $525,000 and $629,000 at December 31, 2016 and June 30, 2017, respectively. Total depreciation expense related to financed equipment was approximately $27,000 and $52,000 for the three months ended June 30, 2016 and 2017, respectively. Total depreciation expense related to financed equipment was approximately $53,000 and $108,000 for the six months ended June 30, 2016 and 2017, respectively. Fixed assets purchased totaling $165,516 during the six months ended June 30, 2017 were recorded as equipment financings. The aggregate weighted average effective annual interest rate related to the equipment financings was 13.18% and 13.78% at December 31, 2016 and June 30, 2017, respectively, and the maturity dates on such outstanding arrangements range from July 2017 to May 2023.

The following schedule sets forth the remaining future minimum lease payments outstanding under financed equipment arrangements, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred, due within each respective fiscal year ending December 31, as well as the present value of the total amount of remaining minimum lease payments, as of June 30, 2017:

				Maintenance
	Minimum			and Sales Tax
	Lease			Obligation
	Payments			Payments
2017	$	236,430		$	15,957
2018		301,490			57,294
2019		261,284			64,994
2020		223,105			47,664
2021		217,319			43,055
Thereafter		367,769			66,987
Total payments		1,607,397			295,951
Less amount representing interest		(450,300	)		—
Present value of payments	$	1,157,097		$	295,951

At June 30, 2017, the present value of minimum lease payments due within one year was $362,777.

8. Stock-Based Compensation

Equity Incentive Plans

The Company maintains two equity incentive plans: the Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. On July 25, 2016, the Company’s Board of Directors approved an amendment to the 2013 Plan to reserve 333,333 shares of the Company’s common stock exclusively for the grant of stock awards to employees who have not previously been an employee or director of the Company, except following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Company, as defined under applicable Nasdaq Listing Rules. At the Company’s annual meeting of stockholders held on May 2, 2017, the Company’s stockholders approved amendments to the 2013 Plan, which included an increase in the number of non-inducement shares of common stock authorized for issuance under the 2013 Plan by 2,500,000. As of June 30, 2017, under all plans, a total of 3,522,955 non-inducement shares were authorized for issuance, 2,674,028 non-inducement stock options and restricted stock units, or RSUs, had been issued and were outstanding, and 741,614 non-inducement shares were available for grant. As of June 30, 2017, a total of 333,333 inducement shares were authorized for issuance, 158,049 inducement stock options and RSUs had been issued and were outstanding, and 175,284 inducement shares were available for grant under the 2013 Plan.

Stock Options

A summary of stock option activity for the six months ended June 30, 2017 is as follows:

						Weighted
						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Outstanding at December 31, 2016		896,662		$	8.80		8.5
Granted		1,579,399		$	1.52
Exercised		—			—
Cancelled/forfeited/expired		(94,902	)	$	5.75
Outstanding at June 30, 2017		2,381,159		$	4.06		9.1
Vested and unvested expected to vest, June 30, 2017		2,187,470		$	4.28		9.1

The intrinsic values of options outstanding at December 31, 2016 and June 30, 2017 were zero and $7,623, respectively, and the intrinsic value of options vested and unvested expected to vest at June 30, 2017 was $6,721. The total weighted-average grant date fair value of the 173,157 stock options that vested during the six months ended June 30, 2017 was $6.09.

The assumptions used in the Black-Scholes pricing model for stock options granted during the six months ended June 30, 2017 were as follows:

Stock and exercise prices	$1.37 – $2.13
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield	1.79% – 2.08%
Expected life (in years)	5.12 – 6.09
Expected volatility	80.0% - 90.0%

Using the assumptions described above, with stock and exercise prices being equal on date of grant, the weighted-average estimated fair value of options granted in the six months ended June 30, 2017 was $1.04 per share.

On August 31, 2015, the Company’s Board of Directors approved the issuance of 33,333 performance stock options with an estimated grant date fair value of $4.40 per share and an exercise price of $6.03 per share to its Chief Executive Officer, or CEO, pursuant to the 2013 Plan. On February 29, 2016, the Company’s Board of Directors approved the issuance of 33,333 performance stock options with an estimated grant date fair value of $2.87 per share and an exercise price of $4.02 per share to its CEO pursuant to the 2013 Plan. Vesting of these stock options was based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors. During the six months ended June 30, 2017, 6,333 of the performance stock options granted on August 31, 2015 and 10,000 of the performance stock options granted on February 29, 2016 were declared vested by the Company’s Board of Directors, and the remaining 50,333 shares underlying these awards were forfeited.

On July 25, 2016, the Company entered into an employment agreement with its new Chief Financial Officer, Senior Vice President of Operations and Secretary, or CFO. Pursuant to the terms of this employment agreement, on July 29, 2016 the CFO was granted inducement stock option awards with an exercise price of $1.95 per share to purchase up to (i) 66,666 shares of the Company’s common stock with an estimated grant date fair value of $1.45 per share, 25% of which vested on the one-year anniversary of the commencement of the CFO’s employment with the Company, and remainder of which vest in equal monthly installments over the following three years, and (ii) 33,333 shares of the Company’s common stock with an estimated grant date fair value of $1.26 per share, which vested upon the Company’s achievement of specified corporate goals for 2016 and the consummation of a specified financing transaction. During the six months ended June 30, 2017, 16,383 shares of the performance option award granted on July 29, 2016 were declared vested by the Company’s Board of Directors, and the remaining 16,950 shares underlying this award were forfeited.

On May 2, 2017, the Company’s Board of Directors approved the issuance of an aggregate of 550,000 performance stock options to be granted on May 31, 2017 to certain of the Company’s employees and all of its executive officers pursuant to the 2013 Plan, of which 200,000 performance stock options were granted to the Company’s CEO, 100,000 performance stock options were granted to its CFO, and 75,000 performance stock options were granted to each of its Chief Scientific Officer, Senior Vice President and Senior Medical Director, Senior Vice President. Each performance stock option granted on May 31, 2017 has an exercise price of $1.50 per share, an estimated grant date fair value of $0.99 per share, and is subject to vesting as determined by the Company’s Board of Directors based on the achievement of specified corporate goals for 2017, provided that none shall vest unless a minimum level of 70% of the Company’s corporate goals for 2017 are achieved, as follows:


	Percentage of
	Overall Performance Stock
	Option Grant Subject to
	Vesting
Target
Minimum revenue	20%
Cost of revenue reductions and improvements	15%
Increase cash generated from operations	15%
Minimum cash on-hand at December 31, 2017	15%
Minimum customer agreements, product licensing and product launch	20%
Implementation of new products and utility trials	15%
Total	100%

Restricted Stock

A summary of RSU activity for the six months ended June 30, 2017 is as follows:

				Weighted
	Number of			Average Grant
	Shares			Date Fair Value
Outstanding at December 31, 2016		174,249		$	2.68
Granted		350,000		$	1.50
Vested and issued		(65,831	)	$	2.09
Forfeited		(7,500	)	$	2.10
Outstanding at June 30, 2017		450,918		$	1.87
Vested and unvested expected to vest, June 30, 2017		408,481		$	1.91

At June 30, 2017, the intrinsic values of RSUs outstanding and RSUs unvested and expected to vest were $617,758 and $559,619, respectively. Of the 450,918 RSUs outstanding at June 30, 2017, 10,920 are fully vested. On July 6, 2016, the Compensation Committee of the Company’s Board of Directors approved retention RSUs for an aggregate of 58,332 shares of common stock to three of the Company’s executive officers pursuant to the 2013 Plan, including retention RSUs for 25,000 shares of common stock to its CEO. Each of these retention RSUs had a grant date fair value of $1.86 per share for a grant date fair value of $108,498 to all three officers, in aggregate. These retention RSUs vested fully on the one-year anniversary of the date of grant, and were subject to continuing service by the holders of such RSUs. Pursuant to the terms of the Company’s employment agreement with its CFO dated July 25, 2016, the CFO was granted an inducement RSU award on July 29, 2016 covering 25,000 shares of the Company’s common stock with a grant date fair value of $1.95 per share, 100% of which vested on the one-year anniversary of the commencement of the CFO’s employment with the Company.

On May 2, 2017, the Company’s Board of Directors approved the issuance of an aggregate of 175,000 time-based RSUs and 175,000 performance RSUs to be granted on May 31, 2017 to certain of the Company’s employees and all of its executive officers pursuant to the 2013 Plan, of which 50,000 time-based RSUs and 25,000 performance RSUs were granted to its CEO, and 25,000 time-based RSUs and 25,000 performance RSUs were granted to each other executive officer. Each RSU granted on May 31, 2017 has a grant date fair value of $1.50 per share. Vesting of the time-based RSUs granted on May 31, 2017 is subject to continuing service and occurs on the one year anniversary of the vesting commencement date, or May 2, 2018, while the performance RSUs are subject to continuous service and vesting is as determined by the Company’s Board of Directors based on the achievement of specified corporate goals for 2017, provided that none shall vest unless a minimum level of 70% of the Company’s corporate goals for 2017 are achieved, as follows:


	Percentage of
	Overall Performance RSU
	Grant Subject to
	Vesting
Target
Minimum revenue	20%
Cost of revenue reductions and improvements	15%
Increase cash generated from operations	15%
Minimum cash on-hand at December 31, 2017	15%
Minimum customer agreements, product licensing and product launch	20%
Implementation of new products and utility trials	15%
Total	100%

Stock-based Compensation Expense

The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented:

	For the three months ended				For the six months ended
	June 30,				June 30,
	2016		2017		2016		2017
Stock Options
Cost of revenues	$	29,412	$	41,615	$	55,487	$	73,385
Research and development expenses		25,961		39,172		58,964		68,428
General and administrative expenses		264,566		157,683		537,135		349,736
Sales and marketing expenses		1,897		19,606		39,240		60,146
Total expenses related to stock options		321,836		258,076		690,826		551,695
RSUs
Cost of revenues		1,916		23,133		1,916		38,300
Research and development expenses		1,452		22,714		1,452		37,072
General and administrative expenses		1,008		56,473		1,008		86,406
Sales and marketing expenses		4,508		22,843		4,508		42,988
Total stock-based compensation	$	330,720	$	383,239	$	699,710	$	756,461

Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 8% per annum during the six months ended June 30, 2016 and 2017. As of June 30, 2017, total unrecognized stock-based compensation expense related to unvested stock options and RSUs, adjusted for estimated forfeitures, was approximately $2,694,000 and is expected to be recognized over a weighted-average period of approximately 2.2 years.

9. Common Stock Warrants Outstanding

A summary of equity-classified common stock warrant activity for the six months ended June 30, 2017 is as follows:

						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Outstanding at December 31, 2016		11,623,987		$	1.93		4.6
Issued		2,160,000		$	2.50
Exercised		(6,811,850	)	$	1.10
Expired		—			—
Outstanding at June 30, 2017		6,972,137		$	2.92		4.3

All warrants outstanding at June 30, 2017 are exercisable, except for the 2,160,000 warrants issued on March 31, 2017, which first become exercisable for a five-year period beginning on September 30, 2017, or the six-month anniversary of the closing of the associated offering. The intrinsic value of equity-classified common stock warrants outstanding at June 30, 2017 was $787,126.

10. Net Loss per Common Share

Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the three and-six months ended June 30, 2016 and 2017, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same.

On September 29, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The calculation of weighted-average shares outstanding has been adjusted for this reverse stock split as if it had occurred on December 31, 2015.

The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:

	For the three and six-months ended
	June 30,
	2016		2017
Preferred warrants outstanding (number of common stock equivalents)		529		529
Common warrants outstanding		1,896,856		6,972,137
RSUs outstanding		86,756		450,918
Common options outstanding		731,400		2,381,159
Total anti-dilutive common share equivalents		2,715,541		9,804,743

11. Commitments and Contingencies

In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity.

In February 2016, the Company signed a firm, non-cancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in quarterly installments of $62,500 through May 2020. At June 30, 2017, a total of $628,760 remained outstanding under this purchase commitment.

12. Related Party Transactions

A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received payments totaling $19,047 and $15,325 during the year ended December 31, 2016 and the six months ended June 30, 2017, respectively, from Aegea as reimbursements for shared patent costs under the Cross-License Agreement.

Pursuant to a sublease agreement dated March 30, 2015, the Company subleased 9,849 square feet, plus free use of an additional area, of its San Diego facility to an entity affiliated with the Company’s non-executive Chairman for $12,804 per month, with a refundable security deposit of $12,804 due from the subtenant. The initial term of the sublease expired on July 31, 2015, and was subject to renewal on a month-to-month basis thereafter. On February 1, 2017, the Company received notice from the subtenant terminating the sublease effective March 31, 2017. A total of $76,824 and $38,412 in rental income was recorded to other income/(expense) in the Company’s unaudited condensed statements of operations and comprehensive loss during the six months ended June 30, 2016 and 2017, respectively.

Three members of the Company’s Board of Directors participated in its public offering in May 2016, purchasing an aggregate of 58,335 shares of the Company’s common stock and warrants to purchase up to an aggregate of 40,832 shares of its common stock for total gross proceeds to the Company of $175,000. Additionally, a trust affiliated with Claire K.T. Reiss, who at the time was the beneficial owner of more than 10% of the Company’s outstanding common stock, participated in the Company’s public offering in May 2016, purchasing 204,758 shares of its common stock and warrants to purchase up to 143,330 shares of its common stock for total gross proceeds to the Company of $614,273.

Seven members of the Company’s Board of Directors, including its CEO, and all three of the Company’s other executive officers participated in the Company’s public offering in October 2016, purchasing an aggregate of 534,088 shares of common stock and warrants to purchase up to an aggregate of 534,088 shares of common stock for total gross proceeds to the Company of $587,497. Additionally, a trust affiliated with Claire K.T. Reiss, who at the time was the beneficial owner of more than 10% of the Company’s outstanding common stock, participated in the Company’s public offering in October 2016, purchasing 227,272 shares of its common stock and warrants to purchase up 227,272 shares of its common stock for total gross proceeds to the Company of $249,999. Further, several of the Company’s employees and one of its consultants participated in the Company’s public offering in October 2016, purchasing an aggregate of 79,090 shares of its common stock and warrants to purchase up to an aggregate of 79,090 shares of its common stock for total aggregate gross proceeds to the Company of $86,999.

13. Subsequent Events

common stock was effected at a combined offering price of $1.50 per unit for total gross proceeds to the Company of $2.2 million. All warrants sold in this offering have a per share exercise price of $1.50, are exercisable immediately and expire five years from the date of issuance. The estimated grant date fair value of these warrants of approximately $1.03 per share, or a total of approximately $1.5 million, was recorded as an offset to additional paid-in capital upon the closing of this offering, and was estimated using Black-Scholes valuation models with the following assumptions:

Stock price	$	1.39
Exercise price	$	1.50
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		1.81	%
Expected life (in years)		5.00
Expected volatility		100.0	%

Subsequent to August 9, 2017 and through the date that these unaudited condensed financial statements were available to be issued, no additional cash proceeds had been received from the exercise of warrants sold in this offering. As such, the total increase in capital as a result of the sale of these shares and warrants has been approximately $2.0 million after deducting an estimated $0.2 million of associated costs incurred, which were offset against these proceeds under applicable accounting guidance.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December 31, 2016 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on March 28, 2017. Past operating results are not necessarily indicative of results that may occur in future periods.

Company Overview

We are an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or “liquid biopsy.” Our current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Often, traditional methodologies such as tissue biopsies are insufficient or unavailable to provide the molecular subtype information necessary for clinical decisions. Our assays have the potential to provide more contemporaneous information on the characteristics of a patient’s disease compared with traditional methodologies such as tissue biopsy and radiographic imaging. Additionally, our proprietary blood collection tubes, which allow for the intact transport of liquid biopsy samples for research use only from regions around the world, are anticipated to be sold to laboratory supply distributor(s) commencing in the six months ended December 31, 2017.

Our current assays and our planned future assays focus on key solid tumor indications utilizing our Target-Selector^s liquid biopsy technology platform for the biomarker analysis of CTCs and ctDNA from a standard blood sample. Our patented Target-Selector CTC offering is based on an internally developed microfluidics-based cell capture and analysis platform, with enabling features that change how CTC testing is used by clinicians. Our patent pending Target-Selector ctDNA technology enables mutation detection with enhanced sensitivity and specificity, and is applicable to nucleic acid from ctDNA or other sample types, such as CTCs, bone marrow, or cerebrospinal fluid. Our Target-Selector CTC and ctDNA platforms provide both biomarker detection as well as monitoring capabilities, and require only a patient blood sample. We believe that our Target-Selector platform technology has the potential to be developed and commercialized as in vitro diagnostic (IVD) test kits, and we are currently pursuing this option.

At our corporate headquarters facility located in San Diego, California, we operate a clinical laboratory that is certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, and accredited by the College of American Pathologists, or CAP. We also performed research and development that led to our current assays, and we also intend to perform research and development for planned assays, at this facility. In addition, we manufacture our microfluidic channels, related equipment and certain reagents. The assays we offer and intend to offer are classified as laboratory developed tests, or LDTs, under CLIA regulations. CLIA certification is required before any clinical laboratory, including ours, may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, or treatment of disease or the assessment of health. In addition, we participate in and have received CAP accreditation, which includes rigorous bi-annual laboratory inspections and adherence to specific quality standards.

Our revenue generating efforts are focused in three areas:

•

providing clinical testing that oncologists use in order to determine the best treatment plan for their patients;

•

providing clinical trial, research and development services to biopharmaceutical companies developing drug candidates to treat cancer; and

•

licensing our proprietary testing and/or technologies to partners in the United States and abroad.

Assays, Products and Services

We have commercialized our Target-Selector assays for a number of solid tumor indications such as: breast cancer, non-small cell lung cancer, or NSCLC, small cell lung cancer, or SCLC, gastric cancer, colorectal cancer, prostate cancer, and melanoma. These assays utilize our dual CTC and ctDNA technology platforms and provide biomarker analysis from a patient’s blood sample.

In the case of our breast and gastric cancer offerings, biomarker analysis involves fluorescence in situ hybridization, or FISH, for the detection and quantitation of the human epidermal growth factor receptor 2, or HER2, gene copy number as well as immunocytochemical, or ICC, analysis of estrogen receptor, or ER, protein, progesterone receptor, or PR, protein, and androgen receptor, or AR, protein, which are currently commercially available. A patient’s HER2 status provides the physician with information about the appropriateness of therapies such as Herceptin^® or Tykerb^®. ER and PR status provides the physician with information about the appropriateness of endocrine therapies such as tamoxifen and aromatase inhibitors.

Our lung cancer biomarker analysis offering currently includes FISH testing for ALK, ROS1, RET, MET and FGFR1 gene rearrangements, as well as analysis for the T790M, Deletion 19, and L858R mutations of the epidermal growth factor receptor, or EGFR gene, as well as BRAF and KRAS. The L858R mutation of the EGFR gene and Exon 19 deletions as activators of EGFR kinase activity are associated with the use of the drugs Tarceva^®, Gilotrif^® and Iressa^®. For lung cancer, we also offer a resistance profile assay consisting of the biomarkers MET, HER2 (both of which we perform using our technology for CTCs), KRAS, and T790M (both of which are performed using ctDNA in plasma). These assays can be used by physicians to identify the mechanism causing disease progression for patients with NSCLC who are being treated with tyrosine kinase inhibitor, or TKI, therapy and therefore may qualify patients for inclusion in a clinical trial. In November 2015, Tagrisso^® was approved by the U.S. Food and Drug Administration, or FDA, providing another biomarker-based therapy for the treatment of patients with EGFR-related lung cancer. Tagrisso^® is indicated for the treatment of patients with metastatic disease, who have progressed on or after EGFR TKI therapy, and who have acquired a T790M resistance mutation. Recently, the FDA approved the combination of Novartis' Tafinlar^® (dabrafenib) and Mekinist^® (trametinib) for the treatment of patients with metastatic NSCLC whose tumors express the BRAF V600E mutation, an FDA “breakthrough therapy” designation for patients who have received prior chemotherapy. This combination was approved in Europe for the same indication in March 2017. BRAF mutations, which appear in approximately 1-3% of NSCLC cases globally, are associated with Zelboraf^® and Tafinlar^® treatment, as these BRAF inhibitors are both approved for the treatment of patients with melanoma.

Fibroblast growth receptor 1, or FGFR1, amplification is offered using our CTC technology. FGFR1 is present in several tumor types, including both NSCLC and SCLC and has been shown to be a prognostic indicator of progression. FGFR1 is also a key target for several drugs undergoing clinical development.

We analytically validated PD-L1 testing utilizing our CTC technology in 2016. PD-L1 is a biomarker that is informative for immuno-oncology therapies currently marketed for lung cancer and melanoma, as well as therapies in development for multiple tumor types. We collaborated with David Rimm, M.D., Ph.D., a pathologist at Yale Medical School and a scientific advisor to us, on the analytical development of this assay.

We plan to release additional blood-based biomarker assays, such as those that test for ESR1 and NRAS, to our current menu of liquid biopsy assays using blood samples. In addition, we plan to complete the development and offer multiplexed biomarker tests, which will allow the detection and quantitative monitoring of multiple biomarkers in a single assay.

In August 2017, we announced that we had executed a distribution agreement for our proprietary blood collection tubes with VWR International, LLC which can preserve intact cells (such as CTCs) for up to 96 hours and ctDNA for up to 8 days, allowing for the intact transport of research use only liquid biopsy samples from regions around the world.

Pharmaceutical and Research Collaborations

We continue to execute on our strategies intended to expand our business globally, as well as to engage with pharmaceutical companies on clinical trials and assay development. We have distribution agreements in place in Mexico with Quest Diagnostics to support testing for a large pharmaceutical company partner. In addition, we have distribution agreements in place in Turkey, the Czech Republic, the Philippines, Lebanon, Columbia, Israel and Canada.

During 2016, we announced three pharmaceutical collaborations. The first agreement provides testing for a clinical trial that includes patients who have leptomeningeal disease or metastatic lung cancer in the brain. In this exploratory trial, we are testing both cerebral spinal fluid and blood for molecular alterations that could be impacted by treatment. The second agreement is a milestone-based assay development project focused on hepatocellular carcinoma, or liver cancer, whereby we intend to develop assays utilizing both our CTC and ctDNA technologies for clinical trials. The third collaboration involves a study presented at the European Society for Medical Oncology, or ESMO, Annual Congress in October 2016, evaluating the detection of EGFR alterations (del19, L858R and T790M) by our Target-Selector liquid biopsy. Subsequent to this study, we have earned business in both Mexico and Columbia for EGFR testing in blood to qualify patients for the pharmaceutical company’s targeted therapy.

In March 2017, we announced a collaboration with Catalyst Pharmaceuticals for the provision of our Target-Selector platform to screen patients diagnosed with Lambert Eaton Myasthenic Syndrome, or LEMS, for early onset or recurrence of SCLC. Under this agreement, our liquid biopsy tests will be offered by Catalyst Pharmaceuticals at no cost to all patients enrolled in its ongoing Phase III clinical trial designed to demonstrate the safety and efficacy of Firdapse® (amifampridine phosphate) for the treatment of LEMS. Catalyst Pharmaceuticals will pay us for tests ordered and utilized as part of the agreement. Patients in the Phase III clinical trial will also have access to our liquid biopsy testing in the long-term extension study phase of the trial allowing for testing every six months for up to two years to monitor for early signals of SCLC.

In April 2017, we announced our entry into a preferred provider collaboration and services agreement with Oregon Health & Sciences University on behalf of the OHSU Knight Cancer Institute, or collectively OHSU. The multiphase agreement grants OHSU the rights to commercially offer our Target-Selector liquid biopsy testing services exclusively throughout the state of Oregon. Additionally, we

and OHSU plan to engage in technology transfer, whereby OHSU will have the ability to use Target-Selector assays in-house, and act as a secondary laboratory for our research and testing activities. We and OHSU also plan to co-develop additional liquid biopsy assay technologies and platform capabilities including highly sensitive, multiplexed assay panels for molecular biomarker detection and assessment. Additional research and development and commercial pilot projects are anticipated under the agreement.

In May 2017, we announced jointly with the Addario Lung Cancer Medical Institute, or ALCMI, entry into a clinical collaboration and initiation of the ALCMI-009 liquid biopsy clinical trial. This large-scale trial was developed, and will be conducted, by ALCMI and its consortium of leading U.S. and international oncology centers. The prospective, multi-center study, which plans to enroll 400 patients, will utilize our Target-Selector testing platform and services to detect and assess cancer biomarkers found in both CTCs and ctDNA from the blood of patients with lung cancer.

Provider Agreements

In January 2017, we announced that we had secured an in-network provider agreement with Blue Cross Blue Shield of Texas, the largest provider of health benefits in Texas. In addition, we entered into a national master business agreement with the Blue Cross Blue Shield Association, a not-for-profit trade association that provides multiple services for its 38-member Blue Cross and Blue Shield health plan companies across the U.S., including forming national strategic vendor partnerships. We were selected by the Blue Cross Blue Shield Association based on a rigorous request-for-proposal progress. This agreement establishes pricing for our Target-Selector liquid biopsy testing service through the Blue Cross Blue Shield Association’s group purchasing organization, CareSource Workgroup. The pricing offered by the CareSource Workgroup group purchasing organization is available to those Blue Cross and Blue Shield member health plans that have, or may seek, in-network agreements with us.

In June 2017, we entered into a participating provider agreement with MediNcrease Health Plans, LLC and a preferred provider agreement with Scripps Health Plan Services, Inc., both establishing pricing for our Target-Selector liquid biopsy testing service.

We are currently contracted with nine preferred provider organization networks, two large health plans, and four regional independent physician associations, and expect to continue to gain contracts in order to be considered as an “in-network” provider with additional plans.

Patents and Technology

We have issued patents with broad claims covering our blood collection tube, antibody cocktail approach, microchannel, and CTC detection methodologies. In addition to issuance of patents in the U.S., we have patents for our proprietary microchannel in China, Korea, Europe, Hong Kong, and Japan, and for our antibody cocktail in Australia, Europe, Hong Kong, and Japan. Our patent estate continues to evolve, and in addition to the broad patent estate around our CTC platform, we expect issuances of multiple patents for our novel switch blocker technology in the near future, solidifying our proprietary enrichment methodology for detecting ctDNA with very high sensitivity. Our CTC platform patents were filed from 2005 through 2012, and we expect to have patent protection into the 2030’s. Our patents and applications cover not only cancer as a target, but also prenatal and other rare cells of interest. Recently allowed patents in the U.S. cover the capture of “any target of interest” using our antibody capture approach. Patents for our proprietary specimen collection tubes expire in 2031.

As of July 2017, we owned 20 issued patents and 27 patents pending related to our current technologies. Of these, 8 are issued and 5 are pending patents in the U.S., while 12 are issued and 22 are pending patents in non-U.S. territories. Separately, we also own 6 issued patents related to our earlier microarray and cell analysis technology.

Results of Operations

Three Months Ended June 30, 2016 and 2017

The following table sets forth certain information concerning our results of operations for the periods shown:

	Three months ended June 30,						Change
	2016			2017			$			%
(dollars in thousands)
Net revenues	$	663		$	1,279		$	616			93	%
Cost of revenues		1,669			2,369			700			42	%
Research and development expenses		716			842			126			18	%
General and administrative expenses		1,518			1,798			280			18	%
Sales and marketing expenses		1,292			1,747			455			35	%
Loss from operations		(4,532	)		(5,477	)		(945	)		21	%
Interest expense		(99	)		(214	)		(115	)		116	%
Other income		38			—			(38	)		(100	%)
Loss before income taxes		(4,593	)		(5,691	)		(1,098	)		24	%
Income tax expense		(1	)		(2	)		(1	)		100	%
Net loss	$	(4,594	)	$	(5,693	)	$	(1,099	)		24	%

Net Revenues

Net revenues were approximately $1,279,000 for the three months ended June 30, 2017, compared with approximately $663,000 for the same period in 2016, an increase of $616,000, or 93%. Of the $1,279,000 of revenues recognized during the three months ended June 30, 2017, $1,036,000 related to revenues recognized on an accrual basis, while $159,000 related to revenues recognized upon the receipt of cash, as compared to the same period in 2016 when $66,000 of revenues were recognized on an accrual basis and $596,000 of revenues were recognized upon the receipt of cash. During the three months ended March 31, 2017, we converted from cash-based revenue recognition for our commercial revenues, to accrual-based revenue recognition. As a result of the change to accrual-based revenue recognition, we recognized total nonrecurring revenue of $135,000 during the three months ended June 30, 2017 for cases delivered on or prior to December 31, 2016, and the incremental revenue as a result of the change to accrual-based revenue recognition for commercial cases was $191,000.

Total cash collections for commercial cases were $1,004,000 during the three months ended June 30, 2017 as compared to $596,000 during the same period in 2016, an increase of $408,000 owed primarily to improvements in billing and collection timeliness and effectiveness, as well as increases in accession volume and in the expected value per accession received prior to and during the three months ended June 30, 2017 as compared to the same period in 2016. The $191,000 in incremental net revenues recognized was primarily related to an increase in the expected value per accession received prior to and during the three months ended June 30, 2017 as compared to the same period in 2016, as well as the increasing commercial case volumes received, as follows:

	Three months ended June 30,				Change
	2016		2017		# / $		%
# Commercial accessions received		966		1,005		39		4	%
$ Value estimated per commercial accession received	$	1,140	$	1,196	$	56		5	%

The $17,000 increase in development services revenues during the three months ended June 30, 2017 as compared to the same period in 2016 was primarily related to increasing development services case volumes delivered, as follows:

Three months ended

June 30,

Change

2016

2017

# Development services cases delivered

146

233

Costs and Expenses

Cost of Revenues. Cost of revenues was approximately $2,369,000 for the three months ended June 30, 2017, compared with approximately $1,669,000 for the three months ended June 30, 2016, an increase of $700,000, or 42%. The increase was primarily attributable to an increase of $402,000 in personnel and travel costs mainly related to higher assay volume as the average number of laboratory and manufacturing employees increased from an average of 23 employees during the three months ended June 30, 2016 to 38 employees during the same period in 2017, as we created excess laboratory accession throughput capacity of approximately 35% as

of June 30, 2017 in advance of an anticipated increase in accession volumes resulting from our expanded sales force. Additionally, there was an increase of $148,000 in depreciation expense, computer equipment, software amortization, and allocated information technology and facility charges as we invest in upgrading our laboratory equipment and information system and maintaining our facility, an increase of $130,000 in materials, shipping and other direct costs due to increased assay volume, as well as an increase of $20,000 related to fewer laboratory costs charged to research and development.

Research and Development Expenses. Research and development expenses were approximately $842,000 for the three months ended June 30, 2017, compared with approximately $716,000 for the three months ended June 30, 2016, an increase of $126,000, or 18%. The increase was primarily attributable to an increase of $101,000 in higher personnel and travel costs as the average headcount in our research and development function increased to 12 employees during the three months ended June 30, 2017 from 9 employees during the same period in 2016, as we focus on the development and deployment of next generation sequencing, support and implementation of data-intensive laboratory processes, and new product validations. Additionally, an increase of $45,000 in materials and other costs associated with research and development activities was partially offset by a decrease of $20,000 in fewer laboratory costs charged to research and development.

General and Administrative Expenses. General and administrative expenses were approximately $1,798,000 for the three months ended June 30, 2017, compared with approximately $1,518,000 for the three months ended June 30, 2016, an increase of $280,000, or 18%. The increase was primarily due to an increase of $292,000 in non-stock compensation personnel and travel costs as the average number of employees included in the general and administrative function rose from 8 employees during the three months ended June 30, 2016 to 14 employees during the same period in 2017, primarily resulting from bringing our billing function in-house in April 2017. Additionally, an increase of $47,000 during the three months ended June 30, 2017 in external independent audit and accounting fees primarily associated with the commencement of recognition of commercial revenues on an accrual basis on March 31, 2017 was partially offset by a decrease of $51,000 in stock-based compensation expense.

Sales and Marketing Expenses. Sales and marketing expenses were approximately $1,747,000 for the three months ended June 30, 2017, compared with approximately $1,292,000 for the three months ended June 30, 2016, an increase of $455,000, or 35%. The increase was primarily attributable to an increase of $336,000 in personnel and travel costs as the average number of employees included in the sales and marketing function rose from 15 employees during the three months ended June 30, 2016 to 23 employees during the same period in 2017 as we expand our sales force, and increases of $49,000 in computer equipment, allocated information technology costs, shipping and other office expenses, $44,000 in marketing materials, trade show and conference costs, and $26,000 in third party service provider and consulting costs, all associated with expanded commercial activities.

Income Taxes

Over the past several years we have generated operating losses in all jurisdictions in which we may be subject to income taxes. As a result, we have accumulated significant net operating losses and other deferred tax assets. Because of our history of losses and the uncertainty as to the realization of those deferred tax assets, a full valuation allowance has been recognized. We do not expect to report a provision for income taxes until we have a history of earnings, if ever, that would support the realization of our deferred tax assets.

We have not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation, due to the complexity and cost associated with such a study, and the fact that there may be additional ownership changes in the future, however, we believe ownership changes likely occurred during both 2015 and 2016. As a result, we have estimated that the use of our net operating loss is limited and the remaining net operating loss carryforwards and research and development credits we estimate can be used in the future remain fully offset by a valuation allowance to reduce the net asset to zero.

Six Months Ended June 30, 2016 and 2017

The following table sets forth certain information concerning our results of operations for the periods shown:

	Six months ended June 30,						Change
	2016			2017			$			%
(dollars in thousands)
Net revenues	$	884		$	2,962		$	2,078			235	%
Cost of revenues		3,144			4,498			1,354			43	%
Research and development expenses		1,444			1,599			155			11	%
General and administrative expenses		3,005			3,705			700			23	%
Sales and marketing expenses		2,597			3,025			428			16	%
Loss from operations		(9,306	)		(9,865	)		(559	)		6	%
Interest expense		(238	)		(297	)		(59	)		25	%
Other income		77			38			(39	)		(51	%)
Loss before income taxes		(9,467	)		(10,124	)		(657	)		7	%
Income tax expense		(2	)		(2	)		—			—
Net loss	$	(9,469	)	$	(10,126	)	$	(657	)		7	%

Net Revenues

Net revenues were approximately $2,962,000 for the six months ended June 30, 2017, compared with approximately $884,000 for the same period in 2016, an increase of $2,078,000, or 235%. Of the $2,962,000 of revenues recognized during the six months ended June 30, 2017, $1,762,000 related to revenues recognized on an accrual basis, while $1,056,000 related to revenues recognized upon the receipt of cash, as compared to the same period in 2016 when $98,000 of revenues were recognized on an accrual basis and $786,000 of revenues were recognized upon the receipt of cash. During the three months ended March 31, 2017, we converted from cash-based revenue recognition for our commercial revenues, to accrual-based revenue recognition. As a result of the change to accrual-based revenue recognition, we recognized total nonrecurring revenue of $1,012,000 during the six months ended June 30, 2017 for cases delivered on or prior to December 31, 2016, and the incremental revenue as a result of the change to accrual-based revenue recognition for commercial cases was $917,000.

Total cash collections for commercial cases were $1,901,000 during the six months ended June 30, 2017 as compared to $786,000 during the same period in 2016, an increase of $1,115,000 owed primarily to improvements in billing and collection timeliness and effectiveness, as well as increases in accession volume and the expected value per accession received prior to and during the six months ended June 30, 2017 as compared to the same period in 2016. The $917,000 in incremental net revenues recognized was primarily related to an increase in the expected value per accession received prior to and during the six months ended June 30, 2017 as compared to the same period in 2016, as well as the increasing commercial case volumes received, as follows:

	Six months ended June 30,				Change
	2016		2017		# / $		%
# Commercial accessions received		1,706		1,938		232		14	%
$ Value estimated per commercial accession received	$	1,049	$	1,131	$	82		8	%

The $46,000 increase in development services revenues during the six months ended June 30, 2017 as compared to the same period in 2016 was primarily related to increasing development services case volumes delivered, as follows:

	Six months ended June 30,				Change
	2016		2017		#		%
# Development services cases delivered		223		397		174		78	%

Costs and Expenses

Cost of Revenues. Cost of revenues was approximately $4,498,000 for the six months ended June 30, 2017, compared with approximately $3,144,000 for the six months ended June 30, 2016, an increase of $1,354,000, or 43%. The increase was primarily attributable to an increase of $842,000 in personnel and travel costs mainly related to higher assay volume as the average number of laboratory and manufacturing employees increased from an average of 23 employees during the six months ended June 30, 2016 to 36 employees during the same period in 2017, as we created excess laboratory accession throughput capacity of approximately 35% as of June 30, 2017 in advance of an anticipated increase in accession volumes resulting from our expanded sales force. Additionally, there was an increase of $259,000 in depreciation expense, computer equipment, software amortization, and allocated information

technology and facility charges as we invest in upgrading our laboratory equipment and information system and maintaining our facility, an increase of $150,000 in materials, shipping and other direct costs due to increased assay volume, an increase of $53,000 related to fewer laboratory costs charged to research and development, and an increase of $50,000 related to third party service provider and consulting costs associated with higher assay volume.

Research and Development Expenses. Research and development expenses were approximately $1,599,000 for the six months ended June 30, 2017, compared with approximately $1,444,000 for the six months ended June 30, 2016, an increase of $155,000, or 11%. The increase was primarily attributable to an increase of $110,000 in higher personnel and travel costs as the average headcount in our research and development function increased to 11 employees during the six months ended June 30, 2017 from 9 employees during the same period in 2016, as we focus on the development and deployment of next generation sequencing, support and implementation of data-intensive laboratory processes, and new product validations. Additional increases of $78,000 in materials and other costs associated with research and development activities and $20,000 in allocated facilities charges were partially offset by a decrease of $53,000 in fewer laboratory costs charged to research and development.

General and Administrative Expenses. General and administrative expenses were approximately $3,705,000 for the six months ended June 30, 2017, compared with approximately $3,005,000 for the six months ended June 30, 2016, an increase of $700,000, or 23%. The increase was primarily due to an increase of $533,000 in non-stock compensation personnel costs and travel expenses as the average number of employees included in the general and administrative function rose from 8 employees during the six months ended June 30, 2016 to 13 employees during the same period in 2017, primarily resulting from bringing our billing function in-house in April 2017. Additionally, there was an increase of $157,000 in third party service provider and consulting fees associated with increased commercial activities and our expanded investor relations and corporate strategy functions during the six months ended June 30, 2017, an increase of $79,000 in computer equipment, allocated facilities charges, office expenses, and other general and administrative costs associated with increased commercial activities, an increase of $60,000 in legal costs, an increase of $45,000 in third party billing provider costs due to higher cash collections, as well as an increase of $38,000 in external independent audit and accounting fees primarily associated with the commencement of recognition of commercial revenues on an accrual basis on March 31, 2017, which were partially offset by decreases of $110,000 in directors and officers insurance costs and $102,000 in stock-based compensation expense.

Sales and Marketing Expenses. Sales and marketing expenses were approximately $3,025,000 for the six months ended June 30, 2017, compared with approximately $2,597,000 for the six months ended June 30, 2016, an increase of $428,000, or 16%. The increase was primarily attributable to an increase of $353,000 in personnel and travel costs as the average number of employees included in the sales and marketing function rose from 15 employees during the six months ended June 30, 2016 to 20 employees during the same period in 2017 as we expand our sales force, and increases associated with expanded commercial activities of $51,000 in computer equipment, allocated information technology costs, shipping and other office expenses, and $24,000 in marketing materials, trade show and conference costs.

Income Taxes

Liquidity and Capital Resources

Cash Flows

Our net cash flow from operating, investing and financing activities for the periods below were as follows:

	Six months ended June 30,
	2016			2017
(dollars in thousands)
Cash provided by/ (used in):
Operating activities	$	(8,294	)	$	(8,947	)
Investing activities		(324	)		(527	)
Financing activities		3,548			14,865
Net increase/ (decrease) in cash	$	(5,070	)	$	5,391

Cash Used in Operating Activities. Net cash used in operating activities was approximately $8,947,000 for the six months ended June 30, 2017, compared to net cash used in operating activities of approximately $8,294,000 for six months ended June 30, 2016. The net increase of $653,000 was primarily related to an increase of $656,000 in cash used to fund our net loss, as well as a net increase of $104,000 in cash used to fund operating assets and liabilities, partially offset by a $107,000 increase in non-cash depreciation and amortization, inventory reserve, interest and stock-based compensation expenses.

Cash Used in Investing Activities. Net cash used in investing activities of approximately $527,000 and $324,000 during the six months ended June 30, 2017 and 2016, respectively, was related to purchases of fixed assets.

Cash Provided by Financing Activities. Net cash provided by financing activities was $14.9 million for the six months ended June 30, 2017, compared to net cash provided by financing activities of $3.5 million for the six months ended June 30, 2016. Our primary sources of cash from financing activities during the six months ended June 30, 2017 consisted of $8.6 million in net proceeds from our offering in March 2017, as well as proceeds of $7.5 million from the exercise of common stock warrants sold in our offering in October 2016, which were partially offset by $1.2 million of principal payments made on indebtedness. Our primary sources of cash from financing activities during the six months ended June 30, 2016 related to $4.3 million in net proceeds from our offering in May 2016 as well as $0.3 million in net proceeds received from the sale of common stock to Aspire Capital, which were partially offset by $1.1 million of principal payments made on indebtedness.

Capital Resources and Expenditure Requirements

We expect to continue to incur substantial operating losses in the future. It may take several years to achieve positive operational cash flow or we may not ever achieve positive operational cash flow. We expect that we will use the net proceeds from our sale of equity securities, if any, cash received from the licensing of our technology, if any, and our revenues from operations to hire sales and marketing personnel, support increased sales and marketing activities, fund further research and development, clinical utility studies and future enhancements of our assays, acquire equipment, implement automation and scale our capabilities to prepare for significant assay volume, for general corporate purposes and to fund ongoing operations and the expansion of our business, including the increased costs associated with expanded commercial activities. We may also use the net proceeds from our sale of equity securities, if any, cash received from the licensing of our technology, if any, and our revenues from operations to acquire or invest in businesses, technologies, services or products, although we do not have any current plans to do so.

As of June 30, 2017, our cash totaled $10.0 million, and our outstanding net indebtedness totaled $3.8 million. While we currently are in the commercialization stage of operations, we have not yet achieved profitability and anticipate that we will continue to incur net losses for the foreseeable future. Management expects that we will need additional financing to execute on our current or future business strategies beyond January 2018.

Subsequent to the closing of a follow-on offering in February 2015, cash proceeds of approximately $9.8 million have been received from the exercise of warrants sold in that offering, while approximately $2.7 million in gross warrant proceeds remain outstanding and available to be exercised at $4.68 per share until their expiration in February 2020.

In May 2015, the SEC declared effective a shelf registration statement filed by us. The shelf registration statement allows us to issue any combination of our common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as our public float is less than $75 million. Pursuant to an exclusive placement agent agreement dated April 25, 2016 between us and H.C. Wainwright & Co., LLC, or Wainwright, and a securities purchase agreement dated April 29, 2016 between us and the purchasers signatory thereto, we received approximately $4.3 million of net cash proceeds upon the sale of our common stock and warrants to purchase our common stock. Subsequent to the closing of this offering on May 4, 2016, no warrants sold in this offering have been exercised, with approximately $4.5 million in gross warrant

proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. Pursuant to an exclusive placement agent agreement dated March 28, 2017 between us and Roth Capital Partners, LLC as lead placement agent, and WestPark Capital and Chardan Capital as co-placement agents, a securities purchase agreement for an offering of 4,320,000 shares of our common stock was effected under this registration statement at a per share price of $2.15. In a concurrent private placement, we sold unregistered warrants to purchase up to an aggregate of 2,160,000 shares of our common stock that closed concurrently with the offering common stock sold pursuant to this shelf registration statement. All warrants sold in this offering have a per share exercise price of $2.50, are exercisable beginning on the six-month anniversary of the date of issuance, and expire five years from the date first exercisable. The closing of the sale of these securities to the purchasers occurred on March 31, 2017, when we received approximately $8.6 million of net cash proceeds. In connection with the closing of this offering, we have agreed to certain contractual terms that limit our ability to issue variable rate securities for a period of one year following the closing of this offering, with certain exceptions. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings.

On October 19, 2016, we received net cash proceeds of approximately $9.0 million as a result of the closing of a follow-on public offering. Subsequent to the closing of this offering on October 19, 2016, the offering’s underwriters exercised their overallotment option to purchase 627,131 option warrants for total proceeds of $564. Subsequent to December 31, 2016, approximately $7.5 million of additional cash proceeds had been received from the exercise of warrants sold in this offering, with approximately $3.2 million in gross warrant proceeds remaining outstanding and available to be exercised at $1.10 per share until their expiration in October 2021.

Pursuant to a common stock and warrant purchase agreement dated August 9, 2017, we received net cash proceeds of approximately $2.0 million as a result of the sale of our common stock and warrants. Subsequent to the closing of this offering, no additional cash proceeds had been received from the exercise of warrants sold in this offering, with approximately $2.2 million in gross warrant proceeds remaining outstanding and available to be exercised at $1.50 per share until their expiration in August 2022.

We expect that we will need additional financing to execute on our current or future business strategies. Until we can generate significant cash from operations, including assay revenues, we expect to continue to fund operations with the proceeds from offerings of our equity securities or debt, or transactions involving product development, technology licensing or collaboration. For example, we have an effective shelf registration statement on file with the SEC which allows us to issue any combination of our common stock, preferred stock, debt securities and warrants from time to time, subject to certain restrictions that apply for so long as our public float is less than $75 million. In connection with our offering in March 2017, we have agreed to certain contractual terms that limit our ability to issue variable rate securities for a period of one year, subject to certain exceptions. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. We can provide no assurances that any sources of a sufficient amount of financing will be available to us on favorable terms, if at all. If we are unable to raise a sufficient amount of financing in a timely manner, we would likely need to scale back our general and administrative activities and certain of our research and development activities. Our forecast pertaining to our current financial resources and the costs to support our general and administrative and research and development activities are forward-looking statements and involve risks and uncertainties. Actual results could vary materially and negatively as a result of a number of factors, including:

•

our ability to secure financing and the amount thereof;

•

the costs of operating and enhancing our laboratory facilities;

•

the costs of developing our anticipated internal sales and marketing capabilities;

•

the scope, progress and results of our research and development programs, including clinical utility studies;

•

the scope, progress, results, costs, timing and outcomes of the clinical utility studies for our cancer diagnostic assays;

•

our ability to manage the costs for manufacturing our microfluidic channels;

•

the costs of maintaining, expanding and protecting our intellectual property portfolio, including potential litigation costs and liabilities;

•

our ability to obtain adequate reimbursement from governmental and other third-party payers for our assays and services;

•

the costs of additional general and administrative personnel, including accounting and finance, legal and human resources, as a result of becoming a public company;

•

our ability to collect revenues; and

•

other risks discussed in our other filings with the SEC.

We may raise additional capital to fund our current operations and to fund expansion of our business to meet our long-term business objectives through public or private equity offerings, debt financings, borrowings or strategic partnerships coupled with an investment in our company or a combination thereof. If we raise additional funds through the issuance of convertible debt securities, or other debt

securities, these securities could be secured and could have rights senior to those of our common stock. In addition, any new debt incurred by us could impose covenants that restrict our operations. The issuance of any new equity securities will also dilute the interest of our current stockholders. Given the risks associated with our business, including our unprofitable operating history and our ability or inability to develop additional assays, additional capital may not be available when needed on acceptable terms, or at all. If adequate funds are not available, we will need to curb our expansion plans or limit our research and development activities, which would have a material adverse impact on our business prospects and results of operations.

Off-Balance Sheet Arrangements

We have not engaged in any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.

Critical Accounting Policies and Significant Judgments and Estimates

For a discussion of accounting policies that we consider critical to our business operations and understanding of our results of operations, and that affect the more significant judgments and estimates used in the preparation of our financial statements, please see the information listed below, along with the information listed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Significant Judgments and Estimates” contained in our Annual Report on Form 10-K for the year ended December 31, 2016. Except as provided below, there have been no material changes to our critical accounting policies and estimates from the information provided in our Annual Report on Form 10-K for the year ended December 31, 2016.

Revenue Recognition and Related Reserves

Our commercial revenues are generated from diagnostic services provided to physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. We recognize revenue in accordance with the provision of ASC 954-605, Health Care Entities—Revenue Recognition, which requires that four basic criteria must be met prior to recognition of revenue: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. Commencing on March 31, 2017, we recognize commercial revenue related to billings for assays delivered and billed to Medicare and other third-party payers on an accrual basis when amounts that will ultimately be realized can be estimated upon delivery, whereby prior to March 31, 2017, we recognized revenues for our commercial diagnostic services on a cash basis as collected because the amounts ultimately expected to be received could not be estimated upon delivery due to insufficient collection history experience.

We bill third-party payers on a fee-for-service basis at our list price and third-party commercial revenue is recorded net of contractual discounts, payer-specific allowances and other reserves. Our development services revenues are supported by contractual agreements and generated from assay development services provided to entities, as well as certain other diagnostic services provided to physicians. Diagnostic services are completed upon the delivery of assay results to the prescribing physician, at which time we bill for the service.

Our gross commercial revenues billed are subject to estimated deductions for such contractual discounts, payer-specific allowances and other reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected. These third-party payer discounts and sales allowances are estimated based on a number of assumptions and factors, including historical payment trends, seasonality associated with the annual reset of patient deductible limits on January 1 of each year, and current and estimated future payments. Specifically, we maintain four such reserves: the reserve for contractual discounts, the reserve for aged non-patient receivables, the reserve for estimated patient receivables, and the reserve for other payer-specific sales allowances. The reserve for contractual discounts relates to discounts to gross amounts billed to Medicare and contracted third-party payers to arrive at the deemed “allowed expense" amount covered by that payer. Our contracted third-party commercial sales are recorded using an actual or contracted fee schedule at the time of sale, while estimated fee schedules are maintained for each non-contracted payer separately as part of other payer-specific sales allowances. Contractual discounts are recorded at the transaction level at the time of sale based on a fee schedule that is maintained for each contracted third-party payer. We periodically adjust fee schedules for both contracted and non-contracted third-party payers based upon historical payment trends. The reserve for aged non-patient receivables reduces gross amounts billed to non-contracted third-party payers for amounts estimated to be collected according to the age of the outstanding balance. The reserve for estimated patient receivables reduces gross amounts billed to third-party payers for amounts estimated to be collected directly from individual patients, such as copayments, deductibles, or amounts otherwise designated as patient responsibility. The reserve for other payer-specific sales allowances relates to the amounts billed to non-contracted third-party payers that are estimated to not be covered by that specific payer’s coverage policies, as well as estimated necessary adjustments to gross amounts billed based on historical collection experience for a particular third-party payer unrelated to the age of outstanding balances.

The estimates of amounts that will ultimately be realized from commercial diagnostic services require significant judgment by management. Patients do not enter into direct agreements with us that commit them to pay any portion of the cost of the tests in the event that they have not met their annual deductible limit under their insurance policy, if any, or if their insurance otherwise declines to reimburse us. Adjustments to the estimated payment amounts are recorded at the time of final collection and settlement of each transaction as an adjustment to commercial revenue. The estimation process used to determine third-party payer discounts and sales allowance has been applied on a consistent basis since March 31, 2017, and no subsequent significant adjustments have been necessary to increase or decrease these discounts and allowances as a result of changes in underlying estimates.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

Item 4. Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As of June 30, 2017, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2017. There were no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

For a discussion of our potential risks and uncertainties, please see the information listed in the item captioned “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016. There have been no material changes to the risk factors as disclosed in the Form 10-K. You should carefully consider the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2016, which could materially affect our business, financial position and results of operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

None.

Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits

The exhibits listed on the accompanying index to exhibits immediately preceding the exhibits are filed as part of, or hereby incorporated by reference into, this Quarterly Report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	BIOCEPT, INC. (Registrant)

Date: August 14, 2017	By:	/s/ Michael W. Nall
		Michael W. Nall
		President, Chief Executive Officer and Director
		(Principal Executive Officer)

Date: August 14, 2017	By:	/s/ Timothy C. Kennedy
		Timothy C. Kennedy
		Chief Financial Officer, Senior Vice President of Operations
		(Principal Financial and Accounting Officer)

Exhibit Index

The exhibits listed below are hereby filed with the SEC as part of this Quarterly Report on Form 10-Q.

EXHIBITS

Exhibit No.		Description of Exhibit

3.1		Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1.4 of the Registrant’s Current Report on Form 8-K, filed with the SEC on February 14, 2014).
3.2		Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2.1 of the Registrant’s Current Report on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
3.3		Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on September 29, 2016).
4.1		Reference is made to Exhibits 3.1, 3.2 and 3.3.
4.2		Amended and Restated Investor Rights Agreement, dated as of October 31, 2011, among the Registrant and certain investors named therein (incorporated by reference to Exhibit 10.12 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.3		Specimen Common Stock certificate of Biocept, Inc. (incorporated by reference to Exhibit 4.3 of the Registrant’s Annual Report on Form 10-K, filed with the SEC on March 28, 2017).
4.4		Form of Representative’s Warrant, dated February 10, 2014 (incorporated by reference to Exhibit 4.2 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), as amended, filed with the SEC on November 20, 2013).
4.5		Form of Warrant issued to the lenders under the Loan and Security Agreement, dated as of April 30, 2014, by and among Biocept, Inc., Oxford Finance LLC, as collateral agent, and the lenders party thereto from time to time, including Oxford Finance LLC (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on May 6, 2014).
4.6		Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.5 of the Registrant’s Registration Statement on Form S-1 (File No. 333-201437), filed with the SEC on February 6, 2015).
4.7		Warrant to Purchase Preferred Stock, dated September 10, 2012, issued by the Registrant in favor of ARE-SD Region No. 18, LLC (incorporated by reference to Exhibit 10.11.3 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.8		Warrant to Purchase Common Stock, dated September 10, 2013, issued by the Registrant in favor of ARE-SD Region No. 18, LLC (incorporated by reference to Exhibit 10.11.6 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.9		Warrant to Purchase Preferred Stock dated as of January 21, 2009, issued by the Registrant in favor of Goodman Co. Ltd. (incorporated by reference to Exhibit 10.17.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.10		Warrant to Purchase Common Stock dated as of July 31, 2013, issued by the Registrant in favor of Goodman Co. Ltd. (incorporated by reference to Exhibit 10.17.3 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.11		Form of Warrant to Purchase Preferred Stock, issued by the Registrant in favor of various investors under the Note and Warrant Purchase Agreement dated as of January 13, 2012 (incorporated by reference to Exhibit 10.19.3 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.12		Form of Amendment of Warrant to Purchase Preferred Stock, dated as of September 13, 2013 (incorporated by reference to Exhibit 10.19.4 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.13		Form of Warrant to Purchase Common Stock, issued by the Registrant in favor of various investors under the Note and Warrant Purchase Agreement dated as of June 28, 2013 (incorporated by reference to Exhibit 10.20.2 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.14		Form of Warrant to Purchase Common Stock, issued by the Registrant in favor of various guarantors under the Reimbursement Agreement dated as of July 11, 2013 (incorporated by reference to Exhibit 10.21.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).

Exhibit No.		Description of Exhibit
4.15		Form of Common Stock Purchase Warrant issued to the investors under the Securities Purchase Agreement, dated April 29, 2016, by and among Biocept, Inc. and the purchasers signatory thereto (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on April 29, 2016).
4.16		Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.16 of the Registrant’s Post-Effective Amendment to Registration Statement on Form S-1 (File No. 333-213111), filed with the SEC on October 14, 2016).
4.17		Form of Common Stock Purchase Warrant issued to the investors under the Securities Purchase Agreement, dated March 28, 2017, by and among Biocept, Inc. and the purchasers signatory thereto (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on March 30, 2017).
4.18		Common Stock Purchase Warrant issued by the Registrant in favor of Ally Bridge LB Healthcare Master Fund Limited under the Common Stock and Warrant Purchase Agreement dated August 9, 2017 (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on August 10, 2017).
10.1+		Biocept, Inc. Amended and Restated 2013 Equity Incentive Plan, Form of Stock Option Grant Notice, Option Agreement, Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit agreement for use thereunder (incorporated by reference to Exhibit 99.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on May 5, 2017).
10.2		Third Amendment to Loan and Security Agreement by and among Biocept, Inc., Oxford Finance LLC, as collateral agent, and the lenders party thereto from time to time, including Oxford Finance LLC, dated as of June 28, 2017.
31.1		Certification of Michael Nall, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Timothy Kennedy, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*		Certification of Michael Nall, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*		Certification of Timothy Kennedy, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

+	Indicates management contract or compensatory plan.

This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the registrant specifically incorporates it by reference.

EX-10.2 2 bioc-ex102_154.htm EX-10.2 bioc-ex102_154.htm

EXHIBIT 10.2

THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT

THIS THIRD AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of June 28, 2017 (the “Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (in its individual capacity, “Oxford”; and in its capacity as Collateral Agent, “Collateral Agent”), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined herein) from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”) and BIOCEPT, INC., a Delaware corporation with offices located at 5810 Nancy Ridge Drive, San Diego, California 92121 ( “Borrower”).

WHEREAS, Collateral Agent, Borrower and Lenders party thereto from time to time have entered into that certain Loan and Security Agreement, dated as of April 30, 2014 (as amended, supplemented or otherwise modified from time to time, the “Loan Agreement”) pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof; and

WHEREAS, Borrower, Lenders and Collateral Agent desire to amend certain provisions of the Loan Agreement as provided herein and subject to the terms and conditions set forth herein;

NOW, THEREFORE, in consideration of the premises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:

Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.

Clause (e) of the definition of “Permitted Indebtedness” set forth in Section 13.1 of the Loan Agreement is hereby amended and restated in its entirety to read as follows:

“(e)Indebtedness consisting of capitalized lease obligations and purchase money Indebtedness, in each case incurred by Borrower or any of its Subsidiaries to finance the acquisition, repair, improvement or construction of fixed or capital assets of such person, provided that (i) the aggregate outstanding principal amount of all such Indebtedness does not exceed Three Million Dollars ($3,000,000.00) at any time and (ii) the principal amount of such Indebtedness does not exceed the lower of the cost or fair market value of the property so acquired or built or of such repairs or improvements financed with such Indebtedness (each measured at the time of such acquisition, repair, improvement or construction is made);”

Limitation of Amendment.

The amendment set forth in Section 2 above is effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Lenders may now have or may have in the future under or in connection with any Loan Document.

This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.

To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:

Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in

which case they are true and correct in all material respects as of such date), and (b) no Event of Default has occurred and is continuing;

Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;

The organizational documents of Borrower delivered to Collateral Agent on the Effective Date remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;

The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (i) any law or regulation binding on or affecting Borrower, (ii) any contractual restriction with a Person binding on Borrower, (iii) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;

The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and

This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights.

Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.

This Amendment shall be deemed effective as of the Amendment Date upon (a) the due execution and delivery to Collateral Agent of this Amendment by each party hereto and (b) Borrower’s payment of all Lenders’ Expenses incurred through the date hereof, which may be debited from any of Borrower’s accounts with Lenders.

This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.

This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of California.

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties hereto have caused this Third Amendment to Loan and Security Agreement to be executed as of the date first set forth above.


BORROWER:

BIOCEPT, INC.


By: /s/ Timothy Kennedy
Name: Timothy Kennedy
Title: Chief Financial Officer, SVP of Operations

COLLATERAL AGENT AND LENDER:

OXFORD FINANCE LLC


By: /s/ Colette Hastings Featherly
Name: Colette Hastings Featherly
Title: SVP, Corporate Finance & Planning

EX-31.1 3 bioc-ex311_8.htm EX-31.1 bioc-ex311_8.htm

EXHIBIT 31.1

CERTIFICATION

I, Michael W. Nall, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Biocept, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2017

/s/ Michael W. Nall

Michael W. Nall

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 4 bioc-ex312_9.htm EX-31.2 bioc-ex312_9.htm

EXHIBIT 31.2

CERTIFICATION

I, Timothy Kennedy, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Biocept, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2017

/s/ Timothy Kennedy

Timothy Kennedy

Chief Financial Officer, Senior Vice President of Operations

(Principal Financial and Accounting Officer)

EX-32.1 5 bioc-ex321_6.htm EX-32.1 bioc-ex321_6.htm

EXHIBIT 32.1

CERTIFICATION

I, Michael W. Nall, hereby certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that, to my knowledge, the Quarterly Report on Form 10-Q of Biocept, Inc. for the period ended June 30, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Biocept, Inc.

Date: August 14, 2017

/s/ Michael W. Nall

Michael W. Nall

President and Chief Executive Officer

(Principal Executive Officer)

This certification accompanies the Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934.

EX-32.2 6 bioc-ex322_7.htm EX-32.2 bioc-ex322_7.htm

EXHIBIT 32.2

CERTIFICATION

I, Timothy Kennedy, hereby certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that, to my knowledge, the Quarterly Report on Form 10-Q of Biocept, Inc. for the period ended June 30, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Biocept, Inc.

Date: August 14, 2017		/s/ Timothy Kennedy
		Timothy Kennedy
		Chief Financial Officer, Senior Vice President of Operations
		(Principal Financial and Accounting Officer)

EX-101.INS 7 bioc-20170630.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure bioc:Plan utr:sqft bioc:Director bioc:Consultant 0001044378 2017-01-01 2017-06-30 0001044378 2017-08-10 0001044378 2016-12-31 0001044378 2017-06-30 0001044378 2016-04-01 2016-06-30 0001044378 2017-04-01 2017-06-30 0001044378 2016-01-01 2016-06-30 0001044378 2015-12-31 0001044378 2016-06-30 0001044378 2016-05-04 0001044378 2016-05-03 2016-05-04 0001044378 2015-01-01 2015-12-31 0001044378 2016-01-01 2016-12-31 0001044378 2017-03-31 0001044378 2017-03-30 2017-03-31 0001044378 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-06-30 0001044378 bioc:AllyBridgeLBHealthcareMasterFundLimitedMember 2017-01-01 2017-06-30 0001044378 2016-09-28 2016-09-29 0001044378 us-gaap:MinimumMember 2016-09-27 0001044378 us-gaap:MaximumMember 2016-09-27 0001044378 bioc:CommercialDiagnosticServicesMember 2017-04-01 2017-06-30 0001044378 bioc:CommercialDiagnosticServicesMember 2017-01-01 2017-06-30 0001044378 bioc:AccountsReceivableGrossMember 2016-12-31 0001044378 bioc:AccountsReceivableGrossMember 2017-01-01 2017-06-30 0001044378 bioc:ReserveForContractualDiscountsMember 2017-01-01 2017-06-30 0001044378 bioc:ReserveForAgedNonPatientReceivablesMember 2017-01-01 2017-06-30 0001044378 bioc:ReserveForEstimatedPatientReceivablesMember 2017-01-01 2017-06-30 0001044378 bioc:ReserveForOtherPayerSpecificSalesAllowancesMember 2017-01-01 2017-06-30 0001044378 bioc:AccountsReceivableGrossMember 2017-06-30 0001044378 bioc:ReserveForContractualDiscountsMember 2017-06-30 0001044378 bioc:ReserveForAgedNonPatientReceivablesMember 2017-06-30 0001044378 bioc:ReserveForEstimatedPatientReceivablesMember 2017-06-30 0001044378 bioc:ReserveForOtherPayerSpecificSalesAllowancesMember 2017-06-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:MedicareAndMedicareAdvantageMember us-gaap:SalesRevenueNetMember 2016-04-01 2016-06-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:MedicareAndMedicareAdvantageMember us-gaap:SalesRevenueNetMember 2017-04-01 2017-06-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:MedicareAndMedicareAdvantageMember us-gaap:SalesRevenueNetMember 2016-01-01 2016-06-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:MedicareAndMedicareAdvantageMember us-gaap:SalesRevenueNetMember 2017-01-01 2017-06-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:BlueCrossBlueShieldMember us-gaap:SalesRevenueNetMember 2016-04-01 2016-06-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:BlueCrossBlueShieldMember us-gaap:SalesRevenueNetMember 2017-04-01 2017-06-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:BlueCrossBlueShieldMember us-gaap:SalesRevenueNetMember 2016-01-01 2016-06-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:BlueCrossBlueShieldMember us-gaap:SalesRevenueNetMember 2017-01-01 2017-06-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:UnitedHealthcareMember us-gaap:SalesRevenueNetMember 2016-04-01 2016-06-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:UnitedHealthcareMember us-gaap:SalesRevenueNetMember 2017-04-01 2017-06-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:UnitedHealthcareMember us-gaap:SalesRevenueNetMember 2016-01-01 2016-06-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:UnitedHealthcareMember us-gaap:SalesRevenueNetMember 2017-01-01 2017-06-30 0001044378 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember bioc:MedicareAndMedicareAdvantageMember 2017-01-01 2017-06-30 0001044378 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember bioc:BlueCrossBlueShieldMember 2017-01-01 2017-06-30 0001044378 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember bioc:UnitedHealthcareMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandAndFourteenCreditFacilityMember 2017-06-30 0001044378 2016-02-29 0001044378 us-gaap:MinimumMember 2016-02-01 2016-02-29 0001044378 bioc:ShelfRegistrationStatementMember us-gaap:MaximumMember 2015-05-31 0001044378 bioc:ShelfRegistrationStatementMember 2015-05-31 0001044378 bioc:ShelfRegistrationStatementMember 2016-05-03 2016-05-04 0001044378 bioc:RothCapitalPartnersLLCAndFeltlMember 2016-10-18 2016-10-19 0001044378 bioc:ShelfRegistrationStatementMember 2017-03-30 2017-03-31 0001044378 bioc:RothCapitalPartnersLLCAndFeltlMember 2017-01-01 2017-06-30 0001044378 bioc:ShelfRegistrationStatementMember 2017-03-31 0001044378 bioc:ShelfRegistrationStatementMember 2017-01-01 2017-06-30 0001044378 us-gaap:SubsequentEventMember 2017-08-08 2017-08-09 0001044378 us-gaap:SubsequentEventMember 2017-08-10 2017-08-11 0001044378 us-gaap:SubsequentEventMember 2017-08-11 0001044378 bioc:AspireCapitalFundLLCMember us-gaap:CommonStockMember 2015-12-20 2015-12-21 0001044378 bioc:AspireCapitalFundLLCMember us-gaap:CommonStockMember 2015-12-21 0001044378 bioc:AspireCapitalFundLLCMember 2015-12-21 0001044378 bioc:CommonStockPurchaseAgreementMember 2016-01-01 2016-12-31 0001044378 bioc:ShelfRegistrationStatementMember 2016-05-04 0001044378 bioc:RothCapitalPartnersLLCAndWestParkCapitalAndChardanCapitalMember 2017-03-30 2017-03-31 0001044378 bioc:RothCapitalPartnersLLCAndWestParkCapitalAndChardanCapitalMember 2017-03-31 0001044378 bioc:RothCapitalPartnersLLCAndWestParkCapitalAndChardanCapitalMember 2017-01-01 2017-06-30 0001044378 bioc:RothCapitalPartnersLLCAndFeltlMember 2016-10-13 2016-10-14 0001044378 bioc:RothCapitalPartnersLLCAndFeltlMember 2016-10-14 0001044378 bioc:RothCapitalPartnersLLCAndFeltlMember us-gaap:MaximumMember 2016-10-14 0001044378 bioc:RothCapitalPartnersLLCAndFeltlMember 2016-10-20 2017-06-30 0001044378 us-gaap:SubsequentEventMember bioc:AllyBridgeLBHealthcareMasterFundLimitedMember 2017-08-08 2017-08-09 0001044378 us-gaap:SubsequentEventMember bioc:AllyBridgeLBHealthcareMasterFundLimitedMember 2017-08-09 0001044378 us-gaap:WarrantMember 2017-03-31 0001044378 bioc:LoanFacilityOneMember bioc:OxfordFinanceLLCMember 2014-04-28 2014-04-30 0001044378 bioc:ScenarioOneMember bioc:OxfordFinanceLLCMember 2014-04-28 2014-04-30 0001044378 bioc:ScenarioTwoMember bioc:OxfordFinanceLLCMember 2014-04-28 2014-04-30 0001044378 bioc:DebtInstrumentWithRepaymentPeriodTwoMember bioc:OxfordFinanceLLCMember 2014-04-28 2014-04-30 0001044378 bioc:OxfordFinanceLLCMember 2017-01-01 2017-06-30 0001044378 bioc:OxfordFinanceLLCMember bioc:LoanFacilityOneMember 2016-06-30 0001044378 bioc:OxfordFinanceLLCMember 2017-06-28 0001044378 bioc:OxfordFinanceLLCMember us-gaap:MinimumMember 2014-04-30 0001044378 bioc:OxfordFinanceLLCMember us-gaap:CommonStockMember 2014-04-30 0001044378 bioc:OxfordFinanceLLCMember us-gaap:CommonStockMember 2014-04-28 2014-04-30 0001044378 bioc:OxfordFinanceLLCMember bioc:LoanFacilityOneMember 2014-12-31 0001044378 bioc:OxfordFinanceLLCMember bioc:LoanFacilityOneMember 2014-01-01 2014-12-31 0001044378 bioc:OxfordFinanceLLCMember bioc:LoanFacilityOneMember 2016-12-31 0001044378 bioc:OxfordFinanceLLCMember bioc:LoanFacilityOneMember 2017-06-30 0001044378 us-gaap:MinimumMember us-gaap:AssetsHeldUnderCapitalLeasesMember 2017-01-01 2017-06-30 0001044378 us-gaap:MaximumMember us-gaap:AssetsHeldUnderCapitalLeasesMember 2017-01-01 2017-06-30 0001044378 us-gaap:AssetsHeldUnderCapitalLeasesMember 2016-04-01 2016-06-30 0001044378 us-gaap:AssetsHeldUnderCapitalLeasesMember 2017-04-01 2017-06-30 0001044378 us-gaap:AssetsHeldUnderCapitalLeasesMember 2016-01-01 2016-06-30 0001044378 us-gaap:AssetsHeldUnderCapitalLeasesMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember 2016-07-25 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:NonInducementSharesMember 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:NonInducementSharesMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:InducementSharesMember 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:InducementSharesMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:NonInducementSharesMember 2017-05-01 2017-05-02 0001044378 us-gaap:EmployeeStockOptionMember 2016-12-31 0001044378 us-gaap:EmployeeStockOptionMember 2017-06-30 0001044378 us-gaap:MinimumMember 2017-06-30 0001044378 us-gaap:MaximumMember 2017-06-30 0001044378 us-gaap:MinimumMember 2017-01-01 2017-06-30 0001044378 us-gaap:MaximumMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:ChiefExecutiveOfficerMember us-gaap:EmployeeStockOptionMember 2015-08-31 2015-08-31 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:ChiefExecutiveOfficerMember us-gaap:EmployeeStockOptionMember 2016-02-28 2016-02-29 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:ChiefExecutiveOfficerMember bioc:PerformanceStockOptionsGrantedOnAugust312015Member 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:ChiefExecutiveOfficerMember bioc:PerformanceStockOptionsGrantedOnFebruary292016Member 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:ChiefExecutiveOfficerMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001044378 us-gaap:ChiefFinancialOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2016-07-24 2016-07-25 0001044378 us-gaap:ChiefFinancialOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2016-07-25 0001044378 us-gaap:ChiefFinancialOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2016-07-24 2016-07-25 0001044378 us-gaap:ChiefFinancialOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2016-07-29 0001044378 us-gaap:ChiefFinancialOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2016-07-28 2016-07-29 0001044378 us-gaap:ChiefFinancialOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceStockOptionsGrantedOnJuly292016Member 2017-01-01 2017-06-30 0001044378 us-gaap:ChiefFinancialOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:EmployeesAndExecutiveOfficerMember bioc:PerformanceStockOptionsMember 2017-05-02 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:ChiefExecutiveOfficerMember bioc:PerformanceStockOptionsMember 2017-05-30 2017-05-31 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:ChiefFinancialOfficerMember bioc:PerformanceStockOptionsMember 2017-05-30 2017-05-31 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:ChiefScientificOfficerAndSeniorVicePresidentMember bioc:PerformanceStockOptionsMember 2017-05-30 2017-05-31 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:SeniorMedicalDirectorAndSeniorVicePresidentMember bioc:PerformanceStockOptionsMember 2017-05-30 2017-05-31 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceStockOptionsMember 2017-05-30 2017-05-31 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceStockOptionsMember bioc:AchievementOfCompanySTwoThousandAndSeventeenCorporateGoalsMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceStockOptionsMember bioc:MinimumRevenueInFiscalTwoThousandSeventeenMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceStockOptionsMember bioc:CostOfRevenueReductionsAndImprovementsInFiscalTwoThousandSeventeenMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceStockOptionsMember bioc:IncreaseCashGeneratedFromOperationsInFiscalTwoThousandSeventeenMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceStockOptionsMember bioc:MinimumCashOnHandInFiscalTwoThousandSeventeenMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceStockOptionsMember bioc:MinimumCustomerAgreementsProductLicensingAndProductLaunchInFiscalTwoThousandSeventeenMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceStockOptionsMember bioc:ImplementationOfNewProductsAndUtilityTrialsInFiscalTwoThousandSeventeenMember 2017-01-01 2017-06-30 0001044378 bioc:PerformanceStockOptionsMember 2017-01-01 2017-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2017-06-30 0001044378 us-gaap:ExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:RetentionRestrictedStockUnitsRSUMember 2016-07-05 2016-07-06 0001044378 us-gaap:ChiefExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:RetentionRestrictedStockUnitsRSUMember 2016-07-05 2016-07-06 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:RetentionRestrictedStockUnitsRSUMember 2016-07-05 2016-07-06 0001044378 us-gaap:ChiefFinancialOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2016-07-24 2016-07-25 0001044378 bioc:TimeBasedRestrictedStockUnitsMember us-gaap:ExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2017-05-02 0001044378 bioc:PerformanceBasedRestrictedStockUnitMember us-gaap:ExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2017-05-02 0001044378 bioc:TimeBasedRestrictedStockUnitsMember us-gaap:ChiefExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2017-05-30 2017-05-31 0001044378 bioc:PerformanceBasedRestrictedStockUnitMember us-gaap:ChiefExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2017-05-30 2017-05-31 0001044378 bioc:TimeBasedRestrictedStockUnitsMember bioc:OtherExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2017-05-30 2017-05-31 0001044378 bioc:PerformanceBasedRestrictedStockUnitMember bioc:OtherExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2017-05-30 2017-05-31 0001044378 bioc:TimeBasedRestrictedStockUnitsMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2017-05-31 0001044378 bioc:PerformanceBasedRestrictedStockUnitMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2017-05-31 0001044378 bioc:TimeBasedRestrictedStockUnitsMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2017-01-01 2017-06-30 0001044378 bioc:PerformanceRestrictedStockUnitsMember bioc:AchievementOfCompanySTwoThousandAndSeventeenCorporateGoalsMember bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceRestrictedStockUnitsMember bioc:MinimumRevenueInFiscalTwoThousandSeventeenMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceRestrictedStockUnitsMember bioc:CostOfRevenueReductionsAndImprovementsInFiscalTwoThousandSeventeenMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceRestrictedStockUnitsMember bioc:IncreaseCashGeneratedFromOperationsInFiscalTwoThousandSeventeenMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceRestrictedStockUnitsMember bioc:MinimumCashOnHandInFiscalTwoThousandSeventeenMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceRestrictedStockUnitsMember bioc:MinimumCustomerAgreementsProductLicensingAndProductLaunchInFiscalTwoThousandSeventeenMember 2017-01-01 2017-06-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PerformanceRestrictedStockUnitsMember bioc:ImplementationOfNewProductsAndUtilityTrialsInFiscalTwoThousandSeventeenMember 2017-01-01 2017-06-30 0001044378 bioc:PerformanceRestrictedStockUnitsMember 2017-01-01 2017-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2016-04-01 2016-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2017-04-01 2017-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2016-01-01 2016-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2017-01-01 2017-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2016-04-01 2016-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2016-04-01 2016-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2017-04-01 2017-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-06-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-06-30 0001044378 us-gaap:EmployeeStockOptionMember 2016-04-01 2016-06-30 0001044378 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0001044378 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CostOfSalesMember 2016-04-01 2016-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CostOfSalesMember 2017-04-01 2017-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CostOfSalesMember 2016-01-01 2016-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CostOfSalesMember 2017-01-01 2017-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2016-04-01 2016-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2016-04-01 2016-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2017-04-01 2017-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2016-04-01 2016-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2017-04-01 2017-06-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-06-30 0001044378 bioc:StockOptionsAndRestrictedStockUnitsMember 2017-06-30 0001044378 us-gaap:MinimumMember 2016-01-01 2016-06-30 0001044378 us-gaap:MaximumMember 2016-01-01 2016-06-30 0001044378 us-gaap:WarrantMember 2016-12-31 0001044378 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001044378 us-gaap:WarrantMember 2017-06-30 0001044378 us-gaap:WarrantMember 2016-01-01 2016-12-31 0001044378 bioc:PreferredStockWarrantsMember 2016-04-01 2016-06-30 0001044378 bioc:PreferredStockWarrantsMember 2017-04-01 2017-06-30 0001044378 bioc:WarrantsOutstandingMember 2016-04-01 2016-06-30 0001044378 bioc:WarrantsOutstandingMember 2017-04-01 2017-06-30 0001044378 bioc:CommonStockOptionsOutstandingMember 2016-04-01 2016-06-30 0001044378 bioc:CommonStockOptionsOutstandingMember 2017-04-01 2017-06-30 0001044378 bioc:PreferredStockWarrantsMember 2016-01-01 2016-06-30 0001044378 bioc:PreferredStockWarrantsMember 2017-01-01 2017-06-30 0001044378 bioc:WarrantsOutstandingMember 2016-01-01 2016-06-30 0001044378 bioc:WarrantsOutstandingMember 2017-01-01 2017-06-30 0001044378 bioc:CommonStockOptionsOutstandingMember 2016-01-01 2016-06-30 0001044378 bioc:CommonStockOptionsOutstandingMember 2017-01-01 2017-06-30 0001044378 2016-02-01 2016-02-29 0001044378 bioc:AegeaBiotechnologiesIncMember 2016-01-01 2016-12-31 0001044378 bioc:AegeaBiotechnologiesIncMember 2017-01-01 2017-06-30 0001044378 bioc:SanDiegoCaliforniaFacilityMember bioc:NonExecutiveMember 2017-06-30 0001044378 bioc:SanDiegoCaliforniaFacilityMember bioc:NonExecutiveMember 2017-01-01 2017-06-30 0001044378 bioc:SanDiegoCaliforniaFacilityMember bioc:NonExecutiveMember 2015-01-01 2015-03-31 0001044378 bioc:SanDiegoCaliforniaFacilityMember 2016-01-01 2016-06-30 0001044378 bioc:SanDiegoCaliforniaFacilityMember 2017-01-01 2017-06-30 0001044378 bioc:SanDiegoCaliforniaFacilityMember 2017-01-31 2017-02-01 0001044378 us-gaap:DirectorMember 2016-05-03 2016-05-04 0001044378 us-gaap:DirectorMember 2016-05-04 0001044378 us-gaap:BeneficialOwnerMember 2016-05-03 2016-05-04 0001044378 us-gaap:BeneficialOwnerMember 2016-05-04 0001044378 us-gaap:DirectorMember us-gaap:ChiefExecutiveOfficerMember 2016-10-30 2016-10-31 0001044378 us-gaap:DirectorMember 2016-10-30 2016-10-31 0001044378 us-gaap:DirectorMember 2016-10-31 0001044378 us-gaap:BeneficialOwnerMember 2016-10-30 2016-10-31 0001044378 us-gaap:BeneficialOwnerMember 2016-10-31 0001044378 2016-10-30 2016-10-31 0001044378 bioc:ConsultantMember 2016-10-30 2016-10-31 0001044378 bioc:ConsultantMember 2016-10-31 0001044378 us-gaap:SubsequentEventMember 2017-08-09 0001044378 us-gaap:SubsequentEventMember bioc:AllyBridgeLBHealthcareMasterFundLimitedMember 2017-08-10 2017-08-11 10-Q false 2017-06-30 2017 Q2 BIOC BIOCEPT INC 0001044378 --12-31 Smaller Reporting Company 30253743

4609332

10000155

128969

994746

549045

631210

484649

624827

5771995

12250938

1806331

2402255

7578326

14653193

960486

1777409

1160036

1387767

75691 240913

262674

362777

1934665

1980550

4393552

5749416

778643

794320

1123001

135848

227177 298093

397292

333259

6919665

7310936

1750

2870

174292781

191101115

-173635870

-183761728

658661

7342257

7578326

14653193

0.0001

5000000

0.0001

150000000

28697078

17499397

28697078

17499397

662860

1278961

884229

2962026

1669571

2368705

3144361

4498159

716279

841991

1444355

1599249

1517664

1798026

3004888

3704661

1291709

1746867

2596608

3025178

5195223

6755589

10190212

12827247

-4532363

-5476628

-9305983

-9865221

99720

214377

238160

296903

38412

76824

38412

-61308

-214377

-161336

-258491

-4593671

-5691005

-9467319

-10123712

503

2146

2053

2146

-4594174

-5693151

-9469372

-10125858

7702286

26778549

7134639

23889888

7702286

26778549

7134639

23889888

-0.60

-0.21

-1.33

-0.42

-0.60

-0.21

-1.33

-0.42

157979

226015

37662 28997

699710

756461

32919

6886

52453

865777

109114

53168

-264071

-219444

362648

665882

-163377

204760

36087

81960

-15226

-34762

-8293790

-8947154

323923

527431

-323923

-527431

4657525 8559958

7493035

49061

45012

282207

194400

778303

948173

3547954

14865408

-5069759

5390823

8821329

3751570

187319

225207

2053

2146

1163526

3.90

P5Y 2000000 434475 359622

445386

165516

270377 239994

64300

14032

58066

209107

2160000

2.50

P5Y 2800000 728000

<div> 1. The Company, Business Activities and Basis of Presentation The Company and Business Activities The Company was founded in California in May 1997 and is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Often, traditional methodologies such as tissue biopsies are insufficient or unavailable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays have the potential to provide more contemporaneous information on the characteristics of a patient’s disease compared with traditional methodologies such as tissue biopsy and radiographic imaging. Additionally, the Company’s proprietary blood collection tubes, which allow for the intact transport of research use only liquid biopsy samples from regions around the world, are anticipated to be sold to laboratory supply distributor(s) commencing in the six months ending December 31, 2017. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013. Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2016 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2016, filed with the SEC with our Annual Report on Form 10-K on March 28, 2017 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.   Reverse Stock Split On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares. The one-for-three reverse stock split was effected September 29, 2016. As such, all references to share and per share amounts in the unaudited condensed financial statements and accompanying notes to the unaudited condensed financial statements have been retroactively restated to reflect the one-for-three reverse stock split, except for the authorized number of shares of the Company’s common stock of 150,000,000 shares, which was not affected by the one-for-three reverse stock split. Revenue Recognition and Related Reserves The Company's commercial revenues are generated from diagnostic services provided to physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. The Company recognizes revenue in accordance with the provision of ASC 954-605, Health Care Entities—Revenue Recognition, which requires that four basic criteria must be met prior to recognition of revenue: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. Commencing on March 31, 2017, the Company recognizes commercial revenue related to billings for assays delivered and billed to Medicare and other third-party payers on an accrual basis when amounts that will ultimately be realized can be estimated upon delivery, whereby prior to March 31, 2017, the Company recognized revenues for its commercial diagnostic services on a cash basis as collected because the amounts ultimately expected to be received could not be estimated upon delivery due to insufficient collection history experience. The Company bills third-party payers on a fee-for-service basis at the Company’s list price and third-party commercial revenue is recorded net of contractual discounts, payer-specific allowances and other reserves. The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, as well as certain other diagnostic services provided to physicians. Diagnostic services are completed upon the delivery of assay results to the prescribing physician, at which time the Company bills for the service. The Company’s gross commercial revenues billed are subject to estimated deductions for such contractual discounts, payer-specific allowances and other reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected. These third-party payer discounts and sales allowances are estimated based on a number of assumptions and factors, including historical payment trends, seasonality associated with the annual reset of patient deductible limits on January 1 of each year, and current and estimated future payments. Specifically, the Company maintains four such reserves: the reserve for contractual discounts, the reserve for aged non-patient receivables, the reserve for estimated patient receivables, and the reserve for other payer-specific sales allowances. The reserve for contractual discounts relates to discounts to gross amounts billed to Medicare and contracted third-party payers to arrive at the deemed “allowed expense" amount covered by that payer. The Company’s contracted third-party commercial sales are recorded using an actual or contracted fee schedule at the time of sale, while estimated fee schedules are maintained for each non-contracted payer separately as part of other payer-specific sales allowances. Contractual discounts are recorded at the transaction level at the time of sale based on a fee schedule that is maintained for each contracted third-party payer. The Company periodically adjusts fee schedules for both contracted and non-contracted third-party payers based upon historical payment trends. The reserve for aged non-patient receivables reduces gross amounts billed to non-contracted third-party payers for amounts estimated to be collected according to the age of the outstanding balance. The reserve for estimated patient receivables reduces gross amounts billed to third-party payers for amounts estimated to be collected directly from individual patients, such as copayments, deductibles, or amounts otherwise designated as patient responsibility. The reserve for other payer-specific sales allowances relates to the amounts billed to non-contracted third-party payers that are estimated to not be covered by that specific payer’s coverage policies, as well as estimated necessary adjustments to gross amounts billed based on historical collection experience for a particular third-party payer unrelated to the age of outstanding balances. The estimates of amounts that will ultimately be realized from commercial diagnostic services require significant judgment by management. Patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that they have not met their annual deductible limit under their insurance policy, if any, or if their insurance otherwise declines to reimburse the Company. Adjustments to the estimated payment amounts are recorded at the time of final collection and settlement of each transaction as an adjustment to commercial revenue. The estimation process used to determine third-party payer discounts and sales allowance has been applied on a consistent basis since March 31, 2017, and no subsequent significant adjustments have been necessary to increase or decrease these discounts and allowances as a result of changes in underlying estimates. The composition of the Company’s gross and net revenues recognized during the three and six-months ended June 30, 2016 and 2017 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the six months ended June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial revenues recognized upon delivery</td> <td colspan="2" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  $                —</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,970,630</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  $                —</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,696,596</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development services revenues recognized upon delivery</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,481</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,553</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,329</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,342</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial revenues recognized upon cash collection</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596,379</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,457</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">785,900</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,056,043</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross revenues</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662,860</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,213,640</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,229</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,896,981</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for contractual discounts</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,489,527</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,815,323</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for aged non-patient receivables</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(129,091</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(445,643</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for estimated patient receivables</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,500</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,840</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for other payer-specific sales allowances</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,300,561</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,555,149</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662,860</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,278,961</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,229</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,962,026</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The amount of nonrecurring net revenue recorded during the three and six-months ended June 30, 2017, had the Company commenced recognizing revenue for commercial diagnostic services upon delivery on or prior to December 31, 2016 instead of on March 31, 2017, was $134,915 and $1,012,242, respectively, and the corresponding decrease in net loss per common share was $0.01 and $0.04, respectively. The incremental net revenue and decrease in loss from operations as a result of recognizing revenue on an accrual basis commencing on March 31, 2017, or the total amount of net revenue recorded in excess of the amount of commercial cash collections, was $191,193 and $916,883 during the three and six-months ended June 30, 2017, respectively, and the corresponding decrease in net loss per common share was $0.01 and $0.04, respectively. A summary of activity in the Company’s gross and net accounts receivable balances, as well as corresponding reserves, during the six months ended June 30, 2017 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amounts</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Settlements</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognized</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Upon</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Upon Delivery</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjudication</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, gross</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,969</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,840,938</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,773,573</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,196,334</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for contractual discounts</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,815,323</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">956,314</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,859,009</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for aged non-patient receivables</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(445,643</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,270</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(431,373</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for estimated patient receivables</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,840</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,741</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,099</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for other payer-specific sales allowances</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,555,149</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">749,042</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,806,107</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,969</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,905,983</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,040,206</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994,746</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Concentration of Risk Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types. The Company's third-party payers that represent more than 10% of total net revenues in any period presented, and their related net revenue amount as a percentage of total net revenues, during the three and six-months ended June 30, 2016 and 2017 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the six months ended June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.24%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div> The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at June 30, 2017 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>   Recent Accounting Pronouncements In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or the FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, and may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. As the Company has not yet completed its final review of the impact of the new guidance but expects to during 2017, the Company has not determined whether the adoption of this guidance will have a material impact on its financial statements or disclosures. The Company is still evaluating disclosure requirements under the new guidance, and will continue to evaluate additional changes, modifications or interpretations to the guidance which may impact the current conclusions. The Company expects to adopt the new standard for the fiscal year beginning January 1, 2018 and has not yet determined whether the full or modified retrospective application method will be applied. In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company expects to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently have any equity method investments. In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company anticipates that the adoption of this guidance will materially affect its statement of financial position and will require changes to its processes. The Company has not yet made any decision on the timing of adopting this guidance or the method of adoption with respect to the optional practical expedients, but expects to during 2018. In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require de-designation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In August 2016, the FASB issued authoritative guidance clarifying the classification of certain cash receipts and cash payments in the statement of cash flows. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, on a retrospective transition method to each period presented. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company has not historically engaged in the transactions encompassed by the proposed guidance. In January 2017, the FASB issued authoritative guidance clarifying the definition of a business when evaluating transactions involving acquisitions or disposals of assets or businesses. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Certain applications of this guidance are permitted for early adoption. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company has not historically acquired or disposed of material assets or businesses. In January 2017, the FASB issued authoritative guidance eliminating the “Step 2” requirement for an entity to determine the fair value of its assets and liabilities for goodwill impairment testing in the same manner that would be required for those assumed in a business combination. Instead, the amended guidance allows an entity to perform goodwill impairment testing by comparing the fair value of a reporting unit with its carrying amount. This guidance is effective for any goodwill impairment tests in fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning January 1, 2020, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently have any recorded goodwill. In February 2017, the FASB issued authoritative guidance clarifying the definition of the term “in substance nonfinancial asset” when accounting for transfers of financial and nonfinancial assets, and other matters concerning the transfer, sale and partial sale of nonfinancial assets to both consolidated entities and non-consolidated counterparties. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company has not historically engaged in transfers, sales or partial sales of nonfinancial assets. In March 2017, the FASB issued authoritative guidance shortening the amortization period to the earliest call date for certain purchased callable debt securities held at a premium. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2019, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently hold any callable debt securities. In May 2017, the FASB issued authoritative guidance clarifying what modifications to a share-based payment award may be considered substantive, and therefore requiring the application of modification accounting. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently expect any significant modifications to outstanding share-based payment awards. In July 2017, the FASB issued authoritative guidance changing the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features, whereby a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock, and also clarifying existing disclosure requirements for equity-classified instruments. This guidance is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2020, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently hold any significant financial instruments with down round features. </div>

<div> 7. Equipment Financings The Company leases certain laboratory equipment under arrangements accounted for as capital leases and classified as equipment financings. The financed equipment is depreciated on a straight-line basis over periods ranging from 5 to 7 years. The total gross value of fixed assets capitalized under such financing arrangements was $1,559,690 and $1,725,205 at December 31, 2016 and June 30, 2017, respectively. Total accumulated depreciation related to financed equipment was approximately $525,000 and $629,000 at December 31, 2016 and June 30, 2017, respectively. Total depreciation expense related to financed equipment was approximately $27,000 and $52,000 for the three months ended June 30, 2016 and 2017, respectively. Total depreciation expense related to financed equipment was approximately $53,000 and $108,000 for the six months ended June 30, 2016 and 2017, respectively. Fixed assets purchased totaling $165,516 during the six months ended June 30, 2017 were recorded as equipment financings. The aggregate weighted average effective annual interest rate related to the equipment financings was 13.18% and 13.78% at December 31, 2016 and June 30, 2017, respectively, and the maturity dates on such outstanding arrangements range from July 2017 to May 2023. The following schedule sets forth the remaining future minimum lease payments outstanding under financed equipment arrangements, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred, due within each respective fiscal year ending December 31, as well as the present value of the total amount of remaining minimum lease payments, as of June 30, 2017:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maintenance</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Sales Tax</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Obligation</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,430</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,957</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301,490</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,294</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261,284</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,994</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,105</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,664</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,319</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,055</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">367,769</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,987</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total payments</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,607,397</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">295,951</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.2pt;;text-indent:-9.2pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less amount representing interest</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450,300</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of payments</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,157,097</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">295,951</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> At June 30, 2017, the present value of minimum lease payments due within one year was $362,777.</div>

<div> 8. Stock-Based Compensation Equity Incentive Plans The Company maintains two equity incentive plans: the Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. On July 25, 2016, the Company’s Board of Directors approved an amendment to the 2013 Plan to reserve 333,333 shares of the Company’s common stock exclusively for the grant of stock awards to employees who have not previously been an employee or director of the Company, except following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Company, as defined under applicable Nasdaq Listing Rules. At the Company’s annual meeting of stockholders held on May 2, 2017, the Company’s stockholders approved amendments to the 2013 Plan, which included an increase in the number of non-inducement shares of common stock authorized for issuance under the 2013 Plan by 2,500,000. As of June 30, 2017, under all plans, a total of 3,522,955 non-inducement shares were authorized for issuance, 2,674,028 non-inducement stock options and restricted stock units, or RSUs, had been issued and were outstanding, and 741,614 non-inducement shares were available for grant. As of June 30, 2017, a total of 333,333 inducement shares were authorized for issuance, 158,049 inducement stock options and RSUs had been issued and were outstanding, and 175,284 inducement shares were available for grant under the 2013 Plan. Stock Options A summary of stock option activity for the six months ended June 30, 2017 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per Share</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term in Years</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">896,662</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.80</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,579,399</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.52</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited/expired</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94,902</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.75</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at June 30, 2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,381,159</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.06</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest, June 30, 2017</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,187,470</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.28</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The intrinsic values of options outstanding at December 31, 2016 and June 30, 2017 were zero and $7,623, respectively, and the intrinsic value of options vested and unvested expected to vest at June 30, 2017 was $6,721. The total weighted-average grant date fair value of the 173,157 stock options that vested during the six months ended June 30, 2017 was $6.09.   The assumptions used in the Black-Scholes pricing model for stock options granted during the six months ended June 30, 2017 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock and exercise prices</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.37 – $2.13</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.79% – 2.08%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.12 – 6.09</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.0% - 90.0%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Using the assumptions described above, with stock and exercise prices being equal on date of grant, the weighted-average estimated fair value of options granted in the six months ended June 30, 2017 was $1.04 per share. On August 31, 2015, the Company’s Board of Directors approved the issuance of 33,333 performance stock options with an estimated grant date fair value of $4.40 per share and an exercise price of $6.03 per share to its Chief Executive Officer, or CEO, pursuant to the 2013 Plan. On February 29, 2016, the Company’s Board of Directors approved the issuance of 33,333 performance stock options with an estimated grant date fair value of $2.87 per share and an exercise price of $4.02 per share to its CEO pursuant to the 2013 Plan. Vesting of these stock options was based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors. During the six months ended June 30, 2017, 6,333 of the performance stock options granted on August 31, 2015 and 10,000 of the performance stock options granted on February 29, 2016 were declared vested by the Company’s Board of Directors, and the remaining 50,333 shares underlying these awards were forfeited. On July 25, 2016, the Company entered into an employment agreement with its new Chief Financial Officer, Senior Vice President of Operations and Secretary, or CFO. Pursuant to the terms of this employment agreement, on July 29, 2016 the CFO was granted inducement stock option awards with an exercise price of $1.95 per share to purchase up to (i) 66,666 shares of the Company’s common stock with an estimated grant date fair value of $1.45 per share, 25% of which vested on the one-year anniversary of the commencement of the CFO’s employment with the Company, and remainder of which vest in equal monthly installments over the following three years, and (ii) 33,333 shares of the Company’s common stock with an estimated grant date fair value of $1.26 per share, which vested upon the Company’s achievement of specified corporate goals for 2016 and the consummation of a specified financing transaction. During the six months ended June 30, 2017, 16,383 shares of the performance option award granted on July 29, 2016 were declared vested by the Company’s Board of Directors, and the remaining 16,950 shares underlying this award were forfeited. On May 2, 2017, the Company’s Board of Directors approved the issuance of an aggregate of 550,000 performance stock options to be granted on May 31, 2017 to certain of the Company’s employees and all of its executive officers pursuant to the 2013 Plan, of which 200,000 performance stock options were granted to the Company’s CEO, 100,000 performance stock options were granted to its CFO, and 75,000 performance stock options were granted to each of its Chief Scientific Officer, Senior Vice President and Senior Medical Director, Senior Vice President. Each performance stock option granted on May 31, 2017 has an exercise price of $1.50 per share, an estimated grant date fair value of $0.99 per share, and is subject to vesting as determined by the Company’s Board of Directors based on the achievement of specified corporate goals for 2017, provided that none shall vest unless a minimum level of 70% of the Company’s corporate goals for 2017 are achieved, as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:66.14%;"> <tr> <td style="width:46.11%;"></td> <td style="width:20.03%;"></td> </tr> <tr style="height:12.75pt;"> <td valign="middle">  </td> <td valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage of</td> </tr> <tr style="height:12.75pt;"> <td valign="middle">  </td> <td valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overall Performance Stock</td> </tr> <tr style="height:12.75pt;"> <td valign="middle">  </td> <td valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Grant Subject to</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" style=" border-bottom:solid 0.75pt transparent;">  </td> <td valign="middle" style=" border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting </td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Target</td> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.75pt;"> <td valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum revenue</td> <td valign="middle" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue reductions and improvements</td> <td valign="middle" bgcolor="#CFF0FC" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase cash generated from operations </td> <td valign="middle" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum cash on-hand at December 31, 2017</td> <td valign="middle" bgcolor="#CFF0FC" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:25.5pt;"> <td valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.1pt;;text-indent:-13.5pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum customer agreements, product licensing and product launch</td> <td valign="middle" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC" style=" border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Implementation of new products and utility trials</td> <td valign="middle" bgcolor="#CFF0FC" style=" border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" style=" border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total </td> <td valign="middle" style=" border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</td> </tr> </table></div>   Restricted Stock A summary of RSU activity for the six months ended June 30, 2017 is as follows:     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Grant</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair Value</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2016</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174,249</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.68</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350,000</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.50</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and issued</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,831</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.09</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,500</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.10</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at June 30, 2017</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450,918</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.87</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest, June 30, 2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">408,481</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.91</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> At June 30, 2017, the intrinsic values of RSUs outstanding and RSUs unvested and expected to vest were $617,758 and $559,619, respectively. Of the 450,918 RSUs outstanding at June 30, 2017, 10,920 are fully vested. On July 6, 2016, the Compensation Committee of the Company’s Board of Directors approved retention RSUs for an aggregate of 58,332 shares of common stock to three of the Company’s executive officers pursuant to the 2013 Plan, including retention RSUs for 25,000 shares of common stock to its CEO. Each of these retention RSUs had a grant date fair value of $1.86 per share for a grant date fair value of $108,498 to all three officers, in aggregate. These retention RSUs vested fully on the one-year anniversary of the date of grant, and were subject to continuing service by the holders of such RSUs. Pursuant to the terms of the Company’s employment agreement with its CFO dated July 25, 2016, the CFO was granted an inducement RSU award on July 29, 2016 covering 25,000 shares of the Company’s common stock with a grant date fair value of $1.95 per share, 100% of which vested on the one-year anniversary of the commencement of the CFO’s employment with the Company.   On May 2, 2017, the Company’s Board of Directors approved the issuance of an aggregate of 175,000 time-based RSUs and 175,000 performance RSUs to be granted on May 31, 2017 to certain of the Company’s employees and all of its executive officers pursuant to the 2013 Plan, of which 50,000 time-based RSUs and 25,000 performance RSUs were granted to its CEO, and 25,000 time-based RSUs and 25,000 performance RSUs were granted to each other executive officer. Each RSU granted on May 31, 2017 has a grant date fair value of $1.50 per share. Vesting of the time-based RSUs granted on May 31, 2017 is subject to continuing service and occurs on the one year anniversary of the vesting commencement date, or May 2, 2018, while the performance RSUs are subject to continuous service and vesting is as determined by the Company’s Board of Directors based on the achievement of specified corporate goals for 2017, provided that none shall vest unless a minimum level of 70% of the Company’s corporate goals for 2017 are achieved, as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:65.56%;"> <tr> <td style="width:46.11%;"></td> <td style="width:19.44%;"></td> </tr> <tr style="height:12.75pt;"> <td valign="middle">  </td> <td valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage of</td> </tr> <tr style="height:12.75pt;"> <td valign="middle">  </td> <td valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overall Performance RSU</td> </tr> <tr style="height:12.75pt;"> <td valign="middle">  </td> <td valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Subject to</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" style=" border-bottom:solid 0.75pt transparent;">  </td> <td valign="middle" style=" border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting </td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Target</td> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.75pt;"> <td valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum revenue</td> <td valign="middle" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue reductions and improvements</td> <td valign="middle" bgcolor="#CFF0FC" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase cash generated from operations </td> <td valign="middle" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum cash on-hand at December 31, 2017</td> <td valign="middle" bgcolor="#CFF0FC" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:25.5pt;"> <td valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.1pt;;text-indent:-13.5pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum customer agreements, product licensing and product launch</td> <td valign="middle" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC" style=" border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Implementation of new products and utility trials</td> <td valign="middle" bgcolor="#CFF0FC" style=" border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" style=" border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total </td> <td valign="middle" style=" border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</td> </tr> </table></div> Stock-based Compensation Expense The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented:     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the six months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Options</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,412</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,615</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,487</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,385</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,961</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,172</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,964</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,428</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264,566</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,683</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">537,135</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">349,736</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,897</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,606</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,240</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,146</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses related to stock options</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321,836</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">258,076</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">690,826</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">551,695</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,916</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,133</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,916</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,300</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,452</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,714</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,452</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,072</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,008</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,473</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,008</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,406</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,508</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,843</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,508</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,988</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">330,720</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383,239</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699,710</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">756,461</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 8% per annum during the six months ended June 30, 2016 and 2017. As of June 30, 2017, total unrecognized stock-based compensation expense related to unvested stock options and RSUs, adjusted for estimated forfeitures, was approximately $2,694,000 and is expected to be recognized over a weighted-average period of approximately 2.2 years. </div>

<div> The Company and Business Activities The Company was founded in California in May 1997 and is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Often, traditional methodologies such as tissue biopsies are insufficient or unavailable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays have the potential to provide more contemporaneous information on the characteristics of a patient’s disease compared with traditional methodologies such as tissue biopsy and radiographic imaging. Additionally, the Company’s proprietary blood collection tubes, which allow for the intact transport of research use only liquid biopsy samples from regions around the world, are anticipated to be sold to laboratory supply distributor(s) commencing in the six months ending December 31, 2017. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.</div>

<div> Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2016 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2016, filed with the SEC with our Annual Report on Form 10-K on March 28, 2017 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.  </div>

<div> Reverse Stock Split On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares. The one-for-three reverse stock split was effected September 29, 2016. As such, all references to share and per share amounts in the unaudited condensed financial statements and accompanying notes to the unaudited condensed financial statements have been retroactively restated to reflect the one-for-three reverse stock split, except for the authorized number of shares of the Company’s common stock of 150,000,000 shares, which was not affected by the one-for-three reverse stock split. </div> <div> Revenue Recognition and Related Reserves The Company's commercial revenues are generated from diagnostic services provided to physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. The Company recognizes revenue in accordance with the provision of ASC 954-605, Health Care Entities—Revenue Recognition, which requires that four basic criteria must be met prior to recognition of revenue: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. Commencing on March 31, 2017, the Company recognizes commercial revenue related to billings for assays delivered and billed to Medicare and other third-party payers on an accrual basis when amounts that will ultimately be realized can be estimated upon delivery, whereby prior to March 31, 2017, the Company recognized revenues for its commercial diagnostic services on a cash basis as collected because the amounts ultimately expected to be received could not be estimated upon delivery due to insufficient collection history experience. The Company bills third-party payers on a fee-for-service basis at the Company’s list price and third-party commercial revenue is recorded net of contractual discounts, payer-specific allowances and other reserves. The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, as well as certain other diagnostic services provided to physicians. Diagnostic services are completed upon the delivery of assay results to the prescribing physician, at which time the Company bills for the service. The Company’s gross commercial revenues billed are subject to estimated deductions for such contractual discounts, payer-specific allowances and other reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected. These third-party payer discounts and sales allowances are estimated based on a number of assumptions and factors, including historical payment trends, seasonality associated with the annual reset of patient deductible limits on January 1 of each year, and current and estimated future payments. Specifically, the Company maintains four such reserves: the reserve for contractual discounts, the reserve for aged non-patient receivables, the reserve for estimated patient receivables, and the reserve for other payer-specific sales allowances. The reserve for contractual discounts relates to discounts to gross amounts billed to Medicare and contracted third-party payers to arrive at the deemed “allowed expense" amount covered by that payer. The Company’s contracted third-party commercial sales are recorded using an actual or contracted fee schedule at the time of sale, while estimated fee schedules are maintained for each non-contracted payer separately as part of other payer-specific sales allowances. Contractual discounts are recorded at the transaction level at the time of sale based on a fee schedule that is maintained for each contracted third-party payer. The Company periodically adjusts fee schedules for both contracted and non-contracted third-party payers based upon historical payment trends. The reserve for aged non-patient receivables reduces gross amounts billed to non-contracted third-party payers for amounts estimated to be collected according to the age of the outstanding balance. The reserve for estimated patient receivables reduces gross amounts billed to third-party payers for amounts estimated to be collected directly from individual patients, such as copayments, deductibles, or amounts otherwise designated as patient responsibility. The reserve for other payer-specific sales allowances relates to the amounts billed to non-contracted third-party payers that are estimated to not be covered by that specific payer’s coverage policies, as well as estimated necessary adjustments to gross amounts billed based on historical collection experience for a particular third-party payer unrelated to the age of outstanding balances. The estimates of amounts that will ultimately be realized from commercial diagnostic services require significant judgment by management. Patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that they have not met their annual deductible limit under their insurance policy, if any, or if their insurance otherwise declines to reimburse the Company. Adjustments to the estimated payment amounts are recorded at the time of final collection and settlement of each transaction as an adjustment to commercial revenue. The estimation process used to determine third-party payer discounts and sales allowance has been applied on a consistent basis since March 31, 2017, and no subsequent significant adjustments have been necessary to increase or decrease these discounts and allowances as a result of changes in underlying estimates. The composition of the Company’s gross and net revenues recognized during the three and six-months ended June 30, 2016 and 2017 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the six months ended June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial revenues recognized upon delivery</td> <td colspan="2" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  $                —</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,970,630</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  $                —</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,696,596</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development services revenues recognized upon delivery</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,481</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,553</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,329</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,342</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial revenues recognized upon cash collection</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596,379</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,457</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">785,900</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,056,043</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross revenues</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662,860</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,213,640</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,229</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,896,981</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for contractual discounts</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,489,527</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,815,323</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for aged non-patient receivables</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(129,091</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(445,643</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for estimated patient receivables</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,500</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,840</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for other payer-specific sales allowances</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,300,561</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,555,149</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662,860</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,278,961</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,229</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,962,026</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The amount of nonrecurring net revenue recorded during the three and six-months ended June 30, 2017, had the Company commenced recognizing revenue for commercial diagnostic services upon delivery on or prior to December 31, 2016 instead of on March 31, 2017, was $134,915 and $1,012,242, respectively, and the corresponding decrease in net loss per common share was $0.01 and $0.04, respectively. The incremental net revenue and decrease in loss from operations as a result of recognizing revenue on an accrual basis commencing on March 31, 2017, or the total amount of net revenue recorded in excess of the amount of commercial cash collections, was $191,193 and $916,883 during the three and six-months ended June 30, 2017, respectively, and the corresponding decrease in net loss per common share was $0.01 and $0.04, respectively. A summary of activity in the Company’s gross and net accounts receivable balances, as well as corresponding reserves, during the six months ended June 30, 2017 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amounts</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Settlements</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognized</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Upon</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Upon Delivery</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjudication</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, gross</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,969</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,840,938</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,773,573</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,196,334</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for contractual discounts</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,815,323</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">956,314</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,859,009</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for aged non-patient receivables</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(445,643</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,270</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(431,373</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for estimated patient receivables</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,840</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,741</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,099</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for other payer-specific sales allowances</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,555,149</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">749,042</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,806,107</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,969</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,905,983</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,040,206</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994,746</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Concentration of Risk Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types. The Company's third-party payers that represent more than 10% of total net revenues in any period presented, and their related net revenue amount as a percentage of total net revenues, during the three and six-months ended June 30, 2016 and 2017 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the six months ended June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.24%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div> The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at June 30, 2017 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

<div> The composition of the Company’s gross and net revenues recognized during the three and six-months ended June 30, 2016 and 2017 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the six months ended June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial revenues recognized upon delivery</td> <td colspan="2" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  $                —</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,970,630</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  $                —</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,696,596</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development services revenues recognized upon delivery</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,481</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,553</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,329</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,342</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial revenues recognized upon cash collection</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596,379</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,457</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">785,900</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,056,043</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross revenues</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662,860</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,213,640</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,229</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,896,981</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for contractual discounts</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,489,527</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,815,323</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for aged non-patient receivables</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(129,091</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(445,643</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for estimated patient receivables</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,500</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,840</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions for other payer-specific sales allowances</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,300,561</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,555,149</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662,860</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,278,961</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,229</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,962,026</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> A summary of activity in the Company’s gross and net accounts receivable balances, as well as corresponding reserves, during the six months ended June 30, 2017 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amounts</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Settlements</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognized</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Upon</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Upon Delivery</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjudication</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, gross</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,969</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,840,938</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,773,573</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,196,334</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for contractual discounts</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,815,323</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">956,314</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,859,009</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for aged non-patient receivables</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(445,643</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,270</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(431,373</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for estimated patient receivables</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,840</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,741</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,099</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for other payer-specific sales allowances</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,555,149</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">749,042</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,806,107</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,969</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,905,983</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,040,206</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994,746</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The Company's third-party payers that represent more than 10% of total net revenues in any period presented, and their related net revenue amount as a percentage of total net revenues, during the three and six-months ended June 30, 2016 and 2017 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the six months ended June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.24%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div> The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at June 30, 2017 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

<div> As of the closing of the Company’s March 31, 2017 offering, the estimated grant date fair value of $1.31 per share associated with the warrants to purchase 2,160,000 shares of common stock issued in this offering, or a total of approximately $2.8 million, was recorded as an offset to additional paid-in capital, and was estimated using a Black-Scholes valuation model with the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.13</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.50</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.93</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.0</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

<div> The following provides certain balance sheet details:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</td> <td colspan="6" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,728,468</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,012,178</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,726</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,976</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620,582</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">925,206</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517,968</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523,665</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financed equipment</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,559,690</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,725,205</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in process</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169,896</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,474</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total fixed assets, gross</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,740,330</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,570,704</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,933,999</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,168,449</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total fixed assets, net</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,806,331</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,402,255</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accrued Liabilities</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,776</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,495</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,727</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199,024</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued vacation</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364,953</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498,676</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonuses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">422,868</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448,380</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued sales commissions</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,844</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,354</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of deferred rent</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,085</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,356</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,783</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,482</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,160,036</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,387,767</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following schedule sets forth the remaining future minimum lease payments outstanding under financed equipment arrangements, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred, due within each respective fiscal year ending December 31, as well as the present value of the total amount of remaining minimum lease payments, as of June 30, 2017:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maintenance</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Sales Tax</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Obligation</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,430</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,957</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301,490</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,294</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261,284</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,994</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,105</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,664</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,319</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,055</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">367,769</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,987</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total payments</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,607,397</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">295,951</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.2pt;;text-indent:-9.2pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less amount representing interest</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450,300</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of payments</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,157,097</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">295,951</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> A summary of stock option activity for the six months ended June 30, 2017 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per Share</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term in Years</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">896,662</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.80</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,579,399</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.52</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited/expired</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94,902</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.75</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at June 30, 2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,381,159</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.06</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest, June 30, 2017</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,187,470</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.28</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Each performance stock option granted on May 31, 2017 has an exercise price of $1.50 per share, an estimated grant date fair value of $0.99 per share, and is subject to vesting as determined by the Company’s Board of Directors based on the achievement of specified corporate goals for 2017, provided that none shall vest unless a minimum level of 70% of the Company’s corporate goals for 2017 are achieved, as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:66.14%;"> <tr> <td style="width:46.11%;"></td> <td style="width:20.03%;"></td> </tr> <tr style="height:12.75pt;"> <td valign="middle">  </td> <td valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage of</td> </tr> <tr style="height:12.75pt;"> <td valign="middle">  </td> <td valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overall Performance Stock</td> </tr> <tr style="height:12.75pt;"> <td valign="middle">  </td> <td valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Grant Subject to</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" style=" border-bottom:solid 0.75pt transparent;">  </td> <td valign="middle" style=" border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting </td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Target</td> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.75pt;"> <td valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum revenue</td> <td valign="middle" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue reductions and improvements</td> <td valign="middle" bgcolor="#CFF0FC" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase cash generated from operations </td> <td valign="middle" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum cash on-hand at December 31, 2017</td> <td valign="middle" bgcolor="#CFF0FC" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:25.5pt;"> <td valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.1pt;;text-indent:-13.5pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum customer agreements, product licensing and product launch</td> <td valign="middle" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC" style=" border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Implementation of new products and utility trials</td> <td valign="middle" bgcolor="#CFF0FC" style=" border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" style=" border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total </td> <td valign="middle" style=" border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</td> </tr> </table></div>  </div>

<div> A summary of RSU activity for the six months ended June 30, 2017 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Grant</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair Value</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2016</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174,249</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.68</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350,000</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.50</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and issued</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,831</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.09</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,500</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.10</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at June 30, 2017</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450,918</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.87</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest, June 30, 2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">408,481</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.91</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Vesting of the time-based RSUs granted on May 31, 2017 is subject to continuing service and occurs on the one year anniversary of the vesting commencement date, or May 2, 2018, while the performance RSUs are subject to continuous service and vesting is as determined by the Company’s Board of Directors based on the achievement of specified corporate goals for 2017, provided that none shall vest unless a minimum level of 70% of the Company’s corporate goals for 2017 are achieved, as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:65.56%;"> <tr> <td style="width:46.11%;"></td> <td style="width:19.44%;"></td> </tr> <tr style="height:12.75pt;"> <td valign="middle">  </td> <td valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage of</td> </tr> <tr style="height:12.75pt;"> <td valign="middle">  </td> <td valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overall Performance RSU</td> </tr> <tr style="height:12.75pt;"> <td valign="middle">  </td> <td valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Subject to</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" style=" border-bottom:solid 0.75pt transparent;">  </td> <td valign="middle" style=" border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting </td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Target</td> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.75pt;"> <td valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum revenue</td> <td valign="middle" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue reductions and improvements</td> <td valign="middle" bgcolor="#CFF0FC" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase cash generated from operations </td> <td valign="middle" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum cash on-hand at December 31, 2017</td> <td valign="middle" bgcolor="#CFF0FC" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:25.5pt;"> <td valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.1pt;;text-indent:-13.5pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum customer agreements, product licensing and product launch</td> <td valign="middle" style="white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" bgcolor="#CFF0FC" style=" border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Implementation of new products and utility trials</td> <td valign="middle" bgcolor="#CFF0FC" style=" border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</td> </tr> <tr style="height:12.75pt;"> <td valign="middle" style=" border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:20pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total </td> <td valign="middle" style=" border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</td> </tr> </table></div>  </div>

<div> The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented:     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the six months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Options</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,412</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,615</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,487</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,385</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,961</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,172</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,964</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,428</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264,566</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,683</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">537,135</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">349,736</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,897</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,606</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,240</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,146</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses related to stock options</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321,836</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">258,076</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">690,826</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">551,695</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,916</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,133</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,916</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,300</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,452</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,714</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,452</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,072</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,008</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,473</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,008</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,406</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,508</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,843</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,508</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,988</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">330,720</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383,239</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699,710</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">756,461</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> A summary of equity-classified common stock warrant activity for the six months ended June 30, 2017 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per Share</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term in Years</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.75pt;;text-indent:-6.9pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2016</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,623,987</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.93</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,160,000</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.50</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,811,850</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.10</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at June 30, 2017</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,972,137</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.92</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.82%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three and six-months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.82%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.82%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.25pt;;text-indent:-9.25pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred warrants outstanding (number of common stock equivalents)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">529</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">529</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common warrants outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,896,856</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,972,137</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,756</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450,918</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.82%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common options outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">731,400</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,381,159</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.82%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total anti-dilutive common share equivalents</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,715,541</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,804,743</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The estimated grant date fair value of these warrants of approximately $1.03 per share, or a total of approximately $1.5 million, was recorded as an offset to additional paid-in capital upon the closing of this offering, and was estimated using Black-Scholes valuation models with the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.50</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.81</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.0</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

0.33

40000000

150000000

3970630 8696596 66481 83553 98329 144342 596379 159457 785900 1056043

662860

4213640

884229

9896981

1489527 2815323 129091 445643 15500 118840 1300561 3555149 134915 1012242 0.01 0.04 191193 916883 0.01 0.04 128969 128969 8840938 -2815323 -445643 -118840 -3555149 1905983 -2773573 956314 14270 13741 749042 -1040206 6196334 -1859009 -431373 -105099 -2806107 994746

0.47

0.45

0.44

0.39

0.08

0.15

0.09

0.18

0.09

0.18

0.11

0.26

0.24

0.12

-18400000

3800000 2600000 3200000

1062500

62500 Quarterly

2020-05-31

628760

50000000 75000000 4300000

4500000 3.90 2021-05 9000000 8600000

5400000 2.50 2022-03

7500000

3200000 1.10 2021-10 2160000 Warrant proceeds remaining outstanding and available to be exercised at $2.50 per share commencing on the six month anniversary of the closing of the offering, or September 30, 2017, until their expiration in March 2022. 2000000

2200000

1.50

2022-08

15000000

P30M

208334

4.80

1000000

55000

173145

544051

42000

79000

1400000

50000000 2016-04-25 2016-04-29 1662191 1163526

3.00

3.90

P5Y 2000000

700000

4500000

2017-03-28

4320000

2160000

2.15

2800000

2.50

P5Y Exercisable beginning on the six-month anniversary of the date of issuance, and expire five years from the date first exercisable.

700000

8600000 P1Y

9100000

1.10

5200000 P30D 1365000 1.0331 1365000

0.0009

627131

564

800000

1.10

P5Y

1000000

7500000

16500000

1466667

1434639

1.50

2200000

1.31

2.13

2.50

0.0000

0.0193

P5Y

0.800

1.03

1.5

2728468

3012178

143726

147976

620582 925206

517968

523665

1559690

1725205

169896

236474

5740330

6570704

3933999

4168449

20776

14495

168727

199024

364953

498676

422868

448380

77844

67354

67085

96356

37783

63482

4898000

50000

0.0795

0.0771

0.0795

0.055 0.01 50000

1200000

3000000

250000 250000

17655

14.16

P10Y

102498

4897502 233107

78408

71503

0.1387

986492

1201409

P5Y

P7Y

525000

629000

27000

52000

53000

108000

0.1318 0.1378 2017-07 2023-05

236430

301490

261284

223105

217319

367769

1607397

450300

1157097

15957 57294 64994 47664 43055 66987 295951 295951 362777 2

333333

3522955

2674028

741614

333333

158049

175284

2500000

896662

1579399

94902

2381159

2187470

8.80

1.52

5.75

4.06

4.28

P8Y6M

P9Y1M6D

7623

6721

173157

6.09

Black-Scholes pricing model

1.37

2.13

0.0000

0.0179 0.0208

P5Y1M13D

P6Y1M2D

0.800

0.900

1.04

33333

4.40

6.03

33333

2.87

4.02

6333

10000

50333

1.95

66666

1.45

0.25

P1Y

P3Y

33333

1.26

16383

16950

550000

200000

100000

75000

0.99

1.50

0.70

0.20

0.15

0.20

0.15

1.00

174249

350000

65831

7500

450918

408481

2.68

1.50

2.09

2.10

1.87

1.91

617758

559619

10920

58332

25000

1.86

108498

P1Y

25000

1.95

1.00

P1Y

175000

50000

25000

1.50

P1Y

0.70

0.20

0.15

0.20

0.15

1.00

29412

41615

55487

73385

25961

39172

58964

68428

264566

157683

537135

349736

1897

19606

39240

60146

321836

258076

690826

551695

1916

23133

1916

38300

1452

22714

1452

37072

1008

56473

1008

86406

4508

22843

4508

42988

330720

383239

699710

756461

2694000

P2Y2M12D

0.00 0.00 0.08 0.08

11623987

2160000 6811850

6972137

1.93 2.50 1.10 2.92 P4Y7M6D P4Y3M19D P5Y

2017-09-30

P6M 787126 P5Y

529

1896856

6972137

86756

450918

731400

2381159

2715541

9804743

529

1896856

6972137

86756

450918

731400

2381159

2715541

9804743

62500 19047 15325

9849

2015-03-30 12804

12804

2015-07-31

76824

38412

2017-03-31

58335

40832

175000

0.10

204758

143330

614273

7 3

534088

587497

0.10

227272

249999

79090

86999

1500000

1.39

1.50

0.0000

0.0181

P5Y

1.000

2000000

200000

EX-101.SCH 8 bioc-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Statements of Cash Flows (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - The Company, Business Activities and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Liquidity and Going Concern Uncertainty link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Sales of Equity Securities link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Fair Value Measurement link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Balance Sheet Details link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - April 2014 Credit Facility link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Equipment Financings link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Common Stock Warrants Outstanding link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Net Loss per Common Share link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - The Company, Business Activities and Basis of Presentation (Policies) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - The Company, Business Activities and Basis of Presentation (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Fair Value Measurement (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Balance Sheet Details (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Equipment Financings (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Common Stock Warrants Outstanding (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Net Loss per Common Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Subsequent Events (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - The Company, Business Activities and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - The Company, Business Activities and Basis of Presentation - Composition of Gross and Net Revenues Recognized (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - The Company, Business Activities and Basis of Presentation - Summary of Activity in Gross and Net Accounts Receivable Balances and Reserves (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - The Company, Business Activities and Basis of Presentation - Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Liquidity and Going Concern Uncertainty- Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Sales of Equity Securities - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Fair Value Measurement - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - April 2014 Credit Facility - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Equipment Financings - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Equipment Financings - Schedule of Remaining Future Minimum Lease Payments for Financed Equipment Obligations (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Stock-Based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Stock-Based Compensation - Schedule of Percentage Of Overall Performance Grant Subject To Vesting (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Stock-Based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Common Stock Warrants Outstanding - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Net Loss per Common Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Subsequent Events - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 bioc-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 bioc-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 bioc-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document and entity information. Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Supplier financings. Carrying value as of the balance sheet date of noncurrent portion of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Statement Of Financial Position [Abstract] Current assets: Assets Current [Abstract] Cash Cash Accounts receivable, net Accounts Receivable Net Current Inventories, net Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Fixed assets, net Property Plant And Equipment Net Total assets Assets Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued liabilities Accrued Liabilities Current Supplier financings Supplier Financings Current portion of equipment financings Capital Lease Obligations Current Current portion of credit facility, net Lines Of Credit Current Total current liabilities Liabilities Current Non-current portion of equipment financings Capital Lease Obligations Noncurrent Non-current portion of credit facility, net Long Term Line Of Credit Non-current portion of interest payable Interest Payable Noncurrent Non-current portion of deferred rent Deferred Rent Credit Noncurrent Total liabilities Liabilities Commitments and contingencies (see Note 11) Commitments And Contingencies Shareholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.0001 par value, 5,000,000 authorized; no shares issued and outstanding at December 31, 2016 and June 30, 2017. Preferred Stock Value Common stock, $0.0001 par value, 150,000,000 authorized; 17,499,397 issued and outstanding at December 31, 2016; 28,697,078 issued and outstanding at June 30, 2017. Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total shareholders’ equity Stockholders Equity Total liabilities and shareholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Net revenues Revenues Costs and expenses: Costs And Expenses [Abstract] Cost of revenues Cost Of Revenue Research and development expenses Research And Development Expense General and administrative expenses General And Administrative Expense Sales and marketing expenses Selling And Marketing Expense Total costs and expenses Costs And Expenses Loss from operations Operating Income Loss Other income/ (expense): Nonoperating Income Expense [Abstract] Interest expense Interest Expense Other income Other Income Total other income/ (expense): Nonoperating Income Expense Loss before income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax expense Income Tax Expense Benefit Net loss and comprehensive loss Net Income Loss Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders: Weighted Average Number Of Shares Outstanding [Abstract] Basic Weighted Average Number Of Shares Outstanding Basic Diluted Weighted Average Number Of Diluted Shares Outstanding Net loss per common share: Earnings Per Share [Abstract] Basic Earnings Per Share Basic Diluted Earnings Per Share Diluted Increase decrease in inventory reserve. Proceeds from issuance of common stock and warrants. Cash paid during period. Statement Of Cash Flows [Abstract] Cash Flows from Operating Activities Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation And Amortization Inventory reserve Increase Decrease In Inventory Reserve Stock-based compensation Share Based Compensation Non-cash interest expense related to credit facility and other financing activities Paid In Kind Interest Increase/ (decrease) in cash resulting from changes in: Increase Decrease In Operating Capital [Abstract] Accounts receivable, net Increase Decrease In Accounts Receivable Inventory Increase Decrease In Inventories Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued liabilities Increase Decrease In Accrued Liabilities Accrued interest Increase Decrease In Interest Payable Net Deferred rent Increase Decrease In Deferred Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash Flows from Investing Activities: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Purchases of fixed assets Payments To Acquire Property Plant And Equipment Net cash used in investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash Flows from Financing Activities: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Net proceeds from issuance of common stock and warrants Proceeds From Issuance Of Common Stock And Warrants Proceeds from exercise of common stock warrants Proceeds From Warrant Exercises Payments on equipment financings Repayments Of Long Term Capital Lease Obligations Payments on supplier and other third-party financings Repayments Of Other Debt Payments on credit facility Repayments Of Lines Of Credit Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Net increase/ (decrease) in Cash Cash Period Increase Decrease Cash at Beginning of Period Cash at End of Period Supplemental Disclosures of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Cash paid during the period for: Cash Paid During Period [Abstract] Interest Interest Paid Net Income taxes Income Taxes Paid Net Class of warrant or right expiry period. Unregistered warrants issued grant date fair value. Issuance of unregistered warrants to purchase shares of common stock Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Exercise price of unregistered warrants Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Unregistered warrants to purchase common stock, period Class Of Warrant Or Right Expiry Period Issuance of unregistered warrants to purchase shares of common stock, grant date fair value Unregistered Warrants Issued Grant Date Fair Value Financial Guarantee Insurance Contracts Premium Payable. Financed insurance premium through third party financing Financial Guarantee Insurance Contracts Premium Payable Aggregate net book value of fixed assets. Equipment financings with remaining outstanding balances. Fixed assets purchased under capital lease obligations Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 Fixed assets with an aggregate net book value Aggregate Net Book Value Of Fixed Assets Equipment financings with remaining outstanding balances Equipment Financings With Remaining Outstanding Balances Purchases of fixed assets Capital Expenditures Incurred But Not Yet Paid Offering fees and costs recorded within common stock issuance costs as an offset to additional paid in capital. Issuance of unregistered warrants to purchase common stock shares. Issuance of unregistered warrants to purchase shares of common stock Issuance Of Unregistered Warrants To Purchase Common Stock Shares Offering fees and costs recorded within common stock issuance costs as an offset to additional paid in capital Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital Accounting Policies [Abstract] The Company, Business Activities and Basis of Presentation Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Text Block] Liquidity and Going Concern Uncertainty Substantial Doubt About Going Concern [Text Block] Sales of equity securities. Equity [Abstract] Sales of Equity Securities Sales Of Equity Securities Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurement Fair Value Disclosures [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Credit facility disclosure. Debt Disclosure [Abstract] April 2014 Credit Facility Credit Facility Disclosure [Text Block] Capital Lease Obligations [Abstract] Equipment Financings Capital Leases In Financial Statements Of Lessor Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Common stock warrants outstanding disclosure. Other Liabilities Disclosure [Abstract] Common Stock Warrants Outstanding Common Stock Warrants Outstanding Disclosure [Text Block] Net Loss per Common Share Earnings Per Share [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Nature of operations. The Company and Business Activities Nature Of Operations Policy [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Reverse stock split policy. Reverse Stock Split Reverse Stock Split Policy Policy [Text Block] Revenue recognition and related reserves. Revenue Recognition and Related Reserves Revenue Recognition And Related Reserves Policy [Text Block] Concentration of Risk Concentration Risk Credit Risk Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Schedule of composition of gross and net revenues recognized. Composition of Gross and Net Revenues Recognized Schedule Of Composition Of Gross And Net Revenues Recognized Table [Text Block] Schedule of activity in gross and net accounts receivable balance and reserves. Summary of Activity in Gross and Net Accounts Receivable Balances and Reserves Schedule Of Activity In Gross And Net Accounts Receivable Balance And Reserves Table [Text Block] Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage Schedules Of Concentration Of Risk By Risk Factor [Text Block] Assumptions Used for Determining Fair Values of Common Stock Warrants Fair Value Inputs Instruments Classified In Shareholders Equity Quantitative Information Table [Text Block] Schedule of Fixed Assets and Accrued Liabilities Schedule Of Condensed Balance Sheet Table [Text Block] Schedule of Remaining Future Minimum Lease Payments for Financed Equipment Obligations Schedule Of Future Minimum Lease Payments For Capital Leases Table [Text Block] Statement [Table] Statement [Table] Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Stock Options [Member] Employee Stock Option [Member] RSUs [Member] Restricted Stock Units R S U [Member] Statement [Line Items] Statement [Line Items] Summary of Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Schedule of percentage of overall performance grant subject to vesting. Schedule of Percentage Of Overall Performance Grant Subject To Vesting Schedule Of Percentage Of Overall Performance Grant Subject To Vesting Table [Text Block] Summary of RSU Activity Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of common stock warrants activity. Equity classified warrants. Equity Classified Warrants [Abstract] Summary of Equity-Classified Common Stock Warrant Activity Schedule Of Common Stock Warrants Activity Table [Text Block] Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Subsequent Event [Table] Subsequent Event [Table] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Ally Bridge LB Healthcare Master Fund Limited. Ally Bridge [Member] Ally Bridge L B Healthcare Master Fund Limited [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] The company, business activities and basis of presentation. The company, business activities and basis of presentation. The Company Business Activities And Basis Of Presentation [Table] The Company Business Activities And Basis Of Presentation [Table] Range Range [Axis] Range Range [Member] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Products and Services Product Or Service [Axis] Products and Services Products And Services [Domain] Commercial diagnostic services. Commercial Diagnostic Services [Member] Commercial Diagnostic Services [Member] The Company, Business Activities and Basis of Presentation [Line Items] The Company Business Activities And Basis Of Presentation [Line Items] Stockholders equity reverse stock split ratio Stockholders Equity Note Stock Split Conversion Ratio1 Description of reverse stock split Stockholders Equity Reverse Stock Split Commercial revenues recognized upon delivery gross. Development services revenues recognized upon delivery gross. Commercial revenues recognized upon cash collection gross. Provisions for contractual discounts. Provisions for aged non-patient receivables. Provisions for estimated patient receivables. Provisions for other payer-specific sales allowances. Revenue Recognition [Abstract] Commercial revenues recognized upon delivery Commercial Revenues Recognized Upon Delivery Gross Development services revenues recognized upon delivery Development Services Revenues Recognized Upon Delivery Gross Commercial revenues recognized upon cash collection Commercial Revenues Recognized Upon Cash Collection Gross Total gross revenues Sales Revenue Goods Gross Provisions for contractual discounts Provisions For Contractual Discounts Provisions for aged non-patient receivables Provisions For Aged Non Patient Receivables Provisions for estimated patient receivables Provisions For Estimated Patient Receivables Provisions for other payer-specific sales allowances Provisions For Other Payer Specific Sales Allowances Net revenues Net revenue recorded in excess of commercial cash collections. Increase decrease in net income loss per common share. Nonrecurring net revenue recognized upon delivery. EX-101.PRE 12 bioc-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 10, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Trading Symbol	BIOC
Entity Registrant Name	BIOCEPT INC
Entity Central Index Key	0001044378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		30,253,743

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash	$ 10,000,155	$ 4,609,332
Accounts receivable, net	994,746	128,969
Inventories, net	631,210	549,045
Prepaid expenses and other current assets	624,827	484,649
Total current assets	12,250,938	5,771,995
Fixed assets, net	2,402,255	1,806,331
Total assets	14,653,193	7,578,326
Current liabilities:
Accounts payable	1,777,409	960,486
Accrued liabilities	1,387,767	1,160,036
Supplier financings	240,913	75,691
Current portion of equipment financings	362,777	262,674
Current portion of credit facility, net	1,980,550	1,934,665
Total current liabilities	5,749,416	4,393,552
Non-current portion of equipment financings	794,320	778,643
Non-current portion of credit facility, net	135,848	1,123,001
Non-current portion of interest payable	298,093	227,177
Non-current portion of deferred rent	333,259	397,292
Total liabilities	7,310,936	6,919,665
Commitments and contingencies (see Note 11)
Shareholders’ equity:
Preferred stock, $0.0001 par value, 5,000,000 authorized; no shares issued and outstanding at December 31, 2016 and June 30, 2017.
Common stock, $0.0001 par value, 150,000,000 authorized; 17,499,397 issued and outstanding at December 31, 2016; 28,697,078 issued and outstanding at June 30, 2017.	2,870	1,750
Additional paid-in capital	191,101,115	174,292,781
Accumulated deficit	(183,761,728)	(173,635,870)
Total shareholders’ equity	7,342,257	658,661
Total liabilities and shareholders’ equity	$ 14,653,193	$ 7,578,326

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	28,697,078	17,499,397
Common stock, shares outstanding	28,697,078	17,499,397

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Net revenues	$ 1,278,961	$ 662,860	$ 2,962,026	$ 884,229
Costs and expenses:
Cost of revenues	2,368,705	1,669,571	4,498,159	3,144,361
Research and development expenses	841,991	716,279	1,599,249	1,444,355
General and administrative expenses	1,798,026	1,517,664	3,704,661	3,004,888
Sales and marketing expenses	1,746,867	1,291,709	3,025,178	2,596,608
Total costs and expenses	6,755,589	5,195,223	12,827,247	10,190,212
Loss from operations	(5,476,628)	(4,532,363)	(9,865,221)	(9,305,983)
Other income/ (expense):
Interest expense	(214,377)	(99,720)	(296,903)	(238,160)
Other income		38,412	38,412	76,824
Total other income/ (expense):	(214,377)	(61,308)	(258,491)	(161,336)
Loss before income taxes	(5,691,005)	(4,593,671)	(10,123,712)	(9,467,319)
Income tax expense	(2,146)	(503)	(2,146)	(2,053)
Net loss and comprehensive loss	$ (5,693,151)	$ (4,594,174)	$ (10,125,858)	$ (9,469,372)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic	26,778,549	7,702,286	23,889,888	7,134,639
Diluted	26,778,549	7,702,286	23,889,888	7,134,639
Net loss per common share:
Basic	$ (0.21)	$ (0.60)	$ (0.42)	$ (1.33)
Diluted	$ (0.21)	$ (0.60)	$ (0.42)	$ (1.33)

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash Flows from Operating Activities
Net loss	$ (10,125,858)	$ (9,469,372)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	226,015	157,979
Inventory reserve	(28,997)	(37,662)
Stock-based compensation	756,461	699,710
Non-cash interest expense related to credit facility and other financing activities	6,886	32,919
Increase/ (decrease) in cash resulting from changes in:
Accounts receivable, net	(865,777)	(52,453)
Inventory	(53,168)	(109,114)
Prepaid expenses and other current assets	219,444	264,071
Accounts payable	665,882	362,648
Accrued liabilities	204,760	(163,377)
Accrued interest	81,960	36,087
Deferred rent	(34,762)	(15,226)
Net cash used in operating activities	(8,947,154)	(8,293,790)
Cash Flows from Investing Activities:
Purchases of fixed assets	(527,431)	(323,923)
Net cash used in investing activities	(527,431)	(323,923)
Cash Flows from Financing Activities:
Net proceeds from issuance of common stock and warrants	8,559,958	4,657,525
Proceeds from exercise of common stock warrants	7,493,035
Payments on equipment financings	(45,012)	(49,061)
Payments on supplier and other third-party financings	(194,400)	(282,207)
Payments on credit facility	(948,173)	(778,303)
Net cash provided by financing activities	14,865,408	3,547,954
Net increase/ (decrease) in Cash	5,390,823	(5,069,759)
Cash at Beginning of Period	4,609,332	8,821,329
Cash at End of Period	10,000,155	3,751,570
Cash paid during the period for:
Interest	225,207	187,319
Income taxes	$ 2,146	$ 2,053

XML 18 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)		6 Months Ended		12 Months Ended
	Mar. 31, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Statement Of Cash Flows [Abstract]
Exercise price of unregistered warrants	$ 2.50
Unregistered warrants to purchase common stock, period	5 years
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value	$ 2,800,000
Financed insurance premium through third party financing		$ 359,622	$ 434,475
Fixed assets purchased under capital lease obligations		165,516	445,386
Fixed assets with an aggregate net book value			270,377
Equipment financings with remaining outstanding balances			239,994
Purchases of fixed assets		$ 209,107	$ 14,032	$ 58,066	$ 64,300
Issuance of unregistered warrants to purchase shares of common stock	2,160,000
Offering fees and costs recorded within common stock issuance costs as an offset to additional paid in capital	$ 728,000

XML 19 R7.htm IDEA: XBRL DOCUMENT

The Company, Business Activities and Basis of Presentation

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

The Company, Business Activities and Basis of Presentation

1. The Company, Business Activities and Basis of Presentation

The Company and Business Activities

Basis of Presentation

The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America.

Reverse Stock Split

Revenue Recognition and Related Reserves

The Company's commercial revenues are generated from diagnostic services provided to physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. The Company recognizes revenue in accordance with the provision of ASC 954-605, Health Care Entities—Revenue Recognition, which requires that four basic criteria must be met prior to recognition of revenue: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. Commencing on March 31, 2017, the Company recognizes commercial revenue related to billings for assays delivered and billed to Medicare and other third-party payers on an accrual basis when amounts that will ultimately be realized can be estimated upon delivery, whereby prior to March 31, 2017, the Company recognized revenues for its commercial diagnostic services on a cash basis as collected because the amounts ultimately expected to be received could not be estimated upon delivery due to insufficient collection history experience.

The composition of the Company’s gross and net revenues recognized during the three and six-months ended June 30, 2016 and 2017 is as follows:

	For the three months ended June 30,					For the six months ended June 30,
	2016		2017			2016		2017
Commercial revenues recognized upon delivery	$ —		$	3,970,630		$ —		$	8,696,596
Development services revenues recognized upon delivery		66,481		83,553			98,329		144,342
Commercial revenues recognized upon cash collection		596,379		159,457			785,900		1,056,043
Total gross revenues		662,860		4,213,640			884,229		9,896,981
Provisions for contractual discounts		—		(1,489,527	)		—		(2,815,323	)
Provisions for aged non-patient receivables		—		(129,091	)		—		(445,643	)
Provisions for estimated patient receivables		—		(15,500	)		—		(118,840	)
Provisions for other payer-specific sales allowances		—		(1,300,561	)		—		(3,555,149	)
Net revenues	$	662,860	$	1,278,961		$	884,229	$	2,962,026

The amount of nonrecurring net revenue recorded during the three and six-months ended June 30, 2017, had the Company commenced recognizing revenue for commercial diagnostic services upon delivery on or prior to December 31, 2016 instead of on March 31, 2017, was $134,915 and $1,012,242, respectively, and the corresponding decrease in net loss per common share was $0.01 and $0.04, respectively. The incremental net revenue and decrease in loss from operations as a result of recognizing revenue on an accrual basis commencing on March 31, 2017, or the total amount of net revenue recorded in excess of the amount of commercial cash collections, was $191,193 and $916,883 during the three and six-months ended June 30, 2017, respectively, and the corresponding decrease in net loss per common share was $0.01 and $0.04, respectively.

A summary of activity in the Company’s gross and net accounts receivable balances, as well as corresponding reserves, during the six months ended June 30, 2017 is as follows:

	Balance at		Amounts			Settlements			Balance at
	December 31,		Recognized			Upon			June 30,
	2016		Upon Delivery			Adjudication			2017
Accounts receivable, gross	$	128,969	$	8,840,938		$	(2,773,573	)	$	6,196,334
Reserve for contractual discounts		—		(2,815,323	)		956,314			(1,859,009	)
Reserve for aged non-patient receivables		—		(445,643	)		14,270			(431,373	)
Reserve for estimated patient receivables		—		(118,840	)		13,741			(105,099	)
Reserve for other payer-specific sales allowances		—		(3,555,149	)		749,042			(2,806,107	)
Accounts receivable, net	$	128,969	$	1,905,983		$	(1,040,206	)	$	994,746

Concentration of Risk

	For the three months ended June 30,						For the six months ended June 30,
	2016			2017			2016			2017
Medicare and Medicare Advantage		47	%		45	%		44	%		39	%
Blue Cross Blue Shield		8	%		15	%		9	%		18	%
United Healthcare		18	%		9	%		18	%		11	%

Medicare and Medicare Advantage	26	%
Blue Cross Blue Shield	24	%
United Healthcare	12	%

Recent Accounting Pronouncements

In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures.

XML 20 R8.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern Uncertainty	6 Months Ended
Liquidity and Going Concern Uncertainty	Jun. 30, 2017
Accounting Policies [Abstract]
Liquidity and Going Concern Uncertainty	2. Liquidity and Going Concern Uncertainty As of June 30, 2017, cash totaled $10.0 million and the Company had an accumulated deficit of $183.8 million. For the year and six-month periods ended December 31, 2016 and June 30, 2017, the Company incurred net losses of $18.4 million and $10.1 million, respectively. At June 30, 2017, the Company had aggregate net interest-bearing indebtedness of $3.8 million, of which $2.6 million was due within one year in the absence of subjective acceleration of amounts due under a credit facility entered into in April 2014 with Oxford Finance LLC, or the April 2014 Credit Facility, in addition to $3.2 million of other non-interest bearing current liabilities. Additionally, in February 2016, the Company signed a firm, non-cancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly installments of $62,500 through May 2020, under which $628,760 remained outstanding at June 30, 2017 (see Note 11). These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these unaudited condensed financial statements were issued. The accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern. The unaudited condensed financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses for the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. A public offering of the Company’s common stock and warrants to purchase its common stock closed on May 4, 2016, pursuant to which the Company received net cash proceeds of approximately $4.3 million (see Note 3). Subsequent to the closing of this offering on May 4, 2016, no warrants sold in this offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. A second offering of the Company’s common stock was effected under this shelf registration statement on March 28, 2017, the closing of which occurred on March 31, 2017, pursuant to which the Company received net cash proceeds of approximately $8.6 million (see Note 3). In a concurrent private placement, the Company sold unregistered warrants to purchase up to 2,160,000 shares of the Company’s common stock that closed concurrently with the March 31, 2017 offering of common stock sold pursuant to this shelf registration statement. Subsequent to the closing of the sales of these unregistered warrants, no warrants sold have been exercised, with $5.4 million in gross warrant proceeds remaining outstanding and available to be exercised at $2.50 per share commencing on the six month anniversary of the closing of the offering, or September 30, 2017, until their expiration in March 2022. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. A public offering of the Company’s common stock and warrants to purchase its common stock was effected under an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, the closing of which occurred on October 19, 2016, pursuant to which the Company received net cash proceeds of approximately $9.0 million (see Note 3). Subsequent to the closing of this offering, cash proceeds of approximately $7.5 million have been received from the exercise of warrants sold in this offering, while approximately $3.2 million in gross warrant proceeds remain outstanding and available to be exercised at $1.10 per share until their expiration in October 2021. Pursuant to a common stock and warrant purchase agreement dated August 9, 2017 between the Company and Ally Bridge, the Company received net cash proceeds of approximately $2.0 million as a result of the sale of its common stock and warrants. Subsequent to August 9, 2017, no additional cash proceeds had been received from the exercise of warrants sold in this offering, with approximately $2.2 million in gross warrant proceeds remaining outstanding and available to be exercised at $1.50 per share until their expiration in August 2022. Management’s Plan to Continue as a Going Concern In order to continue as a going concern, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all.

XML 21 R9.htm IDEA: XBRL DOCUMENT

Sales of Equity Securities	6 Months Ended
Sales of Equity Securities	Jun. 30, 2017
Equity [Abstract]
Sales of Equity Securities	3. Sales of Equity Securities On December 21, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC, or Aspire Capital, which committed to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock over the 30-month term of the common stock purchase agreement. On November 4, 2016, the Company voluntarily terminated this common stock purchase agreement. Upon execution of the common stock purchase agreement, the Company sold to Aspire Capital 208,334 shares of common stock at $4.80 per share for proceeds of $1,000,000, and concurrently also entered into a registration rights agreement with Aspire Capital, pursuant to which the Company filed a registration statement registering the sale of the shares of the Company’s common stock that were issued to Aspire Capital under the common stock purchase agreement. In consideration for entering into, and concurrently with the execution of, the common stock purchase agreement, the Company issued to Aspire Capital 55,000 shares of its common stock. The proceeds received by the Company under the common stock purchase agreement were used for working capital and general corporate purposes. During the year ended December 31, 2016, the Company submitted purchase notices to Aspire Capital for an aggregate of 173,145 shares of common stock for gross proceeds of $544,051. Costs associated with this offering of approximately $42,000 and $79,000 during the years ended December 31, 2015 and 2016, respectively, were also recorded to common stock issuance costs under applicable accounting guidance, and as such, the total net increase in capital related to these transactions was approximately $1.4 million. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. Pursuant to an exclusive placement agent agreement dated April 25, 2016 between the Company and H.C. Wainwright & Co., LLC, and a securities purchase agreement dated April 29, 2016 between the Company and the purchasers signatory thereto, a public offering of 1,662,191 shares of the Company’s common stock and warrants to purchase up to an aggregate of 1,163,526 shares of common stock was effected under this registration statement at a combined offering price of $3.00. All warrants sold in this offering have a per share exercise price of $3.90, are exercisable immediately and expire five years from the date of issuance. The estimated grant date fair value of these warrants of approximately $2.0 million was recorded as an offset to additional paid-in capital upon the closing of this offering. The closing of the sale of these securities to the purchasers occurred on May 4, 2016, pursuant to which the Company received, after deducting $0.7 million of costs directly associated with the offering that were recorded as an offset to additional paid-in capital under applicable accounting guidance, approximately $4.3 million of net cash proceeds. Subsequent to the closing of this offering on May 4, 2016, no warrants sold in this offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. Pursuant to an exclusive placement agent agreement dated March 28, 2017 between the Company and Roth Capital Partners, LLC as lead placement agent, and WestPark Capital and Chardan Capital as co-placement agents, a securities purchase agreement for a second offering of 4,320,000 shares of the Company’s common stock was effected under this registration statement at per share price of $2.15, which closed on March 31, 2017. In a concurrent private placement, the Company sold unregistered warrants to purchase up to an aggregate of 2,160,000 shares of the Company’s common stock that closed concurrently with the March 2017 offering of common stock sold pursuant the shelf registration statement. All warrants sold in this offering have a per share exercise price of $2.50, are exercisable beginning on the six-month anniversary of the date of issuance, and expire five years from the date first exercisable. The estimated grant date fair value of these warrants of approximately $2.8 million was recorded as an offset to additional paid-in capital upon the closing of this offering (see Note 4). At the closing of these sales on March 31, 2017, the Company received, after deducting $0.7 million of costs directly associated with the offering that were recorded as an offset to additional paid-in capital under applicable accounting guidance, approximately $8.6 million of net cash proceeds. In connection with the closing of the offering, the Company has agreed to certain contractual terms that limit its ability to issue variable rate securities for a period of one year following the closing of the offering, with certain exceptions. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. Pursuant to an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, a public offering of 9,100,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,100,000 shares of common stock was effected at a combined offering price of $1.10. The estimated grant date fair value of these warrants of approximately $5.2 million was recorded as an offset to additional paid-in capital upon the closing of this offering. Additionally, the underwriters were granted a 30-day option to purchase up to 1,365,000 additional shares of common stock at a price of $1.0331 per share, net of the underwriting discount, and/or additional warrants to purchase up to 1,365,000 shares of common stock at a price of $0.0009 per warrant to cover overallotments, if any, of which the underwriters exercised their overallotment option to purchase 627,131 option warrants for total proceeds to the Company of $564. The estimated aggregate grant date fair value of the overallotment options and warrants of approximately $0.8 million was recorded as an offset to additional paid-in capital upon the closing of this offering. All warrants sold in this offering have a per share exercise price of $1.10, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the underwriters occurred on October 19, 2016, when the Company received, after deducting $1.0 million of costs directly associated with the offering that were recorded as an offset to additional paid-in capital under applicable accounting guidance, $9.0 million of net cash proceeds. Subsequent to the closing of this offering, approximately $7.5 million of additional cash proceeds had been received from the exercise of warrants sold in this offering. As such, the total net increase in capital as a result of the sale of these shares and warrants has been $16.5 million. Pursuant to a common stock and warrant purchase agreement dated August 9, 2017 between the Company and Ally Bridge, an offering of 1,466,667 shares of the Company’s common stock and warrants to purchase up to an aggregate of 1,434,639 shares of common stock was effected at a combined offering price of $1.50 per unit for total gross proceeds to the Company of $2.2 million (see Note 13).

XML 22 R10.htm IDEA: XBRL DOCUMENT

Fair Value Measurement

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurement

4. Fair Value Measurement

Other Fair Value Measurements

Stock price	$	2.13
Exercise price	$	2.50
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		1.93	%
Expected life (in years)		5.00
Expected volatility		80.0	%

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R11.htm IDEA: XBRL DOCUMENT

Balance Sheet Details

6 Months Ended

Jun. 30, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Balance Sheet Details

5. Balance Sheet Details

The following provides certain balance sheet details:

	December 31,			June 30,
	2016			2017
Fixed Assets
Machinery and equipment	$	2,728,468		$	3,012,178
Furniture and office equipment		143,726			147,976
Computer equipment and software		620,582			925,206
Leasehold improvements		517,968			523,665
Financed equipment		1,559,690			1,725,205
Construction in process		169,896			236,474
Total fixed assets, gross		5,740,330			6,570,704
Less accumulated depreciation and amortization		(3,933,999	)		(4,168,449	)
Total fixed assets, net	$	1,806,331		$	2,402,255
Accrued Liabilities
Accrued interest	$	20,776		$	14,495
Accrued payroll		168,727			199,024
Accrued vacation		364,953			498,676
Accrued bonuses		422,868			448,380
Accrued sales commissions		77,844			67,354
Current portion of deferred rent		67,085			96,356
Accrued other		37,783			63,482
Total accrued liabilities	$	1,160,036		$	1,387,767

XML 24 R12.htm IDEA: XBRL DOCUMENT

April 2014 Credit Facility	6 Months Ended
April 2014 Credit Facility	Jun. 30, 2017
Debt Disclosure [Abstract]
April 2014 Credit Facility	6. April 2014 Credit Facility On April 30, 2014, the Company received net cash proceeds of approximately $4,898,000 pursuant to the execution of the April 2014 Credit Facility with Oxford Finance LLC. Upon the entry into the April 2014 Credit Facility, the Company was required to pay the lender a facility fee of $50,000 in conjunction with the funding of the term loan. The April 2014 Credit Facility is secured by substantially all of the Company’s personal property other than its intellectual property. Amounts due to Oxford Finance LLC under the April 2014 Credit Facility are callable before maturity by the lender under certain subjective acceleration clauses of the underlying agreement, including changes deemed to be materially adverse by the lender. The term loan under the April 2014 Credit Facility bears interest at an annual rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the term loan, plus (b) 7.71%. The term loan bears interest at an annual rate of 7.95%. The Company was required to make interest-only payments on the term loan through August 1, 2015. The outstanding term loan under the April 2014 Credit Facility began amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lender in consecutive monthly installments following such interest-only period. The term loan under the April 2014 Credit Facility matures on July 1, 2018. Under the original terms of the underlying agreement, the Company is also required to make a final payment to the lender equal to 5.5% of the original principal amount of the term loan funded. At its option, the Company may prepay the outstanding principal balance of the term loan in whole but not in part, subject to a prepayment fee of 1% of any amount prepaid. On June 30, 2016, the Company entered into an amendment of the April 2014 Credit Facility. This amendment required the Company to make interest-only payments on the term loan from July 1, 2016 through September 30, 2016, and also requires an additional final payment of $50,000 to the lender. The terms of the amendment require the amortization of the outstanding amount due under the term loan to commence at the end of the applicable interest-only period, with monthly payments of principal and interest, in arrears, being made by the Company to the lender in consecutive monthly installments following such interest-only period. Additionally, pursuant to the amendment the aggregate outstanding principal amount of the Company’s permitted indebtedness, consisting of capitalized lease obligations and purchase money indebtedness outstanding at any time, was increased to $1.2 million. The June 30, 2016 amendment of the April 2014 Credit Facility was accounted for as a modification of debt under applicable accounting guidance. On June 28, 2017, the Company entered into an amendment of the April 2014 Credit Facility whereby the aggregate outstanding principal amount of the Company’s permitted indebtedness was increased to $3.0 million. The April 2014 Credit Facility includes affirmative and negative covenants applicable to the Company and any subsidiaries created in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports and maintain insurance coverage. The negative covenants include, among others, restrictions on transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets, and suffering a change in control, in each case subject to certain exceptions. The April 2014 Credit Facility also includes events of default, the occurrence and continuation of which provide Oxford Finance LLC, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the term loan under the April 2014 Credit Facility, including foreclosure against the Company’s properties securing the April 2014 Credit Facility, including its cash. These events of default include, among other things, the Company’s failure to pay any amounts due under the April 2014 Credit Facility, a breach of covenants under the April 2014 Credit Facility, insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $250,000, and a final judgment against the Company in an amount greater than $250,000. A warrant to purchase up to 17,655 shares of the Company’s common stock at an exercise price of $14.16 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. Issuance costs of $102,498 associated with the term loan under the April 2014 Credit Facility were recorded as a discount to outstanding debt as of the closing date, resulting in net proceeds of $4,897,502. The estimated fair value of the warrant issued of $233,107 was also recorded as a discount to outstanding debt as of the closing date. The discounts and other issuance costs are amortized to interest expense utilizing the effective interest method over the underlying term of the loan, with total unamortized discounts of $78,408 and $71,503 remaining at December 31, 2016 and June 30, 2017, respectively. The effective annual interest rate associated with the April 2014 Credit Facility was 13.87% at both December 31, 2016 and June 30, 2017. As of June 30, 2017, total remaining principal payments of $986,492 and $1,201,409 were due under the April 2014 Credit Facility during the fiscal years ending December 31, 2017 and 2018, respectively.

XML 25 R13.htm IDEA: XBRL DOCUMENT

Equipment Financings

6 Months Ended

Jun. 30, 2017

Capital Lease Obligations [Abstract]

Equipment Financings

7. Equipment Financings

				Maintenance
	Minimum			and Sales Tax
	Lease			Obligation
	Payments			Payments
2017	$	236,430		$	15,957
2018		301,490			57,294
2019		261,284			64,994
2020		223,105			47,664
2021		217,319			43,055
Thereafter		367,769			66,987
Total payments		1,607,397			295,951
Less amount representing interest		(450,300	)		—
Present value of payments	$	1,157,097		$	295,951

At June 30, 2017, the present value of minimum lease payments due within one year was $362,777.

XML 26 R14.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

6 Months Ended

Jun. 30, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

8. Stock-Based Compensation

Equity Incentive Plans

Stock Options

A summary of stock option activity for the six months ended June 30, 2017 is as follows:

						Weighted
						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Outstanding at December 31, 2016		896,662		$	8.80		8.5
Granted		1,579,399		$	1.52
Exercised		—			—
Cancelled/forfeited/expired		(94,902	)	$	5.75
Outstanding at June 30, 2017		2,381,159		$	4.06		9.1
Vested and unvested expected to vest, June 30, 2017		2,187,470		$	4.28		9.1

The assumptions used in the Black-Scholes pricing model for stock options granted during the six months ended June 30, 2017 were as follows:

Stock and exercise prices	$1.37 – $2.13
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield	1.79% – 2.08%
Expected life (in years)	5.12 – 6.09
Expected volatility	80.0% - 90.0%


	Percentage of
	Overall Performance Stock
	Option Grant Subject to
	Vesting
Target
Minimum revenue	20%
Cost of revenue reductions and improvements	15%
Increase cash generated from operations	15%
Minimum cash on-hand at December 31, 2017	15%
Minimum customer agreements, product licensing and product launch	20%
Implementation of new products and utility trials	15%
Total	100%

Restricted Stock

A summary of RSU activity for the six months ended June 30, 2017 is as follows:

				Weighted
	Number of			Average Grant
	Shares			Date Fair Value
Outstanding at December 31, 2016		174,249		$	2.68
Granted		350,000		$	1.50
Vested and issued		(65,831	)	$	2.09
Forfeited		(7,500	)	$	2.10
Outstanding at June 30, 2017		450,918		$	1.87
Vested and unvested expected to vest, June 30, 2017		408,481		$	1.91


	Percentage of
	Overall Performance RSU
	Grant Subject to
	Vesting
Target
Minimum revenue	20%
Cost of revenue reductions and improvements	15%
Increase cash generated from operations	15%
Minimum cash on-hand at December 31, 2017	15%
Minimum customer agreements, product licensing and product launch	20%
Implementation of new products and utility trials	15%
Total	100%

Stock-based Compensation Expense

	For the three months ended				For the six months ended
	June 30,				June 30,
	2016		2017		2016		2017
Stock Options
Cost of revenues	$	29,412	$	41,615	$	55,487	$	73,385
Research and development expenses		25,961		39,172		58,964		68,428
General and administrative expenses		264,566		157,683		537,135		349,736
Sales and marketing expenses		1,897		19,606		39,240		60,146
Total expenses related to stock options		321,836		258,076		690,826		551,695
RSUs
Cost of revenues		1,916		23,133		1,916		38,300
Research and development expenses		1,452		22,714		1,452		37,072
General and administrative expenses		1,008		56,473		1,008		86,406
Sales and marketing expenses		4,508		22,843		4,508		42,988
Total stock-based compensation	$	330,720	$	383,239	$	699,710	$	756,461

XML 27 R15.htm IDEA: XBRL DOCUMENT

Common Stock Warrants Outstanding

6 Months Ended

Jun. 30, 2017

Other Liabilities Disclosure [Abstract]

Common Stock Warrants Outstanding

9. Common Stock Warrants Outstanding

A summary of equity-classified common stock warrant activity for the six months ended June 30, 2017 is as follows:

						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Outstanding at December 31, 2016		11,623,987		$	1.93		4.6
Issued		2,160,000		$	2.50
Exercised		(6,811,850	)	$	1.10
Expired		—			—
Outstanding at June 30, 2017		6,972,137		$	2.92		4.3

XML 28 R16.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Net Loss per Common Share

10. Net Loss per Common Share

The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:

	For the three and six-months ended
	June 30,
	2016		2017
Preferred warrants outstanding (number of common stock equivalents)		529		529
Common warrants outstanding		1,896,856		6,972,137
RSUs outstanding		86,756		450,918
Common options outstanding		731,400		2,381,159
Total anti-dilutive common share equivalents		2,715,541		9,804,743

XML 29 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity. In February 2016, the Company signed a firm, non-cancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in quarterly installments of $62,500 through May 2020. At June 30, 2017, a total of $628,760 remained outstanding under this purchase commitment.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received payments totaling $19,047 and $15,325 during the year ended December 31, 2016 and the six months ended June 30, 2017, respectively, from Aegea as reimbursements for shared patent costs under the Cross-License Agreement. Pursuant to a sublease agreement dated March 30, 2015, the Company subleased 9,849 square feet, plus free use of an additional area, of its San Diego facility to an entity affiliated with the Company’s non-executive Chairman for $12,804 per month, with a refundable security deposit of $12,804 due from the subtenant. The initial term of the sublease expired on July 31, 2015, and was subject to renewal on a month-to-month basis thereafter. On February 1, 2017, the Company received notice from the subtenant terminating the sublease effective March 31, 2017. A total of $76,824 and $38,412 in rental income was recorded to other income/(expense) in the Company’s unaudited condensed statements of operations and comprehensive loss during the six months ended June 30, 2016 and 2017, respectively. Three members of the Company’s Board of Directors participated in its public offering in May 2016, purchasing an aggregate of 58,335 shares of the Company’s common stock and warrants to purchase up to an aggregate of 40,832 shares of its common stock for total gross proceeds to the Company of $175,000. Additionally, a trust affiliated with Claire K.T. Reiss, who at the time was the beneficial owner of more than 10% of the Company’s outstanding common stock, participated in the Company’s public offering in May 2016, purchasing 204,758 shares of its common stock and warrants to purchase up to 143,330 shares of its common stock for total gross proceeds to the Company of $614,273. Seven members of the Company’s Board of Directors, including its CEO, and all three of the Company’s other executive officers participated in the Company’s public offering in October 2016, purchasing an aggregate of 534,088 shares of common stock and warrants to purchase up to an aggregate of 534,088 shares of common stock for total gross proceeds to the Company of $587,497. Additionally, a trust affiliated with Claire K.T. Reiss, who at the time was the beneficial owner of more than 10% of the Company’s outstanding common stock, participated in the Company’s public offering in October 2016, purchasing 227,272 shares of its common stock and warrants to purchase up 227,272 shares of its common stock for total gross proceeds to the Company of $249,999. Further, several of the Company’s employees and one of its consultants participated in the Company’s public offering in October 2016, purchasing an aggregate of 79,090 shares of its common stock and warrants to purchase up to an aggregate of 79,090 shares of its common stock for total aggregate gross proceeds to the Company of $86,999.

XML 31 R19.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

13. Subsequent Events

Pursuant to a common stock and warrant purchase agreement dated August 9, 2017 between the Company and Ally Bridge, an offering of 1,466,667 shares of the Company’s common stock and warrants to purchase up to an aggregate of 1,434,639 shares of common stock was effected at a combined offering price of $1.50 per unit for total gross proceeds to the Company of $2.2 million. All warrants sold in this offering have a per share exercise price of $1.50, are exercisable immediately and expire five years from the date of issuance. The estimated grant date fair value of these warrants of approximately $1.03 per share, or a total of approximately $1.5 million, was recorded as an offset to additional paid-in capital upon the closing of this offering, and was estimated using Black-Scholes valuation models with the following assumptions:

Stock price	$	1.39
Exercise price	$	1.50
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		1.81	%
Expected life (in years)		5.00
Expected volatility		100.0	%

XML 32 R20.htm IDEA: XBRL DOCUMENT

The Company, Business Activities and Basis of Presentation (Policies)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

The Company and Business Activities

Basis of Presentation

The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America.

Reverse Stock Split

Revenue Recognition and Related Reserves

The composition of the Company’s gross and net revenues recognized during the three and six-months ended June 30, 2016 and 2017 is as follows:

	For the three months ended June 30,					For the six months ended June 30,
	2016		2017			2016		2017
Commercial revenues recognized upon delivery	$ —		$	3,970,630		$ —		$	8,696,596
Development services revenues recognized upon delivery		66,481		83,553			98,329		144,342
Commercial revenues recognized upon cash collection		596,379		159,457			785,900		1,056,043
Total gross revenues		662,860		4,213,640			884,229		9,896,981
Provisions for contractual discounts		—		(1,489,527	)		—		(2,815,323	)
Provisions for aged non-patient receivables		—		(129,091	)		—		(445,643	)
Provisions for estimated patient receivables		—		(15,500	)		—		(118,840	)
Provisions for other payer-specific sales allowances		—		(1,300,561	)		—		(3,555,149	)
Net revenues	$	662,860	$	1,278,961		$	884,229	$	2,962,026

A summary of activity in the Company’s gross and net accounts receivable balances, as well as corresponding reserves, during the six months ended June 30, 2017 is as follows:

	Balance at		Amounts			Settlements			Balance at
	December 31,		Recognized			Upon			June 30,
	2016		Upon Delivery			Adjudication			2017
Accounts receivable, gross	$	128,969	$	8,840,938		$	(2,773,573	)	$	6,196,334
Reserve for contractual discounts		—		(2,815,323	)		956,314			(1,859,009	)
Reserve for aged non-patient receivables		—		(445,643	)		14,270			(431,373	)
Reserve for estimated patient receivables		—		(118,840	)		13,741			(105,099	)
Reserve for other payer-specific sales allowances		—		(3,555,149	)		749,042			(2,806,107	)
Accounts receivable, net	$	128,969	$	1,905,983		$	(1,040,206	)	$	994,746

Concentration of Risk

	For the three months ended June 30,						For the six months ended June 30,
	2016			2017			2016			2017
Medicare and Medicare Advantage		47	%		45	%		44	%		39	%
Blue Cross Blue Shield		8	%		15	%		9	%		18	%
United Healthcare		18	%		9	%		18	%		11	%

Medicare and Medicare Advantage	26	%
Blue Cross Blue Shield	24	%
United Healthcare	12	%

Recent Accounting Pronouncements

XML 33 R21.htm IDEA: XBRL DOCUMENT

The Company, Business Activities and Basis of Presentation (Tables)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Composition of Gross and Net Revenues Recognized

The composition of the Company’s gross and net revenues recognized during the three and six-months ended June 30, 2016 and 2017 is as follows:

	For the three months ended June 30,					For the six months ended June 30,
	2016		2017			2016		2017
Commercial revenues recognized upon delivery	$ —		$	3,970,630		$ —		$	8,696,596
Development services revenues recognized upon delivery		66,481		83,553			98,329		144,342
Commercial revenues recognized upon cash collection		596,379		159,457			785,900		1,056,043
Total gross revenues		662,860		4,213,640			884,229		9,896,981
Provisions for contractual discounts		—		(1,489,527	)		—		(2,815,323	)
Provisions for aged non-patient receivables		—		(129,091	)		—		(445,643	)
Provisions for estimated patient receivables		—		(15,500	)		—		(118,840	)
Provisions for other payer-specific sales allowances		—		(1,300,561	)		—		(3,555,149	)
Net revenues	$	662,860	$	1,278,961		$	884,229	$	2,962,026

Summary of Activity in Gross and Net Accounts Receivable Balances and Reserves

A summary of activity in the Company’s gross and net accounts receivable balances, as well as corresponding reserves, during the six months ended June 30, 2017 is as follows:

	Balance at		Amounts			Settlements			Balance at
	December 31,		Recognized			Upon			June 30,
	2016		Upon Delivery			Adjudication			2017
Accounts receivable, gross	$	128,969	$	8,840,938		$	(2,773,573	)	$	6,196,334
Reserve for contractual discounts		—		(2,815,323	)		956,314			(1,859,009	)
Reserve for aged non-patient receivables		—		(445,643	)		14,270			(431,373	)
Reserve for estimated patient receivables		—		(118,840	)		13,741			(105,099	)
Reserve for other payer-specific sales allowances		—		(3,555,149	)		749,042			(2,806,107	)
Accounts receivable, net	$	128,969	$	1,905,983		$	(1,040,206	)	$	994,746

Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage

	For the three months ended June 30,						For the six months ended June 30,
	2016			2017			2016			2017
Medicare and Medicare Advantage		47	%		45	%		44	%		39	%
Blue Cross Blue Shield		8	%		15	%		9	%		18	%
United Healthcare		18	%		9	%		18	%		11	%

Medicare and Medicare Advantage	26	%
Blue Cross Blue Shield	24	%
United Healthcare	12	%

XML 34 R22.htm IDEA: XBRL DOCUMENT

Fair Value Measurement (Tables)

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Assumptions Used for Determining Fair Values of Common Stock Warrants

Stock price	$	2.13
Exercise price	$	2.50
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		1.93	%
Expected life (in years)		5.00
Expected volatility		80.0	%

XML 35 R23.htm IDEA: XBRL DOCUMENT

Balance Sheet Details (Tables)

6 Months Ended

Jun. 30, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Fixed Assets and Accrued Liabilities

The following provides certain balance sheet details:

	December 31,			June 30,
	2016			2017
Fixed Assets
Machinery and equipment	$	2,728,468		$	3,012,178
Furniture and office equipment		143,726			147,976
Computer equipment and software		620,582			925,206
Leasehold improvements		517,968			523,665
Financed equipment		1,559,690			1,725,205
Construction in process		169,896			236,474
Total fixed assets, gross		5,740,330			6,570,704
Less accumulated depreciation and amortization		(3,933,999	)		(4,168,449	)
Total fixed assets, net	$	1,806,331		$	2,402,255
Accrued Liabilities
Accrued interest	$	20,776		$	14,495
Accrued payroll		168,727			199,024
Accrued vacation		364,953			498,676
Accrued bonuses		422,868			448,380
Accrued sales commissions		77,844			67,354
Current portion of deferred rent		67,085			96,356
Accrued other		37,783			63,482
Total accrued liabilities	$	1,160,036		$	1,387,767

XML 36 R24.htm IDEA: XBRL DOCUMENT

Equipment Financings (Tables)

6 Months Ended

Jun. 30, 2017

Capital Lease Obligations [Abstract]

Schedule of Remaining Future Minimum Lease Payments for Financed Equipment Obligations

				Maintenance
	Minimum			and Sales Tax
	Lease			Obligation
	Payments			Payments
2017	$	236,430		$	15,957
2018		301,490			57,294
2019		261,284			64,994
2020		223,105			47,664
2021		217,319			43,055
Thereafter		367,769			66,987
Total payments		1,607,397			295,951
Less amount representing interest		(450,300	)		—
Present value of payments	$	1,157,097		$	295,951

XML 37 R25.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2017

Summary of Stock Option Activity

A summary of stock option activity for the six months ended June 30, 2017 is as follows:

						Weighted
						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Outstanding at December 31, 2016		896,662		$	8.80		8.5
Granted		1,579,399		$	1.52
Exercised		—			—
Cancelled/forfeited/expired		(94,902	)	$	5.75
Outstanding at June 30, 2017		2,381,159		$	4.06		9.1
Vested and unvested expected to vest, June 30, 2017		2,187,470		$	4.28		9.1

Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model

The assumptions used in the Black-Scholes pricing model for stock options granted during the six months ended June 30, 2017 were as follows:

Stock and exercise prices	$1.37 – $2.13
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield	1.79% – 2.08%
Expected life (in years)	5.12 – 6.09
Expected volatility	80.0% - 90.0%

Summary of RSU Activity

A summary of RSU activity for the six months ended June 30, 2017 is as follows:

				Weighted
	Number of			Average Grant
	Shares			Date Fair Value
Outstanding at December 31, 2016		174,249		$	2.68
Granted		350,000		$	1.50
Vested and issued		(65,831	)	$	2.09
Forfeited		(7,500	)	$	2.10
Outstanding at June 30, 2017		450,918		$	1.87
Vested and unvested expected to vest, June 30, 2017		408,481		$	1.91

Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss

	For the three months ended				For the six months ended
	June 30,				June 30,
	2016		2017		2016		2017
Stock Options
Cost of revenues	$	29,412	$	41,615	$	55,487	$	73,385
Research and development expenses		25,961		39,172		58,964		68,428
General and administrative expenses		264,566		157,683		537,135		349,736
Sales and marketing expenses		1,897		19,606		39,240		60,146
Total expenses related to stock options		321,836		258,076		690,826		551,695
RSUs
Cost of revenues		1,916		23,133		1,916		38,300
Research and development expenses		1,452		22,714		1,452		37,072
General and administrative expenses		1,008		56,473		1,008		86,406
Sales and marketing expenses		4,508		22,843		4,508		42,988
Total stock-based compensation	$	330,720	$	383,239	$	699,710	$	756,461

Stock Options [Member]

Schedule of Percentage Of Overall Performance Grant Subject To Vesting

Each performance stock option granted on May 31, 2017 has an exercise price of $1.50 per share, an estimated grant date fair value of $0.99 per share, and is subject to vesting as determined by the Company’s Board of Directors based on the achievement of specified corporate goals for 2017, provided that none shall vest unless a minimum level of 70% of the Company’s corporate goals for 2017 are achieved, as follows:


	Percentage of
	Overall Performance Stock
	Option Grant Subject to
	Vesting
Target
Minimum revenue	20%
Cost of revenue reductions and improvements	15%
Increase cash generated from operations	15%
Minimum cash on-hand at December 31, 2017	15%
Minimum customer agreements, product licensing and product launch	20%
Implementation of new products and utility trials	15%
Total	100%

RSUs [Member]

Schedule of Percentage Of Overall Performance Grant Subject To Vesting

Vesting of the time-based RSUs granted on May 31, 2017 is subject to continuing service and occurs on the one year anniversary of the vesting commencement date, or May 2, 2018, while the performance RSUs are subject to continuous service and vesting is as determined by the Company’s Board of Directors based on the achievement of specified corporate goals for 2017, provided that none shall vest unless a minimum level of 70% of the Company’s corporate goals for 2017 are achieved, as follows:


	Percentage of
	Overall Performance RSU
	Grant Subject to
	Vesting
Target
Minimum revenue	20%
Cost of revenue reductions and improvements	15%
Increase cash generated from operations	15%
Minimum cash on-hand at December 31, 2017	15%
Minimum customer agreements, product licensing and product launch	20%
Implementation of new products and utility trials	15%
Total	100%

XML 38 R26.htm IDEA: XBRL DOCUMENT

Common Stock Warrants Outstanding (Tables)

6 Months Ended

Jun. 30, 2017

Equity Classified Warrants [Abstract]

Summary of Equity-Classified Common Stock Warrant Activity

A summary of equity-classified common stock warrant activity for the six months ended June 30, 2017 is as follows:

						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Outstanding at December 31, 2016		11,623,987		$	1.93		4.6
Issued		2,160,000		$	2.50
Exercised		(6,811,850	)	$	1.10
Expired		—			—
Outstanding at June 30, 2017		6,972,137		$	2.92		4.3

XML 39 R27.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share (Tables)

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares

The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:

	For the three and six-months ended
	June 30,
	2016		2017
Preferred warrants outstanding (number of common stock equivalents)		529		529
Common warrants outstanding		1,896,856		6,972,137
RSUs outstanding		86,756		450,918
Common options outstanding		731,400		2,381,159
Total anti-dilutive common share equivalents		2,715,541		9,804,743

XML 40 R28.htm IDEA: XBRL DOCUMENT

Subsequent Events (Tables)

6 Months Ended

Jun. 30, 2017

Subsequent Event [Line Items]

Assumptions Used for Determining Fair Values of Common Stock Warrants

Stock price	$	2.13
Exercise price	$	2.50
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		1.93	%
Expected life (in years)		5.00
Expected volatility		80.0	%

Ally Bridge [Member]

Subsequent Event [Line Items]

Assumptions Used for Determining Fair Values of Common Stock Warrants

The estimated grant date fair value of these warrants of approximately $1.03 per share, or a total of approximately $1.5 million, was recorded as an offset to additional paid-in capital upon the closing of this offering, and was estimated using Black-Scholes valuation models with the following assumptions:

Stock price	$	1.39
Exercise price	$	1.50
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		1.81	%
Expected life (in years)		5.00
Expected volatility		100.0	%

XML 41 R29.htm IDEA: XBRL DOCUMENT

The Company, Business Activities and Basis of Presentation - Additional Information (Detail)		3 Months Ended	6 Months Ended
	Sep. 29, 2016	Jun. 30, 2017 USD ($) $ / shares shares	Jun. 30, 2017 USD ($) $ / shares shares	Dec. 31, 2016 shares	Sep. 27, 2016 shares
The Company, Business Activities and Basis of Presentation [Line Items]
Stockholders equity reverse stock split ratio	0.33
Common stock, shares authorized		150,000,000	150,000,000	150,000,000
Description of reverse stock split			On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares. The one-for-three reverse stock split was effected September 29, 2016.
Net revenue recorded in excess of commercial cash collections \| $		$ 191,193	$ 916,883
Increase decrease in net income (loss) per common share \| $ / shares		$ (0.01)	$ (0.04)
Commercial Diagnostic Services [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Nonrecurring net revenue commenced upon delivery \| $		$ 134,915	$ 1,012,242
Increase (decrease) in net income (loss) per common share on nonrecurring net revenue \| $ / shares		$ (0.01)	$ (0.04)
Minimum [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Common stock, shares authorized					40,000,000
Maximum [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Common stock, shares authorized					150,000,000

XML 42 R30.htm IDEA: XBRL DOCUMENT

The Company, Business Activities and Basis of Presentation - Composition of Gross and Net Revenues Recognized (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue Recognition [Abstract]
Commercial revenues recognized upon delivery	$ 3,970,630		$ 8,696,596
Development services revenues recognized upon delivery	83,553	$ 66,481	144,342	$ 98,329
Commercial revenues recognized upon cash collection	159,457	596,379	1,056,043	785,900
Total gross revenues	4,213,640	662,860	9,896,981	884,229
Provisions for contractual discounts	(1,489,527)		(2,815,323)
Provisions for aged non-patient receivables	(129,091)		(445,643)
Provisions for estimated patient receivables	(15,500)		(118,840)
Provisions for other payer-specific sales allowances	(1,300,561)		(3,555,149)
Net revenues	$ 1,278,961	$ 662,860	$ 2,962,026	$ 884,229

XML 43 R31.htm IDEA: XBRL DOCUMENT

The Company, Business Activities and Basis of Presentation - Summary of Activity in Gross and Net Accounts Receivable Balances and Reserves (Detail)	6 Months Ended
	Jun. 30, 2017 USD ($)
The Company, Business Activities and Basis of Presentation [Line Items]
Gross and net accounts receivable, Beginning Balance	$ 128,969
Amounts Recognized Upon Delivery	1,905,983
Settlements Upon Adjudication	(1,040,206)
Gross and net accounts receivable, Ending Balance	994,746
Accounts Receivable Gross [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Gross and net accounts receivable, Beginning Balance	128,969
Amounts Recognized Upon Delivery	8,840,938
Settlements Upon Adjudication	(2,773,573)
Gross and net accounts receivable, Ending Balance	6,196,334
Reserve for Contractual Discounts [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Amounts Recognized Upon Delivery	(2,815,323)
Settlements Upon Adjudication	956,314
Gross and net accounts receivable, Ending Balance	(1,859,009)
Reserve for Aged Non-patient Receivables [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Amounts Recognized Upon Delivery	(445,643)
Settlements Upon Adjudication	14,270
Gross and net accounts receivable, Ending Balance	(431,373)
Reserve for Estimated Patient Receivables [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Amounts Recognized Upon Delivery	(118,840)
Settlements Upon Adjudication	13,741
Gross and net accounts receivable, Ending Balance	(105,099)
Reserve for Other Payer-specific Sales Allowances [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Amounts Recognized Upon Delivery	(3,555,149)
Settlements Upon Adjudication	749,042
Gross and net accounts receivable, Ending Balance	$ (2,806,107)

XML 44 R32.htm IDEA: XBRL DOCUMENT

The Company, Business Activities and Basis of Presentation - Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Customer Concentration Risk [Member] \| Net Revenues [Member] \| Blue Cross Blue Shield [Member]
Concentration Risk [Line Items]
Concentration risk percentage	15.00%	8.00%	18.00%	9.00%
Customer Concentration Risk [Member] \| Net Revenues [Member] \| Medicare and Medicare Advantage [Member]
Concentration Risk [Line Items]
Concentration risk percentage	45.00%	47.00%	39.00%	44.00%
Customer Concentration Risk [Member] \| Net Revenues [Member] \| United Healthcare [Member]
Concentration Risk [Line Items]
Concentration risk percentage	9.00%	18.00%	11.00%	18.00%
Credit Concentration Risk [Member] \| Net Accounts Receivable [Member] \| Blue Cross Blue Shield [Member]
Concentration Risk [Line Items]
Concentration risk percentage			24.00%
Credit Concentration Risk [Member] \| Net Accounts Receivable [Member] \| Medicare and Medicare Advantage [Member]
Concentration Risk [Line Items]
Concentration risk percentage			26.00%
Credit Concentration Risk [Member] \| Net Accounts Receivable [Member] \| United Healthcare [Member]
Concentration Risk [Line Items]
Concentration risk percentage			12.00%

XML 45 R33.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern Uncertainty- Additional Information (Detail) - USD ($)							1 Months Ended	3 Months Ended		6 Months Ended		8 Months Ended	12 Months Ended
	Aug. 11, 2017	Aug. 09, 2017	Mar. 31, 2017	Oct. 19, 2016	Oct. 14, 2016	May 04, 2016	Feb. 29, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	May 31, 2015
Liquidity And Managements Plans [Line Items]
Cash								$ 10,000,155	$ 3,751,570	$ 10,000,155	$ 3,751,570	$ 10,000,155	$ 4,609,332	$ 8,821,329
Accumulated deficit								(183,761,728)		(183,761,728)		(183,761,728)	(173,635,870)
Net loss								(5,693,151)	$ (4,594,174)	(10,125,858)	$ (9,469,372)		$ (18,400,000)
Other non-interest bearing current liabilities								3,200,000		3,200,000		3,200,000
Unconditional purchase commitment aggregate amount							$ 1,062,500	628,760		$ 628,760		628,760
Unconditional purchase commitment, quarterly payment amount							62,500
Unconditional purchase commitment payment terms										Quarterly
Unconditional purchase commitment period										May 31, 2020
Proceeds from exercise of common stock warrants										$ 7,493,035
Issuance of unregistered warrants to purchase shares of common stock			2,160,000
Exercise price of warrants			$ 2.50			$ 3.90
Subsequent Event [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from issuance of common stock, net of issuance costs		$ 2,000,000
Proceeds from exercise of common stock warrants	$ 0
Exercisable warrant available price per share expiration period	2022-08
Proceeds from issuance of common stock	$ 2,200,000
Exercise price of warrants	$ 1.50
Roth Capital Partners, LLC and Feltl [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from issuance of common stock, net of issuance costs				$ 9,000,000
Proceeds from exercise of common stock warrants					$ 564					7,500,000		7,500,000
Proceeds from gross exercise of common stock warrants outstanding										$ 3,200,000
Exercisable warrant available price per share										$ 1.10
Exercisable warrant available price per share expiration period										2021-10
Issuance of unregistered warrants to purchase shares of common stock					9,100,000
Exercise price of warrants					$ 1.10
Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Aggregate offering price															$ 50,000,000
Minimum public float limit for offering															75,000,000
Proceeds from issuance of common stock, net of issuance costs			$ 8,600,000			$ 4,300,000
Proceeds from exercise of common stock warrants			0			0
Proceeds from gross exercise of common stock warrants outstanding			$ 5,400,000			$ 4,500,000
Exercisable warrant available price per share			$ 2.50			$ 3.90
Exercisable warrant available price per share expiration period			2022-03			2021-05
Issuance of unregistered warrants to purchase shares of common stock			2,160,000			1,163,526
Warrants exercise period description										Warrant proceeds remaining outstanding and available to be exercised at $2.50 per share commencing on the six month anniversary of the closing of the offering, or September 30, 2017, until their expiration in March 2022.
Exercise price of warrants						$ 3.90
April 2014 Credit Facility [Member]
Liquidity And Managements Plans [Line Items]
Aggregate net interest-bearing indebtedness								3,800,000		$ 3,800,000		3,800,000
Due within one year								$ 2,600,000		$ 2,600,000		$ 2,600,000
Minimum [Member]
Liquidity And Managements Plans [Line Items]
Unconditional purchase commitment, quarterly payment amount							$ 62,500
Maximum [Member] \| Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Aggregate offering price															$ 50,000,000

XML 46 R34.htm IDEA: XBRL DOCUMENT

Sales of Equity Securities - Additional Information (Detail) - USD ($)								6 Months Ended	8 Months Ended	12 Months Ended
	Aug. 11, 2017	Aug. 09, 2017	Mar. 31, 2017	Oct. 19, 2016	Oct. 14, 2016	May 04, 2016	Dec. 21, 2015	Jun. 30, 2017	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	May 31, 2015
Class Of Stock [Line Items]
Increase in capital shares value										$ 1,400,000
Stock price								$ 2.13	$ 2.13
Common stock, shares issued								28,697,078	28,697,078	17,499,397
Common stock issuance costs										$ 79,000	$ 42,000
Issuance of unregistered warrants to purchase shares of common stock			2,160,000
Exercise price of warrants			$ 2.50			$ 3.90
Proceeds from exercise of common stock warrants								$ 7,493,035
Common stock, par value								$ 0.0001	$ 0.0001	$ 0.0001
Issuance of warrants to purchase shares of common stock						1,163,526
Subsequent Event [Member]
Class Of Stock [Line Items]
Stock price		$ 1.39
Proceeds from issuance of common stock	$ 2,200,000
Exercise price of warrants	$ 1.50
Net cash proceeds from sale of securities		$ 2,000,000
Proceeds from exercise of common stock warrants	$ 0
Exercisable warrant available price per share expiration period	2022-08
Roth Capital Partners, LLC, WestPark Capital and Chardan Capital [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued			4,320,000
Stock price			$ 2.15
Placement agent agreement, effective date			Mar. 28, 2017
Issuance of unregistered warrants to purchase shares of common stock			2,160,000
Exercise price of warrants			$ 2.50
Class of warrant or rights, term			5 years
Issuance of warrants to purchase shares of common stock, grant date fair value			$ 2,800,000
Cost directly associated with offering			700,000
Net cash proceeds from sale of securities			$ 8,600,000
Warrants exercise period description								Exercisable beginning on the six-month anniversary of the date of issuance, and expire five years from the date first exercisable.
Period of limitation to issue securities at variable rate			1 year
Roth Capital Partners, LLC and Feltl [Member]
Class Of Stock [Line Items]
Increase in capital shares value									$ 16,500,000
Overallotment issued to underwriter to purchase common stock, period					30 days
Public offering, number of shares issued					9,100,000
Stock price					$ 1.10
Issuance of unregistered warrants to purchase shares of common stock					9,100,000
Exercise price of warrants					$ 1.10
Class of warrant or rights, term					5 years
Issuance of warrants to purchase shares of common stock, grant date fair value					$ 5,200,000
Cost directly associated with offering				$ 1,000,000
Net cash proceeds from sale of securities				$ 9,000,000
Proceeds from exercise of common stock warrants					$ 564			$ 7,500,000	$ 7,500,000
Exercisable warrant available price per share expiration period								2021-10
Purchase of common stock by underwriters to cover overallotments, number of shares					627,131
Purchase of common stock by underwriters to cover overallotments, per share					$ 1.0331
Common stock, par value					$ 0.0009
Grant date fair values of overallotment options					$ 800,000
Roth Capital Partners, LLC and Feltl [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Purchase of common stock by underwriters to cover overallotments, number of shares					1,365,000
Issuance of overallotment options to purchase common stock shares					1,365,000
Shelf Registration Statement [Member]
Class Of Stock [Line Items]
Stock price						$ 3.00
Aggregate offering price												$ 50,000,000
Minimum public float limit for offering												75,000,000
Placement agent agreement, effective date						Apr. 25, 2016
Securities purchase agreement, effective date						Apr. 29, 2016
Public offering, number of common stock and warrants issued						1,662,191
Issuance of unregistered warrants to purchase shares of common stock			2,160,000			1,163,526
Exercise price of warrants						$ 3.90
Class of warrant or rights, term						5 years
Issuance of warrants to purchase shares of common stock, grant date fair value						$ 2,000,000
Cost directly associated with offering						700,000
Net cash proceeds from sale of securities			$ 8,600,000			4,300,000
Proceeds from exercise of common stock warrants			$ 0			0
Proceeds from gross exercise of common stock warrants outstanding						$ 4,500,000
Exercisable warrant available price per share expiration period			2022-03			2021-05
Warrants exercise period description								Warrant proceeds remaining outstanding and available to be exercised at $2.50 per share commencing on the six month anniversary of the closing of the offering, or September 30, 2017, until their expiration in March 2022.
Shelf Registration Statement [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Aggregate offering price												$ 50,000,000
Common Stock Purchase Agreement [Member]
Class Of Stock [Line Items]
Proceeds from issuance of common stock										$ 544,051
Aggregate common stock shares purchase										173,145
Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Common stock, shares issued							55,000
Ally Bridge [Member] \| Subsequent Event [Member]
Class Of Stock [Line Items]
Increase in capital shares value	$ 2,000,000
Stock price		$ 1.50
Proceeds from issuance of common stock		$ 2,200,000
Common stock issuance costs	200,000
Exercise price of warrants		$ 1.5
Class of warrant or rights, term		5 years
Issuance of warrants to purchase shares of common stock, grant date fair value		$ 1,500,000
Proceeds from exercise of common stock warrants	$ 0
Private offering, number of common stock and warrants issued		1,466,667
Issuance of warrants to purchase shares of common stock		1,434,639
Common Stock [Member] \| Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Increase in capital shares value							$ 15,000,000
Overallotment issued to underwriter to purchase common stock, period							30 months
Public offering, number of shares issued							208,334
Stock price							$ 4.80
Proceeds from issuance of common stock							$ 1,000,000

XML 47 R35.htm IDEA: XBRL DOCUMENT

Fair Value Measurement - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Aug. 11, 2017	Aug. 09, 2017	Mar. 31, 2017	May 04, 2016	Jun. 30, 2017
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value			$ 2.8	$ 2.0
Issuance of unregistered warrants to purchase shares of common stock			2,160,000
Warrant exercise price					$ 2.50
Issuance of warrants to purchase shares of common stock				1,163,526
Stock price					$ 2.13
Exercise price of warrants			$ 2.50	$ 3.90
Subsequent Event [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant exercise price		$ 1.50
Stock price		$ 1.39
Proceeds from issuance of common stock	$ 2.2
Exercise price of warrants	$ 1.50
Subsequent Event [Member] \| Ally Bridge [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Private offering, number of common stock and warrants issued		1,466,667
Issuance of warrants to purchase shares of common stock		1,434,639
Stock price		$ 1.50
Proceeds from issuance of common stock		$ 2.2
Estimated grant date fair value of warrants		$ 1.03
Exercise price of warrants		$ 1.5
Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant exercise price			$ 1.31

XML 48 R36.htm IDEA: XBRL DOCUMENT

Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail)	6 Months Ended
	Jun. 30, 2017 $ / shares
Fair Value Disclosures [Abstract]
Stock price	$ 2.13
Exercise price	$ 2.50
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	1.93%
Expected life (in years)	5 years
Expected volatility	80.00%

XML 49 R37.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Fixed Assets
Machinery and equipment	$ 3,012,178	$ 2,728,468
Furniture and office equipment	147,976	143,726
Computer equipment and software	925,206	620,582
Leasehold improvements	523,665	517,968
Financed equipment	1,725,205	1,559,690
Construction in process	236,474	169,896
Total fixed assets, gross	6,570,704	5,740,330
Less accumulated depreciation and amortization	(4,168,449)	(3,933,999)
Total fixed assets, net	2,402,255	1,806,331
Accrued Liabilities
Accrued interest	14,495	20,776
Accrued payroll	199,024	168,727
Accrued vacation	498,676	364,953
Accrued bonuses	448,380	422,868
Accrued sales commissions	67,354	77,844
Current portion of deferred rent	96,356	67,085
Accrued other	63,482	37,783
Total accrued liabilities	$ 1,387,767	$ 1,160,036

XML 50 R38.htm IDEA: XBRL DOCUMENT

April 2014 Credit Facility - Additional Information (Detail) - USD ($)				6 Months Ended	12 Months Ended
	Mar. 31, 2017	May 04, 2016	Apr. 30, 2014	Jun. 30, 2017	Dec. 31, 2014	Jun. 28, 2017	Dec. 31, 2016	Jun. 30, 2016
Line of Credit Facility [Line Items]
Warrant issued to lender		1,163,526
Exercise price of unregistered warrants	$ 2.50	$ 3.90
Warrant term	5 years	5 years
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value	$ 2,800,000	$ 2,000,000
Oxford Finance LLC [Member]
Line of Credit Facility [Line Items]
Additional final payment to lender				$ 50,000
Total indebtedness and capital lease obligations outstanding						$ 3,000,000
Oxford Finance LLC [Member] \| Common Stock [Member]
Line of Credit Facility [Line Items]
Warrant issued to lender			17,655
Exercise price of unregistered warrants			$ 14.16
Warrant term			10 years
Oxford Finance LLC [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Debt default limit amount			$ 250,000
Debt default final judgment amount			250,000
Oxford Finance LLC [Member] \| First Term Loan [Member]
Line of Credit Facility [Line Items]
Net cash proceeds on term loan			4,898,000
Line of Credit Facility fees amount payable			$ 50,000
Line of Credit Facility, interest rate during period			7.95%
Percentage of final interest payment due at maturity			5.50%
Total indebtedness and capital lease obligations outstanding								$ 1,200,000
Issuance costs					$ 102,498
Net proceeds from credit facility					4,897,502
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value					$ 233,107
Unamortized discounts				$ 71,503			$ 78,408
Effective annual interest rate				13.87%			13.87%
Total remaining principal payments due during fiscal year ending December 31, 2017				$ 986,492
Total remaining principal payments due during fiscal year ending December 31, 2018				$ 1,201,409
Oxford Finance LLC [Member] \| Two Years [Member]
Line of Credit Facility [Line Items]
Term loan prepayment fee percentage			1.00%
Oxford Finance LLC [Member] \| Scenario One [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, interest rate during period			7.95%
Oxford Finance LLC [Member] \| Scenario Two [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, interest rate during period			7.71%

XML 51 R39.htm IDEA: XBRL DOCUMENT

Equipment Financings - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Equipment Financings and Capital Lease Obligations [Line Items]
Financed equipment	$ 1,725,205		$ 1,725,205		$ 1,559,690
Accumulated depreciation related to financed equipment	629,000		629,000		$ 525,000
Fixed assets purchased as equipment financings			$ 165,516	$ 445,386
Equipment financings aggregate weighted average effective annual interest rate			13.78%		13.18%
Equipment financings maturity date on outstanding arrangements range, Start			2017-07
Equipment financings maturity date on outstanding arrangements range, End			2023-05
Present value of minimum lease payment due within one year	362,777		$ 362,777
Equipment Financings [Member]
Equipment Financings and Capital Lease Obligations [Line Items]
Depreciation expense related to financed equipment	$ 52,000	$ 27,000	$ 108,000	$ 53,000
Minimum [Member] \| Equipment Financings [Member]
Equipment Financings and Capital Lease Obligations [Line Items]
Financed equipment useful life			5 years
Maximum [Member] \| Equipment Financings [Member]
Equipment Financings and Capital Lease Obligations [Line Items]
Financed equipment useful life			7 years

XML 52 R40.htm IDEA: XBRL DOCUMENT

Equipment Financings - Schedule of Remaining Future Minimum Lease Payments for Financed Equipment Obligations (Detail)	Jun. 30, 2017 USD ($)
Capital Lease Obligations [Abstract]
2017	$ 236,430
2018	301,490
2019	261,284
2020	223,105
2021	217,319
Thereafter	367,769
Total payments	1,607,397
Less amount representing interest	(450,300)
Present value of payments	1,157,097
2017	15,957
2018	57,294
2019	64,994
2020	47,664
2021	43,055
Thereafter	66,987
Total payments	295,951
Present value of payments	$ 295,951

XML 53 R41.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Additional Information (Detail)								6 Months Ended
	May 31, 2017 $ / shares shares	May 02, 2017 shares	Jul. 29, 2016 $ / shares shares	Jul. 25, 2016 $ / shares shares	Jul. 06, 2016 USD ($) $ / shares shares	Feb. 29, 2016 $ / shares shares	Aug. 31, 2015 $ / shares shares	Jun. 30, 2017 USD ($) Plan $ / shares shares	Jun. 30, 2016	Dec. 31, 2016 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of equity incentive plans \| Plan								2
Total Shares Outstanding								2,381,159		896,662
Number of Shares, Granted								1,579,399
Weighted average exercise price per share \| $ / shares								$ 1.52
Number of shares remaining forfeited								94,902
Unrecognized stock-based compensation expense, weighted-average recognition period								2 years 2 months 12 days
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate								0.00%	0.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate								8.00%	8.00%
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options outstanding \| $								$ 7,623		$ 0
Intrinsic value of options vested and unvested expected to vest \| $								$ 6,721
Stock options vested								173,157
Total weighted average grant date fair value \| $ / shares								$ 6.09
Option awards assumptions, method used								Black-Scholes pricing model
Weighted-average estimated fair value of options granted \| $ / shares								$ 1.04
Performance Stock Options [Member}
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting								100.00%
Performance RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting								100.00%
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value shares, RSUs outstanding \| $								$ 617,758
Intrinsic value amount, RSUs unvested and vested expected to vest \| $								$ 559,619
RSUs outstanding								450,918		174,249
Vested								10,920
Issuance of restricted stock units								350,000
Weighted-average estimated fair value of options granted \| $ / shares								$ 1.87		$ 2.68
Stock Options and RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense, stock options \| $								$ 2,694,000
2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized				333,333
2013 Equity Incentive Plan [Member] \| Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average exercise price per share \| $ / shares				$ 1.95
Number of shares remaining forfeited								16,950
2013 Equity Incentive Plan [Member] \| Stock Options [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average estimated fair value of options granted \| $ / shares						$ 2.87	$ 4.40
Number of Shares, Granted						33,333	33,333
Weighted average exercise price per share \| $ / shares						$ 4.02	$ 6.03
Number of shares remaining forfeited								50,333
2013 Equity Incentive Plan [Member] \| Performance Stock Options granted on August 31, 2015 [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vested								6,333
2013 Equity Incentive Plan [Member] \| Performance Stock Options Granted on February 29, 2016 [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vested								10,000
2013 Equity Incentive Plan [Member] \| Performance Stock Options Granted on July 29 2016 [Member] \| Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vested								16,383
2013 Equity Incentive Plan [Member] \| Performance Stock Options [Member}
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average estimated fair value of options granted \| $ / shares	$ 0.99
Weighted average exercise price per share \| $ / shares	$ 1.50
2013 Equity Incentive Plan [Member] \| Performance Stock Options [Member} \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Granted	200,000
2013 Equity Incentive Plan [Member] \| Performance Stock Options [Member} \| Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Granted	100,000
2013 Equity Incentive Plan [Member] \| Performance Stock Options [Member} \| Employees and Executive Officers [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized		550,000
2013 Equity Incentive Plan [Member] \| Performance Stock Options [Member} \| Chief Scientific Officer and Senior Vice President [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Granted	75,000
2013 Equity Incentive Plan [Member] \| Performance Stock Options [Member} \| Senior Medical Director and Senior Vice President [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Granted	75,000
2013 Equity Incentive Plan [Member] \| Time-Based RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period								1 year
Weighted-average estimated fair value of options granted \| $ / shares	$ 1.50
2013 Equity Incentive Plan [Member] \| Time-Based RSUs [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of restricted stock units	50,000
2013 Equity Incentive Plan [Member] \| Time-Based RSUs [Member] \| Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized		175,000
2013 Equity Incentive Plan [Member] \| Time-Based RSUs [Member] \| Other Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of restricted stock units	25,000
2013 Equity Incentive Plan [Member] \| Performance RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average estimated fair value of options granted \| $ / shares	$ 1.50
2013 Equity Incentive Plan [Member] \| Performance RSUs [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of restricted stock units	25,000
2013 Equity Incentive Plan [Member] \| Performance RSUs [Member] \| Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized		175,000
2013 Equity Incentive Plan [Member] \| Performance RSUs [Member] \| Other Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of restricted stock units	25,000
2013 Equity Incentive Plan [Member] \| RSUs [Member] \| Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting				100.00%
Vesting period				1 year
Restricted stock units, grant date fair value \| $ / shares				$ 1.95
Restricted stock unit award, shares				25,000
2013 Equity Incentive Plan [Member] \| Retention RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period					1 year
Restricted stock units, grant date fair value \| $ / shares					$ 1.86
Restricted stock units, grant date fair value \| $					$ 108,498
2013 Equity Incentive Plan [Member] \| Retention RSUs [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of restricted stock units					25,000
2013 Equity Incentive Plan [Member] \| Retention RSUs [Member] \| Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of restricted stock units					58,332
2013 Equity Incentive Plan [Member] \| Non-inducement Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized								3,522,955
Stock options and RSUs issued								2,674,028
Total Shares Outstanding								2,674,028
Common stock, shares authorized								741,614
Increase in number of shares of common stock authorized for issuance		2,500,000
2013 Equity Incentive Plan [Member] \| Inducement shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized								333,333
Stock options and RSUs issued								158,049
Total Shares Outstanding								158,049
Common stock, shares authorized								175,284
2013 Equity Incentive Plan [Member] \| Options Vesting on One Year Anniversary [Member] \| Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized				66,666
Weighted-average estimated fair value of options granted \| $ / shares				$ 1.45
Percentage of Overall Stock Grant Subject to Vesting				25.00%
Vesting period				1 year
Stock option units remaining vesting period on Equal monthly basis				3 years
2013 Equity Incentive Plan [Member] \| Options Vesting on Performance Achievement [Member] \| Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized			33,333
Weighted-average estimated fair value of options granted \| $ / shares			$ 1.26
2013 Equity Incentive Plan [Member] \| Achievement of the Company's 2017 Corporate Goals [Member] \| Performance Stock Options [Member} \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting								70.00%
2013 Equity Incentive Plan [Member] \| Achievement of the Company's 2017 Corporate Goals [Member] \| Performance RSUs [Member] \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting								70.00%

XML 54 R42.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares Outstanding, Beginning Balance	896,662
Number of Shares, Granted	1,579,399
Number of Shares, Cancelled/forfeited/expired	(94,902)
Number of Shares Outstanding, Ending Balance	2,381,159	896,662
Number of Shares, Vested and unvested expected to vest, Ending Balance	2,187,470
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 8.80
Weighted Average Exercise Price Per Share, Granted	1.52
Weighted Average Exercise Price Per Share, Cancelled/forfeited/expired	5.75
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	4.06	$ 8.80
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Ending Balance	$ 4.28
Weighted Average Remaining Contractual Term in Years, Outstanding	9 years 1 month 6 days	8 years 6 months
Weighted Average Remaining Contractual Term in Years, Vested and unvested expected to vest	9 years 1 month 6 days

XML 55 R43.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail)	6 Months Ended
	Jun. 30, 2017 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 1.37
Discount rate-bond equivalent yield	1.79%
Expected life (in years)	5 years 1 month 13 days
Expected volatility	80.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 2.13
Discount rate-bond equivalent yield	2.08%
Expected life (in years)	6 years 1 month 2 days
Expected volatility	90.00%

XML 56 R44.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Percentage Of Overall Performance Grant Subject To Vesting (Detail)	6 Months Ended
	Jun. 30, 2017
Performance Stock Options [Member}
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	100.00%
Performance Stock Options [Member} \| 2013 Equity Incentive Plan [Member] \| Minimum Revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
Performance Stock Options [Member} \| 2013 Equity Incentive Plan [Member] \| Cost of Revenue Reductions And Improvements [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Performance Stock Options [Member} \| 2013 Equity Incentive Plan [Member] \| Increase Cash Generated From Operations [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Performance Stock Options [Member} \| 2013 Equity Incentive Plan [Member] \| Minimum Cash On-Hand at December 31, 2017 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Performance Stock Options [Member} \| 2013 Equity Incentive Plan [Member] \| Minimum Customer Agreements, Product Licensing And Product Launch [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
Performance Stock Options [Member} \| 2013 Equity Incentive Plan [Member] \| Implementation Of New Products And Utility Trials [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Performance RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	100.00%
Performance RSUs [Member] \| 2013 Equity Incentive Plan [Member] \| Minimum Revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
Performance RSUs [Member] \| 2013 Equity Incentive Plan [Member] \| Cost of Revenue Reductions And Improvements [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Performance RSUs [Member] \| 2013 Equity Incentive Plan [Member] \| Increase Cash Generated From Operations [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Performance RSUs [Member] \| 2013 Equity Incentive Plan [Member] \| Minimum Cash On-Hand at December 31, 2017 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Performance RSUs [Member] \| 2013 Equity Incentive Plan [Member] \| Minimum Customer Agreements, Product Licensing And Product Launch [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
Performance RSUs [Member] \| 2013 Equity Incentive Plan [Member] \| Implementation Of New Products And Utility Trials [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%

XML 57 R45.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of RSU Activity (Detail) - RSUs [Member]	6 Months Ended
	Jun. 30, 2017 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares Outstanding, Beginning Balance \| shares	174,249
Number of Shares, Granted \| shares	350,000
Number of share, Vested and issued \| shares	(65,831)
Number of share, Forfeited \| shares	(7,500)
Number of Shares Outstanding, Ending Balance \| shares	450,918
Number of Shares, Vested and unvested expected to vest, Ending Balance \| shares	408,481
Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance \| $ / shares	$ 2.68
Weighted Average Grant Date Fair Value, Granted \| $ / shares	1.50
Weighted Average Grant Date Fair Value, Vested and issued \| $ / shares	2.09
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares	2.10
Weighted Average Grant Date Fair Value, Outstanding, Ending Balance \| $ / shares	1.87
Weighted Average Grant Date Fair Value, Vested and unvested expected to vest, Ending Balance \| $ / shares	$ 1.91

XML 58 R46.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 258,076	$ 321,836	$ 551,695	$ 690,826
Stock Options [Member] \| Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	41,615	29,412	73,385	55,487
Stock Options [Member] \| Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	39,172	25,961	68,428	58,964
Stock Options [Member] \| General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	157,683	264,566	349,736	537,135
Stock Options [Member] \| Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	19,606	1,897	60,146	39,240
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	383,239	330,720	756,461	699,710
RSUs [Member] \| Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	23,133	1,916	38,300	1,916
RSUs [Member] \| Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	22,714	1,452	37,072	1,452
RSUs [Member] \| General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	56,473	1,008	86,406	1,008
RSUs [Member] \| Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 22,843	$ 4,508	$ 42,988	$ 4,508

XML 59 R47.htm IDEA: XBRL DOCUMENT

Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) - Warrants [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Class Of Warrant Or Right [Line Items]
Number of Shares, Outstanding, Beginning Balance	11,623,987
Number of Shares, Issued	2,160,000
Number of Shares, Exercised	(6,811,850)
Number of Shares, Outstanding, Ending Balance	6,972,137	11,623,987
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 1.93
Weighted Average Exercise Price Per Share, Issued	2.50
Weighted Average Exercise Price Per Share, Exercised	1.10
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	$ 2.92	$ 1.93
Average Remaining Contractual Term (in years)	4 years 3 months 19 days	4 years 7 months 6 days

XML 60 R48.htm IDEA: XBRL DOCUMENT

Common Stock Warrants Outstanding - Additional Information (Detail) - USD ($)		6 Months Ended
	Aug. 09, 2017	Jun. 30, 2017	Aug. 11, 2017	Mar. 31, 2017	May 04, 2016
Class Of Warrant Or Right [Line Items]
Common stock warrants outstanding, intrinsic value		$ 787,126
Issuance of warrants to purchase shares of common stock					1,163,526
Exercise price of warrants				$ 2.50	$ 3.90
Subsequent Event [Member]
Class Of Warrant Or Right [Line Items]
Exercise price of warrants			$ 1.50
Subsequent Event [Member] \| Ally Bridge [Member]
Class Of Warrant Or Right [Line Items]
Private offering, number of common stock and warrants issued	1,466,667
Issuance of warrants to purchase shares of common stock	1,434,639
Exercise price of warrants	$ 1.5
Class of warrant or rights, term	5 years
Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued		2,160,000
Warrants exercisable period		5 years
Warrants exercisable beginning date		Sep. 30, 2017
Warrants or rights exercisable period from closing of associated offering		6 months

XML 61 R49.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share - Additional Information (Detail)	Sep. 29, 2016
Earnings Per Share [Abstract]
Reverse stock split of common shares outstanding	0.33

XML 62 R50.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	9,804,743	2,715,541	9,804,743	2,715,541
Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	6,972,137	1,896,856	6,972,137	1,896,856
RSUs Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	450,918	86,756	450,918	86,756
Preferred Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	529	529	529	529
Common Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	2,381,159	731,400	2,381,159	731,400

XML 63 R51.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended	6 Months Ended
	Feb. 29, 2016	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Unconditional purchase commitment aggregate amount	$ 1,062,500	$ 628,760
Unconditional purchase commitment, quarterly payment amount	$ 62,500
Unconditional purchase commitment payment terms		Quarterly
Unconditional purchase commitment period		May 31, 2020

XML 64 R52.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail)				3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 01, 2017	Oct. 31, 2016 USD ($) Director Consultant shares	May 04, 2016 USD ($) Director shares	Jun. 30, 2016 USD ($)	Mar. 31, 2015	Jun. 30, 2017 USD ($) ft²	Jun. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)
Related Party Transaction [Line Items]
Rental income				$ 38,412		$ 38,412	$ 76,824
Number of consultants \| Consultant		1
San Diego California Facility [Member]
Related Party Transaction [Line Items]
Lease expiration date	Mar. 31, 2017
Rental income						38,412	$ 76,824
Aegea Biotechnologies, Inc [Member]
Related Party Transaction [Line Items]
Reimbursement for shared patent costs						$ 15,325		$ 19,047
Nonexecutive [Member] \| San Diego California Facility [Member]
Related Party Transaction [Line Items]
Leased facility, expansion of original premises \| ft²						9,849
Lease agreement date of commencement						Mar. 30, 2015
Leased facility, rent expense per month						$ 12,804
Lease facility, refundable security deposit amount						$ 12,804
Lease expiration date					Jul. 31, 2015
Director [Member]
Related Party Transaction [Line Items]
Number of members of board of directors \| Director		3	3
Initial public offering, number of shares issued \| shares		534,088	58,335
Issuance of warrants to purchase shares of common stock \| shares		534,088	40,832
Proceeds from issuance of common stock		$ 587,497	$ 175,000
Director [Member] \| Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Number of members of board of directors \| Director		7
Claire K.T. Reiss [Member]
Related Party Transaction [Line Items]
Initial public offering, number of shares issued \| shares		227,272	204,758
Issuance of warrants to purchase shares of common stock \| shares		227,272	143,330
Proceeds from issuance of common stock		$ 249,999	$ 614,273
Beneficial owner percentage of company's common stock		10.00%	10.00%
Consultants [Member]
Related Party Transaction [Line Items]
Initial public offering, number of shares issued \| shares		79,090
Issuance of warrants to purchase shares of common stock \| shares		79,090
Proceeds from issuance of common stock		$ 86,999

XML 65 R53.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) - USD ($)			6 Months Ended	12 Months Ended
	Aug. 11, 2017	Aug. 09, 2017	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2017	May 04, 2016
Subsequent Event [Line Items]
Issuance of warrants to purchase shares of common stock							1,163,526
Stock price			$ 2.13
Exercise price of warrants						$ 2.50	$ 3.90
Proceeds from exercise of common stock warrants			$ 7,493,035
Increase in capital shares value				$ 1,400,000
Associated costs incurred related to offering				$ 79,000	$ 42,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock price		$ 1.39
Proceeds from issuance of common stock	$ 2,200,000
Exercise price of warrants	$ 1.50
Proceeds from exercise of common stock warrants	$ 0
Subsequent Event [Member] \| Ally Bridge [Member]
Subsequent Event [Line Items]
Private offering, number of common stock and warrants issued		1,466,667
Issuance of warrants to purchase shares of common stock		1,434,639
Stock price		$ 1.50
Proceeds from issuance of common stock		$ 2,200,000
Exercise price of warrants		$ 1.5
Class of warrant or rights, term		5 years
Estimated grant date fair value of warrants		$ 1.03
Issuance of warrants to purchase shares of common stock, grant date fair value		$ 1,500,000
Proceeds from exercise of common stock warrants	0
Increase in capital shares value	2,000,000
Associated costs incurred related to offering	$ 200,000

XML 66 R54.htm IDEA: XBRL DOCUMENT

Subsequent Events - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) - $ / shares		6 Months Ended
	Aug. 09, 2017	Jun. 30, 2017
Subsequent Event [Line Items]
Stock price		$ 2.13
Exercise price		$ 2.50
Expected dividend yield		0.00%
Discount rate-bond equivalent yield		1.93%
Expected life (in years)		5 years
Expected volatility		80.00%
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock price	$ 1.39
Exercise price	$ 1.50
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	1.81%
Expected life (in years)	5 years
Expected volatility	100.00%

EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( Q$#DL?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ #$0.2V;S"V"" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " ,1 Y+1>6'V>\ K @ $0 &1O8U!R;W!S+V-O M&ULS9+/3L,P#(=?!>7>NFG1F**N%Q GD)"8!.(6)=X6K?FCQ*C=V].& MK1."!^ 8^Y?/GR6W*@CE([Y$'S"2P70SVMXEH<*&'8B" $CJ@%:F&$YCW\(5,,,(HTW?!=0+,5?_Q.8.L'-R3&9)#<-0#DW.33MP M>']^>LWK%L8EDD[A]"L90:> &W:9_-;Q:^'47W1=02P,$% @ #$0.2YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " ,1 Y+"MTH/64" 5" & 'AL+W=OV<.3-FQI-B8/Q5U(3(X*VEG=B%M93]8JF6_!:)GA-\,:261C".LZC%31>6A=D[\;)@=TF;CIQX(.YMB_GO Z%L MV(4@?-]X:6ZUU!M16?3X1KX1^;T_<;6*)BN7IB6=:%@7<'+=A7OP? 2))AC$ MCX8,8C8/="AGQE[UXO-E%\;:(T)));4)K(8'.1)*M27EQZ_1:#AI:N)\_F[] MHPE>!7/&@AP9_=E<9+T+-V%P(5=\I_*%#9_(&% :!F/T7\B#4 77GBB-BE%A M?H/J+B1K1RO*E1:_V;'IS#C8DP2--#\!C@0X$6#V7P(:"6@BV-N,K&!_ +(&P$R=#2C)WYZXJ4GAI[,Z.GB EQ$YA=(O0*I0\\7 M BYBXQ?(O *90]\N!%P$B/T*N5+;+PB&U=DD2D' M"\GFD)54V7HEMJY$LI#P0%*_!(C]!16[%K)E27DP*W<%5LH6N!8V2Q7@?!,0 M)PG*5[(+> MX#Z KM4PP#P:N9!CP5S% KH5ECODP<$7%7^S K66(%L_1B)E? M&XIABO)DF6O1[)%M";^9?B2"BMT[TPQGNU//VT/S2/^%VX;Y%?-;TXG@S*1Z MZLV#?&5,$N50_*1YFK.;:.R"\GZL0E'TS^!\@]02P,$% M @ #$0.2]0G,^02! A( !@ !X;"]W;W)KNNSRE:;L[AJIHO]27<(Z_ M'.JF*KIXV;RF[:4)Q7X(JLH4L\RF57$Z)^OE<.^Y62_KMZX\G<-SLVC?JJIH M_MN$LKZN$D@^;GP]O1Z[_D:Z7EZ*U_!7Z+Y=GIMXE=ZS[$]5.+>G^KQHPF&5 M_ Q/6_1]P*#X^Q2N[>1\T9?R4M??^XO?]ZLDZQV%,NRZ/D41#^]A&\JRSQ1] M_#LF3>YM]H'3\X_LOP[%QV)>BC9LZ_*?T[X[KI(\6>S#H7@KNZ_U];.XEM[.JR'?XO=F]M5U=CEFBE*G[ M /K3 #4&*!*0WIP-I?Y2=,5ZV=3717,;K4O13PIX4K$S=_W-H>^&WV*U;;S[ MOD:]3-_[/*-DDL?V["11-X!"OIO%6CE=BO!KB]33>D2)N M$C=(SH,$LO@'QI!:N%#;S"N%LB$M&M+<4$X,W21FTH[WVFE+[' 98.ZME]T8 MT8WA;CQQ8U@S5@%"1MQPF=$^TS.#;44WEKE1I)F-Y6Y0YW1,MURF6;5 MI, '/U[TX[D?1?QXWHZV1H$GPBT7.N-R-;?8(9.1E3%<*#V3809ZP(LRE'K MJW+.Z&4/I*@J5MG8&(" #%CAA-24L<'8:I[T&^OP1A%IY9!@U93T() 4&5R3<$OZ0!5W%[,6))1"YRUFK(6 M.$,Q3B:&6DF'#B;+X'%?)J,6,^Z(;@]'S<."B]LE0SDIZ;Q#/S.14$8WTK9S?=QVTD#472YYI')S*Q4;%'XV2R/F:0 M$8LKH1A##LR?(%?.@J.O)5M1ZY2-V'-S/28# M%CE@#:49-6EDTG+K0FMW:NLV3 (@>L83CS_$U1WLT*2GD[FTY>QONO M(W\6S>OIW"Y>ZBZ^UP]OWX>Z[D),FGV))1Y#L;]?E.'0]:WKQ*WBZZ^ MC%]&PO=V]R M:W-H965T&ULC95OKYL@%,:_BO$#%/ROC359NRQ;LB7-7;:] MIBVMYJ(XH/7NVP_0ZQ19V[ZH@,]SSN\ 0MY1]LI+C(7S5I.&;]Q2B'8- #^6 MN$9\15O,X=? MZQJQ/UM,:+=Q/?=]X*6ZE$(-@")OT05_Q^)'NV>R!\8HIZK&#:]HXS!\WK@? MO/7.@\J@%3\KW/%)VU&E'"A]59TOIXT+%1$F^"A4""0?-[S#A*A(DN/W$-0= M_9,N7A9S0!SO*/E5G42Y<5/7.>$SNA+Q0KO/>"@H*)%'I/DGF+&$%L9X@5# M;&38Q@\9[BEF#(F5(5DR&,N_39[;)0]E,YK42I,N:8S/:ILNZO6&Y3=GYAGE MC"FS,F5+IL!@RA:9_#3.$I@86WRW%'I)F&5!EMB)Y%U@/9_@DBDT#RCX+)1% M^1\J,#E U8WV#;%+U7#G0(4\B_6)>:948!D5KF2\4EZB8X?@LU#-1+99?Y/T M'4';X98$XU5=_ 502P,$% @ #$0.2X@OVA>8! K!0 !@ !X;"]W M;W)K+(D^,YPS0_&,.#N7U?=Z%V,S^5$[6.3U37F*Q_3/4UD5>9,>J^>L/E4QWW9&Q2$#(6Q6Y/OC=#[K MQAZJ^:Q\:0[[8WRH)O5+4>35OXMX*,]W4SE]&_BZ?]XU[4 VGYWRY_@M-G^> M'JKTE%V\;/=%/-;[\CBIXM/=]%[>KD&W!AWBKWT\UU?WDY;*8UE^;Q]^V]Y- M11M1/,1-T[K(T^4U+N/AT'I*YFP-K^_?O/_2D4]D'O,Z+LO#W_MM ML[N;^NED&Y_RET/SM3S_&@="9CH9V/\>7^,AP=M(TAR;\E!WOY/-2]V4Q> E MA5+D/_KK_MA=SX/_-S/> 8#N!BDN3\R4(.!^FF@/S30@X'^[ QF,#!HAJSG MWB5SE3?Y?%:5YTG5KX=3WBX[>6M2N3;M8%>=[K^4SSJ-OLZMF66OK9\!LN@A M< VQ[R$K"I$71);FOP0!7! +(.;P?H(E15B'8OA?)^L/G;P+4[&Y4IV]NK;W MO+UF[75GKZ_M \IU#W$=Y-@G$IP/5J)\4)RUX*U .:$P"!8$H/JM*::CK+>";1BEQ0GK0T&^UM1G-;!2X.JLJ8X M);56=F21.Y:?H_S0 ETX,H_7,@10%3RJ:*X]SI6BT(+5R>-ES MP! <8,UB'08;A,)YXH#*2SLB.Y)794EE&6^ERP'S[EU,6S/@T#\%6S,P9SWH MD;!YN96&A.T%KHWY;&T8H)5*>$R051VA"3?$TC:%'C<%$BJ MSE^,#5*0MH!#:A.4)8T!ATR[#2A'B\E @[9.R9'N2?+M@:3]@NV.O>K(I7XY-6_2KTRK*)*7IQDU;M+N;; MR\,A/C7MK4OW57]^UC\TY6DX&\PN!Y3S_P!02P,$% @ #$0.2VOX!X-[&D_$/^,Z(^ M'I;GIOW>[4/H9S_JZMC=S_=]?[HKBFZ[#W79?6I.X1C_\]RT==G'V_:EZ$YM M*'=C4%T5*(0IZO)PG*^6X[/'=K5L7OOJ< R/[:Q[K>NR_6\=JN9\/X?Y^X.O MAY=]/SPH5LM3^1+^"OVWTV,;[XIK*[M#'8[=H3G.VO!\/W^ NXU40\"H^/L0 MSMW-]6Q(Y:EIO@\WO^_NYV)P%*JP[86# MD]C'MJFZ\>]L^]KU33VU$JW4Y8_+[^$X_IZG]M_#^ "< O :$/O^58"< N3/ M@+&:Q<79F.KGLB]7R[8YS]K+VSJ5PZ" .QF+N1T>CK4;_Q>S[>+3MY5SR^)M M:&>2K"\2O)' 55'$QJ\](-?#&DDX?NQ@0Q7&\CU(-@F6\M,A;TJPE35+RF:(;-M[0E)*JKR\2 M?6,4T0C023Y4!MIZFRFP9=U8ZD8F;BSI9H'.>YNX8632&I.IK6/=..I&)6X< MZ<9JHPPD;JC,1,L@>#>>=>.IF^05K#WMQCF3>*$BB1XRKPD$#P-!AYW)M)#! M"9!TD/ $Z$MT1EN;OFQ.J%%IF;'$\N.O#4$95)(US.#X]5 M8+CJ4S\<,6.)R$MC=*#CC)!QQ*,5*%M!D)%-L;EP7EG09&QS2HQSJ<\@%GC& M@B=U]V1%Q@A5G&XTZHPI'I%($0DB)1)2 M]EGEI9"YOGCX(84?B'320H9J2L=5:9H_I_/"Y#X 'GY(X02TE(9X:5,1SHCC,L3B OAC"D>JY+!*J18E926<:H3<0.5[J 8I;0Z[J(R MDYCDN2H9KN;6G3*S46:XFF[XUI)94*+&%#\;1@?.RMR60_)4E0Q5(:6JI)MJ M!)7N@#B5()N%XN9DI [MRWB(U,VVS>NQ'PXA;IY>#ZH><#A929ZOX6YS.6[Z MVKCPW31^B2?$IUFL?RMWUI@K/_7!IXW5[.76Z MW/3-:3I1*Z['>JO_ 5!+ P04 " ,1 Y+A*& "I4" >"0 & 'AL M+W=O?Q4>OV M,4GZ[5'6HG]0K6S,E[WJ:J%-LSLD?=M)L7.DNDH(0CRI1=G$BYGKVW2+F3KI MJFSDIHOZ4UV+[N^3K-1E'N/XO>.Y/!RU[4@6LU8^JMZ9%-Y4>K5-K[NYC&R$U]_5URYYD\R+Z.525;_+G3[.XSR.=G(O3I5^5IOVTTVG^V8FH#>]YP7&V2PY6Z$1\S1@R TFO\4L0PRY1:Q"!/>,/@,BZ2UD M#<523)C$Y#HE3,"$B1.@UP($P0(4%*!.@-T(8&_$!DSA,,V0R$,*FS#0A $F MWH ^01@*FZ2@20H(,,]DP&37F>3(_F C#AIQP,B;V"4/C&A:<#_I50ACE+'L MSN!F8#@9$ [WPADPZ94/YFF*/=@JA#&6TIS#X>1@.#D0CKA%D>]%@JPRMTT]J^3J M5K OA^^B.Y1-'[TH;2X8=PWLE=+2:*('$_G1/%:F1B7WVE8S4^^&&WMH:-6. MKY%D>A(M_@%02P,$% @ #$0.2Y:X4=2T 0 T@, !@ !X;"]W;W)K M<.3,>YZ.Q3ZX#\.1%2>T*VGG?'QAS50>* MNRO3@\:;QEC%/9JV9:ZWP.L(4I*EN]T-4UQH6N;1=[)E;@8OA8:3)6Y0BMO7 M(T@S%C2A;XY'T78^.%B9][R%K^"_]2>+%EM8:J% .V$TL= 4]"XY'/.>F2,@#7YS?VC[%V MK.7,'=P;^4/4OBOH+24U-'R0_M&,GV"NYYJ2N?@O< &)X4$)YJB,='$EU>"\ M43,+2E'\9=J%COLXW5R_GV';@'0&I O@-N9A4Z*H_ /WO,RM&8F=>M_S\,3) M(<7>5,$96Q'O4+Q#[Z5,LB1GET TQQRGF'0=LT0P9%]2I%LICNE?\'0;GFTJ MS"(\^TWA/PCVFP3[2+#_;XE;,=D?2=BJIPIL&Z?)D(LP$ -(# 8 >&PO=V]R:W-H965T M&UL?5/;;MP@$/T5Q >$7=9)HY5M*9NJ2J566J5J\\S:XXL" MC MXG?Y] 7L=)W7S LPPY\R984@'-,^V 7#D14EM,]HXU^T9LT4#2M@K[$#[ MFPJ-$LZ;IF:V,R#*"%*2\8J]DZV&HR&V5TJ8/P>0.&1T M2R^.Q[9N7'"P/.U$#3_ _>R.QEML9BE;!=JVJ(F!*J-WV_TA"?$QX%<+@UV< M2:CDA/@UG(2% M>Y1/;>F:C-Y24D(E>ND><7B J9YK2J;BO\$9I \/2GR. J6-*REZZU!-+%Z* M$B_CWNJX#^--QTE>>.>!O>/Q35[#QVG_+DS= M:DM.Z/S+QOY7B Z\E,V5'Z'&?[#9D%"Y&PO=V]R:W-H965T&UL?5-A;]L@$/TKB!]0$I(U461;:CI-F[1)4:>MGXE]ME&!\P#'W;\? M8-?S-FM?@#ONO7MW'-F ]L6U )Z\:F5<3EOONQ-CKFQ!"W>''9AP4Z/5P@?3 M-LQU%D250%HQOMG<,RVDH466?!=;9-A[)0U<+'&]UL+^/(/"(:=;^N9XDDWK MHX,562<:^ K^6W>QP6(S2R4U&"?1$ MU3A^VI_,^QJ> [Q(&MSB36,D5\24: MGZJ<;J(@4%#ZR"#"=H-'4"H2!1D_)DXZIXS Y?F-_4.J/=1R%0X>43W+RK\HF8K_##=0(3PJ"3E*5"ZMI.R=1SVQ!"E:O(Z[-&D? MQAM^F&#K #X!^ PXICQL3)24OQ=>%)G%@=BQ]YV(3[P]\=";,CI3*])=$.^" M]U9L=_<9NT6B*>8\QO!ES!S! ON<@J^E./-_X'P=OEM5N$OPW1\*#^L$^U6" M?2+8_[?$M9CC7TG8HJ<:;).FR9$2>Y,F>>&=!_:!IS?Y'3Y.^Q=A&VD/Q$,YV'+/1\-A-/XC-W[CX!5!+ P04 M" ,1 Y+V6(PC+0! #2 P &0 'AL+W=O;$]XW/.7#PN)F.?70_@R8N2VI6T]WXX,N;J'A1W-V8 C3>ML8I[-&W'W&"! M-Y&D)$N3Y!U37&A:%=%WME5A1B^%AK,E;E2*V]\GD&8JZ8&^.AY%U_O@8%4Q M\ Z^@_\QG"U:;%5IA +MA-'$0EO2^\/QE =\!#P)F-SF3$(E%V.>@_&E*6D2 M$@()M0\*'+##RIVA\7]([2AIH M^2C]HYD^PU+/+25+\5_A"A+A(1.,41OIXDKJT7FC%A5,1?&7>1#SP\\>&88F_JX(RMB'>8O$/OM3ID M'PIV#4(+YC1CTBUF13!47T.D>R%.Z7_T=)^>[6:817JVC9XG^P+YKD >!?(W M2]S!Y/\6R38]56"[.$V.U&;4<9(WWG5@[]/X)G_A\[1_X[83VI&+\?BRL?^M M,1XPE>0&1ZC'#[8:$EH?CN_Q;.&PO=V]R:W-H965T6_>#$,^HGUV'8 G+UH95]#.^_[(F*LZT,+=8 \FW#1HM?#!M"USO051)Y!6 MC.]V;YD6TM R3[ZS+7,\HJ:$1@_*/ M.'Z$N9XWE,S%?X8KJ! >E80<%2J75E(-SJ.>68(4+5ZF79JTC]/-[;L9M@W@ M,X O@+N4ATV)DO+WPHLRMS@2._6^%_&)]T<>>E-%9VI%N@OB7?!>RWW&\_0FO\.G:?\B;"N-(Q?TX653_QM$#T'* M[B:,4!<^V&(H:'P\WH:SG<9L,CSV\P]BRST 0 T@, !D !X;"]W;W)K&UL?5-A;]L@ M$/TKB!]0$N(V561;:EI5G;1)4:MMGXE]ME'!N(#C[M_WP*[G;=:^ '?<>_?N M.-+!V%?7 'CRKE7K,MIXWQT8)9UXX.#Y6DG:G@!_[T[ M6;38S%)*#:V3IB46JHS>;0_'),3'@!\2!KF;C-Y24D(E>N6?S? $ M4SW7E$S%?X4+* P/2C!'892+*REZYXV>6%"*%N_C+MNX#^,-WT^P=0"? 'P& MW,8\;$P4E3$+_+4FH'8L?>="$^\/7#L31&+-.D*P2))$@^6^):S'[OY*P M14\UV#I.DR.%Z=LXR0OO/+!W/+[)[_!QVK$6\O6D;/Q^+*Q_Y4Q'E#*Y@I' MJ,$/-AL**A^.>SS;<X,]:'_3H%'<>=.TS/8&>!U!2K(T2=XQQ86F M91Y]9U/F.#@I-)P-L8-2W/P^@<2QH#OZXG@4;>>"@Y5YSUOX!NY[?S;>8@M+ M+11H*U 3 TU![W?'4Q;B8\ / :-=G4FHY(+X%(S/=4&3( @D5"XP<+]=X0&D M#$1>QJ^9DRXI W!]?F'_&&OWM5RXA0>4/T7MNH(>**FAX8-TCSA^@KF>6TKF MXK_ %:0/#TI\C@JEC2NI!NM0S2Q>BN+/TRYTW,?I9G\WP[8!Z0Q(%\ AYF%3 MHJC\ W>\S V.Q$R][WEXXMTQ];VI@C.V(MYY\=9[K^4N.^3L&HCFF-,4DZYC ME@CFV9<4Z5:*4_H&GF[#]YL*]Q&^_T?A^VV";),@BP39?TO2W/@1ZOP' M6PP)C0O'.W\VTYA-AL-^_D%L^<;E'U!+ P04 " ,1 Y++ YK#;0! #2 M P &0 'AL+W=O<.3,>YZ-US[X# M".1%*^,+VH70'QGS50=:^!O;@\&;QCHM IJN9;YW(.H$THKQW>X-TT(:6N;) M=W9E;H>@I(&S(W[06K@?)U!V+&A&7QU/LNU"=+ R[T4+GR%\Z<\.+;:PU%*# M\=(:XJ IZ$-V/!UB? KX*F'TJS.)E5RL?8[&A[J@NR@(%%0A,@CYGEM*YN(_ MPA44AD55(,/5L\L*$6+EVF7)NWC='/'9]@V@,\ O@#N4QXV)4K* MWXH@RMS9D;BI][V(3YP=.?:FBL[4BG2'XCUZKV5VF^7L&HGFF-,4P]>9>!?4B/R'Z%3]/^2;A6&D\N-N#+IOXWU@9 *;L;'*$./]AB*&A" M/-[AV4UC-AG!]O,/8LLW+G\"4$L#!!0 ( Q$#DM\[-PQLP$ -(# 9 M >&PO=V]R:W-H965T-(!S2OM@%PY%U) M;3/:.-<=&+-% TK8&^Q ^YL*C1+.FZ9FMC,@R@A2DO'-YI8IT6J:I]%W,GF* MO9.MAI,AME=*F(\C2!PRNJ57QW-;-RXX6)YVHH;OX'YT)^,M-K.4K0)M6]3$ M0)71^^WAF(3X&/"SA<$NSB14K^Q?8NV^EK.P\(#RI2U=D]$[2DJH1"_=,PY?8:IG3\E4_#>X@/3A M08G/4:"T<25%;QVJB<5+4>)]W%L=]V&\2:ZP=0"? 'P&W$4 &Q-%Y9^%$WEJ M<"!F['TGPA-O#]SWI@C.V(IXY\5;[[WDVWV2LDL@FF*.8PQ?QLP1S+//*?A: MBB/_!\[7X;M5A;L(W_VA<+].D*P2))$@^6^):S&W?R5ABYXJ,'6<)DL*['6< MY(5W'MA['M_D=_@X[4_"U*VVY(S.OVSL?X7HP$O9W/@1:OP'FPT)E0O'3_YL MQC$;#8?=](/8_(WS7U!+ P04 " ,1 Y+#7J2Y;,! #2 P &0 'AL M+W=O**F@%KWRSSA\@*F>>TJFXC_!%50(CTI"CA*5 M2RLI>^=13RQ!BA:OXRY-VH?Q9G>#K0/X!. SX) ;$R4E+\37A29Q8'8L?>= MB$^\/?+0FS(Z4RO271#O@O=:;.\?,G:-1%/,:8SARY@Y@@7V.05?2W'B_\#Y M.GRWJG"7X+L_%![6"?:K!/M$L/]OB6LQ;_]*PA8]U6";-$V.E-B;-,D+[SRP MCSR]R>_P<=H_"]M(X\@%?7C9U/\:T4.0LKD+(]2&#S8;"FH?CP_A;,&UL?5-AC]0@$/TKA!]P=-F]\[)IF]R>,9IHLCFC M?F;;:4L.F IT>_Y[@?9JU>H78(9Y;]X,0SZB?78=@"R/ M$R@<"[JCKXXGV78^.EB9]Z*%S^"_]&<;++:PU%*#<1(-L= 4]&%W/!UB? KX M*F%TJS.)E5P0GZ/QH2YH%@6!@LI'!A&V*SR"4I$HR/@^<](E902NSZ_L[U+M MH9:+TIJ:,2@_!..[V&NYY:2N?B/< 45PJ.2D*-"Y=)*JL%Y MU#-+D*+%R[1+D_9QNKGE,VP;P&< 7P#W*0^;$B7E;X4796YQ)';J?2_B$^^. M//2FBL[4BG07Q+O@O9:[NRQGUT@TQYRF&+Z.62)88%]2\*T4)_X7G&_#]YL* M]PF^_TWA/_(?-@D.B>#PWQ*W8OY4R58]U6#;-$V.5#B8-,DK[S*P#^D1V:_P M:=H_"=M*X\@%?7C9U/\&T4.0DMV$$>K"!UL,!8V/QS?A;*&UL?5-A;]P@#/TKB!]0[DC:G4Y)I%ZK:9,VZ=1IZV^C\ M38U&"^=-TS#;&Q!5!&G%^&YWQ[20'2VRZ#N;(L/!*=G!V1 [:"W,KQ,H''.Z MIV^.)]FT+CA8D?6B@6_@OO=GXRVVL%120V6DKGX+W %Y<.#$I^C1&7C2LK!.M0SBY>B MQ>NTRR[NXW23'&;8-H#/ +X #C$/FQ)%Y8_"B2(S.!(S];X7X8GW1^Y[4P9G M;$6\\^*M]UZ+_5V2L6L@FF-.4PQ?QRP1S+,O*?A6BA/_!\ZWX"F[&S]"K?]@BZ&@=N'XP9_--&:3X;"??Q!;OG'Q&U!+ M P04 " ,1 Y+"/&B3[0! #2 P &0 'AL+W=OM.T29M4W;3M,TV";A,$MSB16;* @4E#XRB+#=X!&4BD1!QH^)D\XI(W!Y?F5_GVH/M5R%@T=4WV7E MVYP>*:F@%KWR3SA\@*F>-Y1,Q7^"&Z@0'I6$'"4JEU92]LZCGEB"%"U>QEV: MM _C#7\[P=8!? +P&7!,>=B8*"E_)[PH,HL#L6/O.Q&?>'OBH3=E=*96I+L@ MW@7OK=@>#AF[1:(IYCS&\&7,',$"^YR"KZ4X\W_@?!V^6U6X2_#='PKOUPGV MJP3[1+#_;XEK,<>_DK!%3S78)DV3(R7V)DWRPCL/[ -/;_([?)SVS$VTCAR M11]>-O6_1O00I&SNP@BUX8/-AH+:Q^-].-MQS$;#8S?](#9_X^(74$L#!!0 M ( Q$#DNV/%M"]P$ ,L% 9 >&PO=V]R:W-H965T0'J DD 2*"U'2J-FF3HD[;/COD J@VIK83NK>?;0A# M]/H%V^??GSL;7]Y+]:IK !.\"][J/:F-Z7:4ZK(&P?2#[*"U.Q>I!#-VJ2JJ M.P7L[$F"TR@,MU2PIB5%[F-'5>3R:GC3PE$%^BH$4W\/P&6_)RMR#[PT56U< M@!9YQRKX">97=U1V12>5V$Z%+"#B4QBDP.]S@"3AW0C:-MU&33):..)_?U9]][;:6$]/P)/F?YFSJ M/4E)<(8+NW+S(ONO,-:S(<%8_'>X ;=PEXGU*"77_AN45VVD&%5L*H*]#V/3 M^K$?=I([#2=$(R&:"*DGT,'(9_Z%&5;D2O:!&LZ^8^Z*5[O(GDWI@OXH_)Y- M7MOHK5AMLYS>G-"(.0R8:(Z9$-2J3Q819G&(/M CG!ZC&<:>'L_=XT\$UJC MV@NLYP))N"@1PWQ2Y 8UV2 "T<($P\2XR18UV2("ZX4)AMG@)@EJDB "VX4) MADEPDQ0U21&!=&&"83+<)$--LH\"Z?+B,&PO M=V]R:W-H965T<$7 XIWN);XKFI:N,2)$LZ5L%/,+^ZL[(1F56*1D"K&]DB!66*'[;' M4^SP'O"[@4$O]LAU[DP#8^2OS2%J5-\P*B DO7'ND]FQRE_1'X;_9XK7-7K/M@2;DZH0FS&G$T"5F1A"K/EO0D,6)_D.G87H4 MK##R]&CI'OU'8!<4V'F!W:<6HU6+( _6WZP,^SNT/IJJFU>@BC;VC_B:5 M4AJPI6SN;,.U?2KF@$-IW/;>[M4X,&-@9#>]!61^D+*_4$L#!!0 ( Q$ M#DL'=G"EM0$ -(# 9 >&PO=V]R:W-H965TVT=]J#]38-&<>=-TS+;&^!U)"G) MTB3YR!07FI9Y])U-F>/@I-!P-L0.2G'SYP02QX+NZ,WQ+-K.!0F"L[8BGCGD[?>>RUWAX><78/0 MC#E-F'2-61#,JR\ATJT0I_0_>KI-WV]FN(_T_3IZEFP+9)L"613(U@(/R;L2 MMS#OBV2KGBHP;9PF2RH<=)SDE7<9V,&PO=V]R:W-H965T^C\38U&"^=-TS#;&Q!5)&G%^&[W MF6DA.UIDT7&8!GP$_)(PVM69A$K.B,_!^%[E=!<2 @6E"PK" M;Q>X!Z6"D$_CSZQ)EY"!N#Z_JW^-M?M:SL+"/:K?LG)M3F\HJ: 6@W)/.'Z# MN9Y/E,S%/\ %E(>'3'R,$I6-*RD'ZU#/*CX5+5ZF779Q'Z>;Z]N9MDW@,X$O MA)L8ATV!8N9?A!-%9G D9NI]+\(3[P_<]Z8,SMB*>.>3M]Y[*?:W/&.7(#1C MCA.&KS$+@GGU)03?"G'D_]'Y-CW9S#")]&0=/4VV!=)-@30*I/^4F'PH<0N3 M?@C"5CW58)HX39:4.'1QDE?>96#O>'R3O_!IVA^%:61GR1F=?]G8_QK1@4]E M=^5'J/4?;#$4U"XQY1L7;U!+ P04 " ,1 Y+B?BP M9[,! #2 P &0 'AL+W=O)[G7GS. M!C3OM@5PY$-);7/:.M?M&;-E"XK;&^Q ^S\U&L6==TW#;&> 5Y&D)$LVFSNF MN-"TR&+L:(H,>R>%AJ,AME>*F]\'D#CD=$LO@5?1M"X$6)%UO('OX'YT1^,] M-JM40H&V C4Q4.?T<;L_I $? 6\"!KNP2>CDA/@>G"]53C>A()!0NJ# _7&& M)Y R"/DR?DV:=$X9B$O[HOX2>_>]G+B%)Y0_1>7:G'ZBI(*:]]*]XO 9IGYN M*9F:_PIGD!X>*O$Y2I0V?DG96X=J4O&E*/XQGD+'^NBYV#[<9NP-N.:C8[#;GI!;'[&Q1]02P,$% @ #$0.2V?E%MS^ 0 M$ 8 !D !X;"]W;W)K&ULC57;;IPP$/T5Q ?$ MP-Y7@)1-%;52*ZU2M7WVPG!1;$QLLZ1_7]NPE+(3J2_8'LZ<<\;80]P+^:HJ M .V]<]:HQ*^T;H^$J*P"3M6#:*$Q;PHA.=5F*4NB6@DT=TF9#;JM<.^,>66BUS0\[&-RM40CYC1@HCEF M0A##/DE$F,0INDN/\/05ZG#ETM?_.#PL'-YCS+G$1=:HR!HA"!GPC06]'8$_^$3 X7+&T)F%Y*#+%TK4EXFNL;UP5ET:G>/D;O0?^%# MK_Q&95DWRKL(;=J"N[R%$!J,E^#!G)_*M.=IP:#0=KHS&PO=V]R:W-H965T MJVJ3-NG4:=MG+G$2 M5(@S()?NWP](FJ5=O@ V?L_/QF0CFF?; CCRHE5G<]HZUQ\9LV4+6M@;[*'S M-S4:+9PW3<-L;T!4$:05X[O=!Z:%[&B11=_9%!D.3LD.SH;806MA_IQ X9C3 MA+XZGF33NN!@1=:+!KZ#^]&?C;?8PE))#9V5V!$#=4[ODN,I#?$QX*>$T:[. M)%1R07P.QI>N^UX G/V#40S3&G*8:O8I(E@GGV)07?2G'B_\'Y-GR_J7 ?X?LW M"O?;!.DF01H)TC<$Z;L2MV(.[Y*P54\UF"9.DR4E#EVRN_$CU/H/MA@*:A>.'_W93&,V&0[[^0>QY1L7 M?P%02P,$% @ #$0.2V\8R42S 0 T@, !D !X;"]W;W)K&UL;5/;;IPP$/T5RQ\0+][-12M RJ:J4JF55HG:/GMA "LV M0VRSI'\?V["4;GG!,\,Y9RX>IP.:-]L ./*A56LSVCC7[1FS10-:V!OLH/5_ M*C1:..^:FMG.@"@C22O&-YL[IH5L:9[&V-'D*?9.R1:.AMA>:V'^'$#AD-&$ M7@(OLFY<"+ \[40-K^!^=D?C/3:KE%)#:R6VQ$"5T<=D?]@%? 3\DC#8A4U" M)R?$M^!\*S.Z"06!@L(%!>&/,SR!4D'(E_$^:=(Y92 N[8OZU]B[[^4D+#RA M^BU+UV3T@9(2*M$K]X+#,TS]W%(R-?\=SJ \/%3B?4[!UU(<^']TOD[?KE:XC?3M,OOMP[K M;E5@%P5V_[1X?]7B&N8Z"5O,5(.IXS994F#?QDU>1.>%?>3Q3O["QVW_(4PM M6TM.Z/S-QOE7B Y\*9L;OT*-?V"SHZ!RP;SWMAG7;'0<=M,+8O,SSC\!4$L# M!!0 ( Q$#DN54JFXU0$ +D$ 9 >&PO=V]R:W-H965T= -@T*O@G=G!22 ]",/7W"%R.&8[QU?'< MUHUQ#I*G/:OA!YB?_4E9BRPJ92N@TZWLD((JPX_QX9@XO ?\:F'4JSURE9RE M?''&US+#D4L(.!3&*3"[7. ).'="-HT_LR9>0CKB>G]5_^QKM[68Z]EA-!?_#2[ +=QE8F,4DFO_1<6@C12SBDU%L-=I M;3N_CM-)+X0&UO"N?TK?!G M-GEMO9>I+"!H*<:0W=!JF;X(9;CQ]LZ;3*"RP M#0ILO JOW0:%3(H?,#N_(N<_E(_=7[#Y^&^CM3==MI=);&7F!_S2HI#=A4HCO; ML<:^(XO!H3)NF]B]FJ9I,HSLYX>"+*]5_@]02P,$% @ #$0.2ZI;PYJH M @ ? H !D !X;"]W;W)K&ULE5;;CMHP$/V5 M*.\EF5P) J0N+&JE5EIMU?;9@(%HDSBU#6S_OK83(I),:)8'8COGG#GCR\3S M*^-OXD2IM-[SK! +^R1E.7, MZT9.3M+"7L[-V M?SME99FE!7[@ESGE.^-\GFK'KP@;[-O":'D]2#SC+>4F. M] >5/\L7KGI.H[)/%_1EF&X@UP2!^I?0J[MJ63F7+V)ON?-TO M;%<[HAG=22U!U.-"5S3+M)+R\:<6M9N8FGC?OJEO3/(JF2T1=,6RW^E>GA;V MU+;V]$#.F7QEUR^T3BBTK3K[;_1",P773E2,'3? : @0/"7Y-\!N"'S\D!#4A&&LIK EA0_ >$Z*:$'4(3C59 M9O;71)+EG+.KQ:L-5!*]3V$6J?7=Z4&SG.:=6@"A1B]+S_/GSD4+U9BG"N.U M,$$;L\(P81NS'H%YQC!1&[/!,'&#<52^3=(>FK1G!/R6P!07\%$!WP@$+8&D M,VL5!EP#*@S(G?@^'B9 PP2],)'7F?<*$MX%@="M?IW9'XU\'H-LN0]1]V%_ MDORN*0P#>) (#1(A MTYJC#Q?3X)0-+9YNL^+(%H.AU8L1BU$R-V.G%6%2:Y MB_/)G;C0<8.C MS,%#4S1HJXG&+5* ["!60:\'(&'&!HH:( 7)/ _L%1XL8'_5YL- M]$M#\+ R %X: #OW0W;Q@P_1!S+&#ROT3VL_XWAT,73NOKGZ7O:=\&-:"&O+ MI/I\FX_L@3%)E:P[48(G=15L.AD]2-V,59M7]Z&J(UE9W_6&ULC5;;CMHP$/V5*._=^)X8 =)RJ5JIE5:MVCYGP4"T24P3LVS_OHZ3 MS8(];/M"[.',F3/VV)[I63=/[4$I$[U49=W.XH,QQTF2M)N#JO+V3A]5;?_9 MZ:;*C9TV^Z0]-BK?.J>J3 A"(JGRHH[G4V=[:.93?3)E4:N')FI/594W?Q:J MU.=9C.-7P[=B?S"=(9E/C_E>?5?FQ_&AL;-D9-D6E:K;0M=1HW:S^!Y/UIAT M#@[QLU#G]F(<=:D\:OW433YO9S'J%*E2;4Q'D=O/LUJJLNR8K([? VD\QNP< M+\>O[!]=\C:9Q[Q52UW^*K;F,(NS.-JJ77XJS3=]_J2&A'@<#=E_4<^JM/!. MB8VQT67K?J/-J36Z&EBLE"I_Z;]%[;[G@?_5#78@@P,9'6SL]QSHX$#?'-B[ M#FQP8/\;@0\.W(N0]+F[Q5SE)I]/&WV.FKX>CGE7=GC"[79M.J/;'?>?7<_6 M6I_GA,II\MP1#9A%CR$7&"&N(:L0@D=$8@6,*@BD8D$"=W(=8!DB1.II^"?) M^EV2*YD47"SJ_.EE!(9@ @82,$? K@BPM]H])G68VF&H3)&@R$LWQ&5""BX% M+(B#@C@@R%NU18_AEX$HY]3;(![($8)E7G*KD LS1OV0ZY!,9I1(.#,!9B: MS#S-"Q&JX9)QK["6(\[-(@ M#B.8"N85TC+$"4$RX==;").9%-+?XG6(RS)&;FU>!J:7 >EQ+[TLB/,!LTQR MXM\+ )!DF%-"84D2E"0!2=XMN)" )"*1]$\!@&.,"W9#$$;PU8T 2:E_=R- M$^?(WUT0A^W.W2A+?.,YP8"FS->$@5@4V.!)<.)JDM<4_4$@""!P; $2D((E[9K $@>&22BT>]4LW>=5AMM-&GVG3/ MTH5U[.+N71/GV1=XLL2 ?=5U?:Z)>*/O6\:O>;,OZC9ZU,:V(JYAV&EME)6/ M[NSV'&R7.DY*M3/=,+7CIF_5^HG1QZ$-3<9>>/X74$L#!!0 ( Q$#DL9 M?Y-X.P, &L. 9 >&PO=V]R:W-H965T;;M)NA?W/!-^:V?,*>+:(SIVCP6;=V\#$AHX6D?$^2@ FL8;9 M H@\R\22G 4B$>9#$;"LTZH@SKJ42F#T50J33G)F"LM%+]["A[% M,AB]JQ9($B821UU2'%7*/.IE,)J*Q32+&>,.+9QJBF'M*#J* TO%!ZH&1Y%B M+,Z.$H$14BH8N+87IY%B.,[.$N%1Q(RZ=A<'DF)$SDXR11XRJ<@(H'X'R7@5((/E3"G\H9S$7/'20).)?A0"7,J*8?$\?($'$GP01+F M2-YP1ID+?\"1! Q)UR'@2,('D 0<2?!!$K#W(^T>L XMG$CP(1+F1)JMY:ZO M*!Q(\ $2,"")()F#1\!Y!(Q'APN&\\@^P"/#>60^/#*$1R:$H-P5+PXD\P&2 MS8%,>$8X.*0]OEM,%&G6K;8DUFQT[J M'FRO\-^\;\.^Y\V^J-O@66G3<=B^8*>4EB8@[V\3<-WW[ MTP^T.@ZM733VEZM_4$L#!!0 ( Q$#DL25Y7FM ( $8+ 9 >&PO M=V]R:W-H965T]R$LQ=@]2 M5B//$YL#+8AX814MU3\[Q@LBU9;O/5%Q2K;&J,@][/NQ5Y"L=">I.5OQ2!-THKLZ4\J?U4KKG9>R[+-"EJ* MC)4.I[NQ.T6C)?:U@4'\SNA97*T=+67-V)O>?-N.75]'1'.ZD9J"J,^)SFF> M:R85Q]^&U&U]:L/K]87]BQ&OQ*R)H'.6_\FV\C!V!ZZSI3MRS.4K.W^EC:#( M=1KUW^F)Y@JN(U$^-BP7YM?9'(5D1<.B0BG(>_W-2O,]-_P7,]@ -P:X-5"^ M'QD$C4'P81 ^- @;@["OAZ@QB"P/7JW=)'-!))FDG)T=7K^'BNAGAT:1NJZ- M/C2W8_Y3^13J]#3!L9]Z)TW48&8U!E]AXO@6LKB'H!;AJ0#:*# 4Q0S?F>-; M!_-[1)Q8,3PE63XDN0DS ),5&/OP)ED=.D.0(#0$P0T!A@DBD" "(@BLZX(P MH95."!-9^80PUKTO(4Q'2F-04 P0#&""!"1(^J=T !(,>J04P@RME *8Q*JD M!81!5DHA3(>@(2AH"! $, 'RX:;@]T\JZN@KJ$=:09!5UG,0=-=_ %!B/?KE M$Z9;66"CFB(,^(DZ*. F@H)/)!=N(RA\GMP%!$JZU,+=!@'EG724-X+K&\6? M4 M7.$KZJ 5 24'7:#GU3K&<(ZWR&1G,$G"_4D%B/=!_T]83Y@_!]5@IGS:2: M7,Q\L6-,4A6[_Z(>U4$-M>TFISNIEXE:\WJRJS>25&PO=V]R:W-H965TQZ3ZDHL'.6?541G$XW7V.T@IG@+!)U-E_O[DT M#.FJPM8'(>&K6U?5U]7)Z#TO?I9+8ZK!K\UZ6UX,EU6U.P^"\FEI-EEYEN_, MMO[E.2\V655?%B]!N2M,MFB%-NM A&$4;++5=C@>M??FQ7B4OU;KU=;,BT'Y MNMEDQ7^79IV_7PQAN+_Q8_6RK)H;P7BTRU[,GZ;Z:S?1\TH3SF^<_F8K*X&(:-1V9MGJI&159_O)DK MLUXWFFH__K5*AP>;C>#Q][WVFS;X.IC'K#17^?J?U:):7@R3X6!AGK/7=?4C M?[\S-B ]'-CH[\V;6=?PQI/:QE.^+MO_@Z?7LLHW5DOMRB;[U7VNMNWGN]6_ M%Z,%A!40!P%0)P6D%9"^ LH**%\!;06TKT!D!2)?@=@*Q+\%Y$F!Q HDOA92 M*Y#Z"D"XSUSH+7)(MG>V89]N\,XW[!,.WAF'?P3SIX9QWV:8?(26/0 M-4G;===9E8U'1?X^*#KBV&4-/\%Y+54K;^ZV?=S^6'=>6=]]&XL$1L%;H\EB M+CN,Z&%$'W-%860?@X=++DJ_#>4^',5^$#!JHH M3*5T$OP=XY)$@!3,VBIZ;15:6^T8FG00?63H"R0RCB 63L-._:$S?^@#!8UE M)'5RM,J]8#4=K$;!IDZ:)AK;TE$J03L\^$VCY?^B=*H@=@AJ2FB$$(1.M!/G M/:$R5;7QV.UM @B):LJ)68^(7H$-Q9:D BY+T7?4A>F)V[V,:[G>4Q['A.> M.QFZBXF.BX1V/9K$R*.HIO[(#1"KHV"S#[7UPDOH\!(B/*<([A+"D.:6,:7M MI(0=9Z.>4AA%6VE&-G*N" D=#N]-25#$&.(&&$ ZZIR[A@!E,E:I#*5FC#$; M&PAL3#C[Y[4%':=)0,37.S![(!";8!J[QCI0>FSL# U#&"3/F$T#F%T#\+8A M4F8L (:,0?L/!L 0&% ,YJ3@RH*.\]TQ#I<"AG, DPXJKDO -,&987H?:-!1T;TY$[K0@\;,6: MVL<]@'W7&1H0>"B3(?(*3SPGIP;!\(7 ?"%#=R.RH'X5,KTE&*X0F"M0$T]) M$+/C"88M!"8"M G="#PKI'!J^1C&$-0L$+O&4O_EDPQ;2,P6,HP9'0P12/C$ MP9,A HFW>!DZ8_O<@GI]%9[J8LF=<-88S)+6'N^.+Q)R1 M1 0=W!) )4]YQ="!Q'2 F.Q:XC,5\N<4I.$PQ62X@KE>H)G"ZW(]<% =8HN M)4,LDN(,[7H5>\R!!(B= R7#/M)C5KFF0(#6AP)QK,'0D\3TA =R"SHUD%N/ M,! @DEHP#*T8+E,$EX$S9DU)$#.U*(;P%)Y\$#O?6I!7UA7#BHI@16".A(KA M.B7]V5EQSZXP@TEPRGRB\)PB$^H!AL(,1@)G'AK[[C-4IXC)!R+7?3SY"(J MI[[ F0>P[S[#CXHX>TEFCU8,FZGX$U7 <)#R>5AB0?VG-^S3$L40C").3,"$ MK!DZT*%_R)KI=$V=<=RQ1./'',Q8$AR](&I>'L^RXF6U+0>/>57EF_:%T'.> M5Z;6&I[5U;,TV>)PL3;/5?,UKK\7W4O;[J+*=_:%='!X*S[^'U!+ P04 M" ,1 Y+V0K8D:\' #S+@ &0 'AL+W=OD*I6MW7UV0( KML7: K)_OY(LB-S= M1\@\!.RZ9Z7.ZYW+\6FQ^;A_SO!S]6BW7VY/Q8UD^?9I,MK>/^6J^/2J> M\G7U/_?%9C4OJX^;A\GV:9//[YI&J^5$9YF?K.:+]?CTN/GNV^;TN'@NEXMU M_FTSVCZO5O/-?V?YLG@]&:OQVQ??%P^/9?W%Y/3X:?Z0_YF7?SU]VU2?)N^] MW"U6^7J[*-:C37Y_,OY#??JJLJ9% _E[D;]N.W^/ZK'\*(J?]8>KNY-Q5KN4 M+_/;LNYC7OUZR:?Y_%ZF;K)O?KVW_;\WD!KIMH-\;*-O;P+0-S- &MFU@?S?PO0U#;!GYH@] V"$-=BFV#.-1":ANDH>N@LK>5RX;:4.^+K08W>5MN-7B]U=N" MJ\Z*FR;<=['8!/?YO)R?'F^*U]%F1]"G>:T#ZE,%K3JOOVWHTOQG%>#;ZMN7 M4Z/B\>2E[JG%G.TPNH/14>]CIA+&[&/..4916Y^E?NP^9B9AW#[F0L+X?%!GN#A,:S'HW%IO5/[(E*UNR@B4RL5<[3.I8TD>*1-WU!Z ] M7YSLBV.^>&+E:@=Q72O1IY %$N#70X$W'*B"3X M?==1(E)"H%JJZHJ30GGCM ?&@! J+40'T%(%I%"9X6JJ@,BI 2HW55S!U)$! M,:B A"FN828CELY:4#<,M>Z1;@4T1W'18>0[:T'[PT+Q#N1$<3TQ-+=.6]#> MJ+*^40%%45Q2&)'/6E#7&#(#Y$)QO3!4B\]$$&"U MCCT:H@&YM1^$W$\;P%=0<6?9\Q( 1&2-^*UNL2R(#E M,D MC* 6QM)122 0@ 9M=02ER)"S0 .,/6#'!>AMA,Q-]US7AF=NY5W?.@)^ M&V&_8$B2FXD@L"TQ@-]&2MV!&N)[@:3Z1@4X;@2.4]6?&5[JJR.04PW@MQ&* M?:K%,\/YW3LJ"PAN.<&9%L]:T*!164!N*_$VHX8X"&JQ!>2V$F\5-:19K+N^ M*M4"@EN!X%2+/UOA-*.O>+3H.$-*](X:L\Q8ZC4&),,*%0&M5&>62X;S1$BO M!% @LM*>LGP,W'<=Z(\5I(4:NQ)!H'*U0'^L5%]$.D=HF5]-!.!(%BW /J>J$PL)X:XF<$RGNM M$M )#SCN.N5( 9]9Y8>B('G8L"JO0O/SPKA<;4'0N %(:#5 MWH4 @M6>1U<3TC9"44/\VJ'W],X#6?%2OJ>RXGF^[]MY>Z M7MINT)VWY]I" M=]ZM4Y$Y94V?5T"#_("+B'//;R*8/URFT"40T*<@2$]&92/PPL'V590!:%00 MY(?.\;D$4G3@(@AH2P!"%@0A8^902 %>!Z&V ML(G:XJ15P2B4AR-@;A28Z]#%+"!D/.#.( (:1B5_&7DYX'!9' &/HL C MM$(1\"@>P*,(>!0'' .>1>$"KX]&$= H2J\&Z+UD/. "+P*N12$K4YY,HW"! MUW?@$]&3 "DM&SJ%/-OVV@*DC)R4K%J;MB"EADQA I1, B5IN3850+!<2X"W M23H%5-208FNE^K)V @1/G.#\LC7QDT!D!K [2>RF\9>$"M[ZZ@>DTP1D($EG M@)8:$[;SMMKKH O_!/0B"7KAT(H#&4@';.<38'B2MO,D:BX39[CJW?DF0/$D MG;31=W\2R%E@"#WJ$9(NO;ZX3#SIZBQVKZO(JQ[XK$?:T),PO7Q#=079'J%7 M+1EZAY-)]3*W)?!<7+!)YREJ_1S\ZWSSL%AO1S^*LBQ6S=/3^Z(H\ZK7[*B: MJ<=\?O?^89G?E_6?=7VXV;W"WGTHBZ>3W1/SR?L[]]/_ 5!+ P04 " , M1 Y+^2FF\0X# ,#0 &0 'AL+W=OB)(7ZI^CJ'(FU; Z M>759<79HC/+,P[Y/O9REA;M9-7./U68E+C)+"_Y8.?4ESUGUYYYGXK9VD?LV M\92>SE)/>)M5R4[\.Y<_RL=*C;S.RR'->5&GHG J?ER[G]#=#H?:H$'\3/FM M[CT[.I5G(5[TX,MA[?HZ(I[QO=0NF+I=><*S3'M2NTO7.? CNV3R2=P^\:$&- YAH$QB"8:Q :@_"? M 7G7@!H#.F+PVL5J5G_+)-NL*G%SJK: 2J;K%-U1M;][/=EL9_.?VH!:S5XW M) Q7WE4[,IC[%H-[&+S$0TP"8<@0L[4Q""V'F ?(#QUB=@"F0W@JVRYE#*:, M&W,R2)G"#@CH@#0.@GX>.!CEVF)0N[!%&^1BG&P+BOH8.(X C", XHA'<;28 ML$^!J*\NF"@$B4*+B(31:%-:3#S(-X1)*$A";9+QJCY0*QN$* GQQ/9%(%$$ M$(W*>1,K&H".X!R&X"Q,?CQ@EV@0F- M(UCDR%:Y54CW!C1OY6"-(TCD4W4"*QC1_Z@36)L($&=H[5]DMX& JBN:X((5 MBFR)6ATG,: A%PGH9+G (D2V"H&ZC.?O(H:EBOV/RS(QH'EEB6%!8TC0\9@( M$K0_T4;QQ&EM*]JJ_\2 !AE-+QVL: PHFDXT\"ZE>)YN7OJ,0DBN/_D)Y/*M/DVZ0\:/4CY%Z MKMKW\W8@16F^/;SN VCS%U!+ P04 " ,1 Y+2$ &,@4" #.!0 &0 M 'AL+W=O.S ):&U,;2=LW[ZV(2PBLS?XP#__-V/P9)U4;[H",,&[X(W> MAY4Q[8X0750@F%[(%AK[YBR58,8NU87H5@$K?9#@A"Z7*1&L;L(\\WM'E6?R M:GC=P%$%^BH$4_\.P&6W#Z/POO%27RKC-DB>M>P"O\#\;H_*KLCH4M8"&EW+ M)E!PWH=/T>ZP=7HO>*VATY-YX"HY2?GF%M_+?;AT"0&'PC@'9H<;/ /GSLBF M\7?P#$>D"YS.[^Y??>VVEA/3\"SYG[HTU3[^_'NO%C-_C?P_ .@30,8 FOI8>Y#/_ MP@S+,R6[0/5GWS+WB:,=M6=3N$U_%/Z=35[;W5L>IU%&;LYHT!QZ#9UH/A3$ MNH\(BB$.]"$\3BEN$*,YQMX@GO*3)6Z0H :)-TBF&5 Z*[+7;+VF\1JZB&*< MLD(IJT=*&L\H*X2RPB$I"DD12#*#8)I/(&L4LD8,TAD$TZQQR :%;!"#S0SR MJ(GH)]]DBT*V"&0[@R":]?SW(I/[)$!=?"?102&OC>]BD]VQ63U1?Q\_Y'VG M^\G4I6YT<)+&WFI_]\Y2&K"I+!?V_ZAL&PO=V]R:W-H965T MR,.=P:V@=I%T0(M$*1H^ZS8M"U$ M$EU)B=._+[7$L,E17R*1OC,\P^6&6IQ=\]P>K>V2MZJLVV5Z[+K3?9:UVZ.M M\O;.G6SM?]F[ILH[WVP.67MJ;+X;@JHRHX3(K,J+.ETMAKZ'9K5P+UU9U/:A M2=J7JLJ;OVM;NO,RA?2]X[$X'+N^(ULM3OG!_K#=S]-#XUO9)B);VFW7I\C]X]5N;%GV MF3S'GREI>AFS#[Q^?\_^>2C>%_.4MW;CRM_%KCLN4YTF.[O/7\KNT9V_V*D@ MD293]=_LJRV]O"?Q8VQ=V0Y_D^U+V[EJRN)1JOQM?!;U\#Q/^=_#\ Z!=!+ M /#_!K I@ 4!V4@VE/HI[_+5HG'GI!E7ZY3WFP+NF9_,;=\YS-WPFZ^V];VO M*Z9@D;WVB2;->M30*PV]56P0A;A(,@]PH: H!1WBV0T%Q1,P- $;$O";!"PH M8]2H05./&@(4E Z*B7544#"9GQZ)XP@4 M1R X(L 1T3B&"DI"G%@F*1%Z9KDDBB,1G&"4BG K(4+01#(&,U"XN0+BKG/'%7![A=A?3;@?)\VM M3W$3%17+*%%J9C\"[JZ V*L._1X0XS2&T'!'8CJI%54S2+C# F*Q.G1\B,V3 M&RTCRT=T_FP;P6:0<)<%Q&9UZ/H0&RCG.CI,&TQ'J9XS6L"=%A"KU:'S0^RA M4C$1K5LL4\H?[AD@W&D!L5H=>C_$)FHD$]&JQ3*IB)ZY"0'NM8"8K8[.&N*V MC.OH6A;+_#\V/;.+*&ZU%+/:T/TGT?6E"?P\*AE,Y083@B2$A0:07=U@^T^* M[WES*.HV>7*=OPP/5]:]&PO=V]R:W-H M965TB_%EMM:XGO_)L7\V\;5T? M[GV_6FUUGE9WQ4'OFU\V19FG=7-9OOO5H=3INC/*,Y^%"/T\W>V]^;2[]UK. MI\5'G>WV^K6<5!]YGI;_/NBL.,X\\KYN?-^];^OVAC^?'M)W_:>N_SJ\ELV5 M?_:RWN5Z7^V*_:34FYGWC>Y?%+<&'>+OG3Y6%^>3MI2WHOC97KRL9YYH,]*9 M7M6MB[0Y?.J%SK+64Y/'/[U3[QRS-;P\__+^U!7?%/.65GI19#]VZWH[\V)O MLM:;]".KOQ?'9]T7%'B3OOK?]:?.&GB;21-C5615]W^R^JCJ(N^]-*GDZ:_3 M<;?OCL?>_Y<9-N#>@,\&I*X:R-Y _F\@KQJHWD"-C1#T!L%8@[ W",<:1+U! M--8@[@WBL09);Y 8!OYI_[J&6*9U.I^6Q7%2GGKZD+;4H?ND:;E5>[/KL.ZW MIB>JYN[G7"9BZG^VCGK,PPG#%QBB>(A9V!B.PR%F:6-D0D/,(_ S1#PA+P;F M-X210\PSB!0,(2\V)(S.$+]9U_/B,EQ<[NSE( V%'4CH0'8.U,"!D>3BA DZ MS+[?G5 &'.) "@925B!B8VL>3ICD(A#?F6*Q*+],Y(!.#'$#1**8$(16!E'-\;003R^&Q/H M( $9&#KPF%BE!NY"26!-$B!08E)<6)'DM44EA_Z1%4LY76"6TPTT)\QS&D'T M)0&F1V$0.")AHM,(IB_)IC&I.W(H"F$FTP@J+P%("7+$P40EFZE*L,,%IA9% M-^P@)A?%( MI5AO;0G"-'IB&9/-0"66&2JQFN1:*,1/99J(2CH9C3#"F\6O+ MCC'*( NSDWK09<$J3F)WQ9B);#-1BV1RQ+2<+Q+" QLR5@-AFA'J4]8R,*3%E[ M1K#XLI>'"6&=D& 04V FA$"AFRX=C_A M<,RWJT=I"TY#&W)*@<22(X&:D,L%5A,9W/!.@X5"@H'-IB!!D$.0)!8)"42" M79N#R2]O>&:6F-,236M3YB'(L3$*$UH!0KO>>!2FH+IA5"M,'(5&M5DM K$9 MQ[_X@M%^>/LC+=]W^VKR5M1UD7>?+#9%4>O&H;AKFG*KT_7Y(M.;NCV-FO/R M],'K=%$7A_YCGG_^HCC_#U!+ P04 " ,1 Y+'LNA:@X# !:# &0 M 'AL+W=O9DU#^+ *_5E*^HRDVI9[X+F4/-L8XS*(L!AR((RRRM_ M.C9[3_5T+(ZRR"O^5'O-L2RS^M^,%^(\\9'_MO$CW^VEW@BFXT.VXS^Y_'5X MJM4JN+!L\I)732XJK^;;B?^(1BN4:@.#^)WS<]-[]W0HST*\Z,77S<0/M2)> M\+74%)EZG/B<%X5F4CK^=J3^Q:*+A6HGRL1=&87V]];*0H.Q8EIVV=>F>>Y M_1*GG1EL@#L#?#%0OM\SB#J#Z&I WC4@G0&YUP/M#.B]'EAGP*X&S)Q'FRR3 M_44FL^FX%F>O;B_0(=/W%(V8.M^UWC3':;ZI VC4[FE*,!T')TW4868M!O

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

-)9IT7 T%V8'QR(-A5IQ7B6[9D6TM"Z3+F3JTM[ M#4H:.#GBKUH+]_<(RHX5S>D]\2(O?8@)5I>#N, /"#^'D\.(+2RMU&"\M(8X MZ"KZ,3\65"*%F^3E2;9<3K9W\L>%_"Y@"\%^3;-,C5*RC^)(.K2 MV9&X:?>#B%><'SCNIHG)M(ITAN(]9F_U/MN5[!:)9LQQPO 5AO/M@F'(OS3A M#YOP1%"L"/+=TV."XB%!D0BV_ZG->&K183W]UWX2[2 M>'*V 7><-M%9&P 9LPU>9H]/?0D4="&Z']!WTX5/0;##_);9\D/5_P!02P,$ M% @ #$0.2WD[;X;' @ *PL !D !X;"]W;W)K&ULE5;;CILP$/T5Q +QF!.]T4EEXT/ M9BYPKX'G_' 4*N#-IS4^D)]$_*HW3.Z\CF67EZ3B.:T<1O8S=P$F&8A4@D;\ MSLF%WZP=)>6%TE>U^;:;N;ZJB!1D*Q0%EH\S69&B4$RRCK\MJ=N=J1)OUU?V M+UJ\%/.".5G1XD^^$\>9F[C.CNSQJ1#/]/*5M(*0Z[3JOY,S*21<52+/V-*" MZU]G>^*"EBV++*7$;\TSK_3STO)?T\P)L$V 78(\^Z.$H$T(WA/"#Q/"-B&T M/0&U"6AP@M=HUV:NL<#S*:,7AS7WH<;JVH$)DI]KJX+ZZ^AWTD\NH^=YY,=3 M[ZR(6LRRPF4& M1K,"G1_TS$K,!*&1(-0$88\@';C=8)#&5!J3)GX8A\' D3$.Q@"A$ QLL>3+ M'O/U!"*C0#06"'PS060DB.PMCHT$L87%\4AJE,80!(,;M1KC0))&"1K>?DN^ M[#%?3V!B%)@8++[SC5(C06IO,?#-3<.W,+D%W:H-D9^"9&"R 9=$\A%,AQY;@-8VH.P!J"_+W 2! MH0N"X Z%N<6= M%RKD>**'B#VE@LCR_2=9^%%.KMVF('NAEK%&PO=V]R:W-H965T,#+'Z[G:C)SC1-F[3)9)MN?S-Z_*.E%[K92#@>$1-D"Q>*!#="KG9IQBJ5: M\@:)@0.N3!(E*/"\!%'<]6Z1F=B9%QD;)>EZ.'-'C)1B_OL(A$VYZ[OO@>>N M::4.H"(;< /?0?X8SERMT%JEZBCTHF.]PZ'.W2?_<$HUW@!>.IC$9NYH)Q?& M7O7B2Y6[GA8$!$JI*V U7.$$A.A"2L:OI::[4NK$[?R]^B?C77FY8 $G1GYV ME6QS]]%U*JCQ2.0SFS[#XB=VG<7\5[@"47"M1'&4C CS=8TSW&7Q%(*5AE!#89Q^ N M/7A,=Q06C)TBM#H-37JX59C\0V-D+1"9 M&6_X._.ZH9DQI,/Y-X21![WL[+ M/2Y1AA//KB>VZHDM>H*=GMC"LU5S0Y-8:1(+3;BS8\-$=I+42I):"NROF V3 M[$C0YMY3X(UI$<(IV=B;]K2)KEWH*3#OYB]\;F'?,&^Z7C@7)M7K,V^D9DR" MDN(]J'-M5==<%P1JJ:>IFO.Y=\P+R8:E+:*U-Q=_ %!+ P04 " ,1 Y+ M8SM^$? # "]$P &0 'AL+W=O[,&RW!UGE[2=UE+7^9J^:*N_T M;?,6ML=&YKLAJ"I#&D5)6.5%':R7P[.79KU4[UU9U/*E6;3O594W_][+4IU6 M 0E^/OA:O!VZ_D&X7A[S-_E-=G\>7QI]%TY9=D4EZ[90]:*1^U7PF=P],]$' M#(B_"GEJSZX7_5!>E?K>WSSO5D'4,Y*EW'9]BEQ_?,B-+,L^D^;QCTD:3#7[ MP//KG]D?AL'KP;SFK=RH\N]BUQU6@0@6.[G/W\ONJSH]23.@.%B8T?\N/V2I MX3T376.KRG;XN]B^MYVJ3!9-IQF^2V(3A &H"Z!1 DHL!S 2P M*8!?KL!- )\"&+\8$)N > J@Y&) 8@*2:\>0FH#T_PJ7*0D3(*ZEE)F S H( MQ_4;&N)+WN7K9:-.BV;LZ6/>2X?<9;KEMOW#H<.&[W1/M/KIQSHAR3+\Z!,9 MS/V(H3-,.L=L$$;,,5\0)IMC?@,8<Q#PA#YIA'A*%SS-,5M9X1ADV84,_M M-,$43C =$K!9 HX3,)B #0GX+$%LS=J(20=,/6"8X,0:[^-5J"<7E2;"1YE# MRAQ0MIIJ,V+BLS($EXAAB1B42'&"!"9(KE^7%"9( 0.KX^\1)L-%!"PB?KWX MC\*92;2LXI9ES2"9S"7#(IR 1-AMHNMGG7@,BP 6COJ),UH2,WOFGA$LB[BG MCP@6.*& $/6DP!(G[(9IP9(C0'.,V=/BBBX3W-.0! N/ .4Q;A="H-A3!^N3 M)"!%8M=)W 6D(O)-'18R 2IEJ5TIO:D25C-!9:98 MJ?0&I5*L5 J4RJW]=6- ,_>RC@T7(7,BGBT8*)03FPAUJL2,1$^Q""<8+[F MIECP%&SJG-J,V)6,7)Q&^2R(8O^@KG^PR&'$'1'$(N59:C-R<22-H\BS65#L M-!28"/>M/#81>L,N3[$[4. .;A>GSA)X-A&*G8$"T7,?42QZFMUPTL2B9]$5 M0C&@\[%2FNI?JPD03N^MLFY.(2PFGJZ7/F^1\!^4EL4T*@Q.9S&30G@ZV$@:.([TS%L/19 M?$,O8^DS<'YP>SEQ=9M%F:\?L$,PY!!./P"'N% )NP1S70)TGGO2%\EYXXV5 MPK,W!/V+K3_RYJVHV\6KZCI5#:\$]DIU4J>,/FG:!YGOIIM2[KO^,M77S?A" M:;SIU-&\+ NG-W;K_P!02P,$% @ #$0.2U!P^+M= P Y X !D !X M;"]W;W)K&ULE5=M;YLP$/XKB!\0$G7*HFTI.TR M:9.J3ML^T\1)4 %GX"3=OY\!-R/N^?.ON>,IV=9OE9[(93UEF=% M-;/W2AWN'*=:[T6>5!-Y$(5^LY5EGB@]+'=.=2A%LFF,\LP!UPVSYM MGCV5\ZD\JBPMQ%-I5<<\3\H_"Y')\\QF]ON#YW2W5_4#9SX])#OQ7:@?AZ=2 MCYR+ETV:BZ)*96&58CNS/[&[%82U08/XF8ISU;FWZE1>I'RM!U\V,]NM(Q*9 M6*O:1:(O)[$4659[TG'\-D[M"V=MV+U_]_[8)*^3>4DJL939KW2C]C,[LJV- MV";'3#W+\TJ8A'S;,ME_%2>1:7@=B>98RZQJ_JWUL5(R-UYT*'GRUE[3HKF> MVS=A;,QH S &<#%@WDT#;@SX6 //&'AC#7QCX(\U"(Q!,-8@- ;A6(/(&$3_ M#'BSXNUR-.M[GZAD/BWEV2K;$CTDM1+87:0K:%T_; JF>:>7N-)/3_/ BZ;. MJ79D,(L6 QT,1'"-65(8?HVY)S#7B <"X5]#'C&$L?@:\YG"])):40$'%XRC M)^TR-]A?$)EMX"KS"&3V(ZD( ,)$"!,#?HI=MBP@Y) MZ,7#U:OXAPAG%79I6/1CEP6 P M,1E,3*QS1#M@+MUSW/'280-MBWU'"H56,@O^ MHU!HC3)"I#XJE!"W62_0OW" BY8IPSI%'7UI0-=X>QB0_W'W %KZ@'=QM+DN#*C+ MTI;=$!?=(P#W"+2_+@#OY&2).YTO[_K\]RTI=VE162]2Z8_XYE-[*Z42VJ<[ MT9'O]9'S,LC$5M6WH;XOVW-7.U#R8,Z4SN5@._\+4$L#!!0 ( Q$#DMH M\YNE6P( )T( 9 >&PO=V]R:W-H965TR8A5[*2,!=6W.]NSJC)..H_?@ZD[,DW@=/QP_V0WKS=SI)+M>?6K/*MB MZR:NJO4,^\^LV%#H>L,N__*[JS2W5.=VDXO7@HE.IZ6M_ M+QM[[P;_1Q@<0(8 ,@;@X)\!_A#@SP)0GYG=ZD>J:)X)WCFB_UHM-46!GWS] M,D]FT;X[^TSO5NK5>QZ%7H;NQFC0['H-F6A(XK_5[ '-J$ Z@S$- J9!;+@_ M#2<>;."#!KXU""8&/B&S''M-:C5-#]E@'Z8$("584J+YFP@ 2@A#0A 2 I!@ M!H$T*Y (A$2 032#0)H8AL0@) 8,DAEDJ<%DY9LD("0!(.D, FCBE?)*04BZ M,"!I AM@#VXT[_]+'*_T*GZ_R'>#:%I_>..G*R"X&S%YO\YW@^@M:*4&,=RT M&.C:>:GO0-$:!VY;#/5M-.QA_+EQ[ #T( ( % 'AL M+W-H87)E9%-T&UL[+U9<]MFFBA\/?@5J/Z<,W(5Q!#@BF2FJV39 M3GO&B=V6TUU34W,!D9"$#@FP ="VNLZ/_Y[MW8 7)*78W>DYOD@LDL"[/OOZ M;TW3AONR^.L^OZSV9?OOOYO/DM^%G[:;LOGWW]VU[>Z[;[]M5G?Y-FM&U2XO MX9>;JMYF+7RL;[]M=G6>K9N[/&^WFV^3\7C^[38KRM_]_M^:XO?_UO[^>;7: M;_.R#;-R';XHVZ*]#U^5/$)1E>%YV-QE==[\V[?M[__M6WR'WYN'/U9E>]? M.^M\W?WU/_;E*)R,HS 9QXONCQ?[VU$8#_RHUW/A7\]_7UPW;9VMVO\9?//] M_2[O_AB/S__86P<\O:8W7FZRV^ZO-]FFZ0VCYWB;UT6%"UR'S[.V]YS:?_ O M_W)PDR^+9I5MPO_*LSI\"5_VCKG[I,SK??:/2?>;]W6V+LK;\.I^>UUMNK\^ M>_7FLON=G/B[_+; 8X:)?\JVO>WAFR_>O@]?_30TP"6LN8;UO@+H^!3^9W[? M?>YR7]?=$Q@ZS?/S.#F?Q -3O2PV>1U>PGNW5=V;YVJ;;?#W=_FNJEL\C,MJ MN\O*WH-JX=5V"V!VU5:K7Z+PBF _?+-OFQ80!%[O[:."'99-O@Z?99NL7.7P M#N!: XCS\]7S\.S)T]Z5YBN C9C ?SYT+%G3P"#?]7[.FKL>&*]62!B:L,Y7 M>?$AN][D45CF;?>Y5^4'&+FJB[SQ_OZVSG=9L0[S3SO<4$,4H6KOX/!6SJIZ M4%:U<(.'GWE9?((CXM^\L_,@_I?5H6R*[+K8%"WLH'@>?W>@]+ ML,;H@7 G!$H!)=1/F?]T7.T+1![VVJO-U >]D*US- M_8$S6?5WWWWPIZH\7SUN:0.OGK*\@5>+LLT!:=JAFQAX;9W?Y/#E.L0?_"=Q MX 00;8L6]\IPNP+F!-O-8=, R6=-GH<_56T>QG$7'Y&5?M?LLE7^[[\#7MGD M]8?\=[\/>\"!E."NVJSSNOD__]\RB1??T_FV]SU0!$22K31,19Z,1^/Q.(8# MJ<,/V68/^#F+X!O\+\SV[1T@Y=_R]?=A60FW#8NF06@E%#3$)\S:$,A'OKT& M*%4DA!X"AI-KACORG0Z<\O!RXMG8NZ!X$4W3-)JDBX>LZ/LP64;S=!&-%\L# M[QU>\\4: !!@ ^X=R=)Y48:K;%< ''A0>[_=;X !K!&*BE4Q #_-X!T>A3=: M_^GO#W*%L[<9PO==WA; ]IX"EW@2?CL@8EVUL"5"WS?%/@S0'#J&WS/ISY='>*H-K .KMQ][.BRO8_[U^Q]].""U67K&VN0 MHKW9Y34)K0P]*'< ^,"3Q8<\?%TU T_E]D>P#Q?/QV6%R8G2]H]:>)5N:JV MN5G6 9#Y*6^!\H*$L/<1UT;(JI(-^H()/()['AKB'1#6K%[=T2AK>&A3,6=2 M(W9?^"$O?8!3NLV]V!/N$=,06H. MH^WIDDHU"1PQOP'LH:V+ZWV+ D385O@PX:1%@7N[?I8UQ:HG;1>;?=M'FY_L M*>W!/9#MQVX4Q4%QK#Z>B,;6\P1/0AU@^QK[//&O^P;D7;@<$#P MKX WP$GIDX1O\>\53JH.O-(S9GK&WG:?YW#%P&>(PQ#R;5%&^QM],:12W(6"]SF$A M@#?KG/]\2F"(T\*4^PT=#=W-ZBX#V1'X0^E!8MGRD(*A=M _V /R[4^GW-4Q MB,*E-1V(Z@NG>Z#"&:IW ,,WEE9V=$F%'O[T);W4%W-@23C3KJY6>;Z6UY O MD]2$FHC%C>G*/V8U&B9Z<[]UAL@_Y?6J:/I##+Z>W0MNERG#EF:]-+6L/HU#JOJ[P'UQ?X: MA<_V35'F(*P8WD +0CF.]O$6I8JR]4H,8N_#G;RM-@69>09QRV_CB4?AX]=C MO\I/>=ZVG_D(IW93(1BNF?)N"J!^99'AIQ^S^S!.TP6-5-#Q CIN[N'\48K> M5IM\M=^ *@QR7K6I;N_#=9'=EG ;Q:HAR0JG:.^ %HMRI27V+5(5F.QOL!Y@ M'4!<\C8#B6U5U#@DG6"[!R$O7.6;313"'Y?O+R-^O??,\Y\NZ)%52W\!@F3W M30AB/$Q ;"@DJ,X 3Z\W%5#X)MON-KESTF(Z:8S)&*;: 0J4C'(X8D::2YO3 M<2&4,].#[XPK""$/H.TNSS;MW0K?D*=J0@SX ^#C!LYP!P+M3;&BP[O-2_@+ MWM"Z.9W:%B[@KWN\DWO%\%Z!!PBHMLU1"BV:;3," M%@(G$84MNG,$T;9Y>U>M$180T)H]JM:P%[)HA-<% "!+QUCL[]!JQ@>-2QF M7V8?LF*C-"MULLB5#9S!";3W._>\RQQH5(.P@WM:;8"0H>L&!(H"-]OX+UDN M] XT0N;\58N[AA>MR;>HJ:+--M_N*B!M>;5OG+GQNN%E.!+$;Z!@#/EP0YFZ M'#WC&IBH\#W@%4+2'GAXC-/X"EQFMKN#NRFV&0A$MZ/06"8W0#5:SYYM/&,T M *R%HV6PW5^C!^8CC G3;D J8*BZ(XB'W>%2RP9-XVQ1$?"L<7IQ#)VSWR5J20L%MX M^$[[S/-/Q'+P9K?%JJYN-G Y "Z(O66^@9M6*JS1*HBVPA9!%H!?@<(K7I[7 M"/)>F#($7Z$4O)P9;7A3K6@6^/8*MO*\R&^KR&(S(SK94$YV92GX U1\Q%4 / +\W=)AM$V^N5'R)MD2JO!9 7KMKHU@IM4(@-*\:8VHZ,E= MAK>6TUEN-9JSVHR8]Q'@>W-_7GU$7HML#F 5J12A&.R<:HWX);/&(9.:K6F%).W0UUPRL^$B])I;'^S:"'=!0&)6HVRV;@V$] M\#NBG >VA6.!S%>HYL"T_;G $9WRN\"&*V2'[@3(7U&#PT^'_/ M6_I!G_Z%.GU;_M;71!O[X>+B;22 9Y\JT*H]3":"E6^U?&6B#844L^3W>(*^ MPQ<":%E\P+TC\\-MJ)WZ#Z,5$1E5.&!M_HJX[#[N&\#]3/S9U\5FPS_8MF[+>I?=(R@I M[8K1' " $*F^!=V6G4K -7[,$>YK%E3X0\%PXRC>"'^P%N27U\1M5I69#E72 M:J?LZ5JI!]JTWKOV![)UP?']C6@YG^@ 0Z?M-T*H+JXNPW0V/9^/9U'X!Y(R M0;Z&55/H(-!$@I#D>\\M*?%,6(>L[P;I[#5Z+<,52 Q(]<(M$!Q<]):<(D55 M*P>?NF_C9/\N/(N?(CUI]AEY9'.\*K$7(H*BD9 I*V@IJ--\'YXE3^$(-_ T MD%)DH]6*K#!\VK"-3:Y1'I3L7QK!7I WUTR%0'*LF[MB9]%2TE?%NR6T -0% M,3=H4#+/UT@7:HPO.IL\E7-&DS=08?9(P6MKX*3U%A@DW/3WM(BSZ5.E1G-8 MSCV^@)A]08(7A+JD?"&SOB;9^N-=CG25 QD)1#["J"&Z)I$K;NZ%U6Z( M7J'&"I]1\=K2.O>[JM2WBR 'BP,918/122>Q-C2"V%;K'(V/1N!.V#7%N\@: M=4^D0JZRO:*ULC-K/^CF71E[!(>PDK2.@@7RQ^$=(F(S/;<,7):A!;@Z:7,X M1UT@8KAD &^L&;H:M(\3M99MJKVU7I:P*9I6@)BQQXSI@:O",K>78F>L2C(C M[.F,&XYEC7A!Y]H\2-8B59>QW9+? I MH\MUN 4A@7]XFVGD0AO15AQ^1/L)@H?8/G@#I_.=4?C<\RRKPBQ\"XB0%4&! M"5)#6JP2IH1&H1@)=/>:Q%HU1X17S,0:@"YW<(0!1@E?,K__V&]KC,+P,5ZA M$WSRUW]!80>/28.X,#A'?/T,T$'6\AJU)=Q@G.0(6QW)@(/[7A5W40B_.-BF4:084MD!S0SE6MX MJ&'.PJ$F35-A4(RM,&#N(P8LBQD&U6& >Z&V]9A*"SL(X&H0MU$SU"[R3!#!'!]8V.0_09/ MI< J7_,5(]0B0%C3,*8V:!5C?IXUY)\G2?&T^[WTWJ>S5;5^%#/%U+Y!ON/; MF$T)G$-0_@7?K@X!@"LSL/;.2"CF@:9S=#CJ-6S>'A6AK'-T'DCCI1,#&Z1+ M?80XA*CP-Q"CO!G$@^.+HBD&2+H1\S)EEU3,-;O5-@Q/J$-_%P<)R-%M/'K= M:]#&5LB0..X,%@EBQYY.G17/2"NP1KN,7"W4FHA@_B,&\:QS-*#1G(03:D_( M)IN"]9?^*9R$,S:QL\7JA]PJ88/+0MM*R=M=TJ570B];9$N"?)5-T)'QS,#& M=I>Y<:O>V]3X:Z& )=0;85[,KKBM@IW6?1D"HV:T#F>!I2_ZAF]#+9M]RZ>J M8APU>EA-$MW?,:S^9;^^)>1&)Y"V@X[0$,=ZRHK;-00@D(+@4:)NX)ZPI;GI/V0B$+L=< IR+[?6^;AQQ'!WQ#CBU M=[E#1IALJCOTY\BH2G[ Y$ =!&8A64>JNO.\ %;Y& M@:X ]115B]'67-(+,A+Z%&0#XZ5.Q4PM. M/5;(2.EJ,[9%PPH\9>,KG6?QZ=P$,.1N#AUGU;&'A!9^4^$^FN^"EZ+^\4#> M ?0S;HR$_01.@?];6']=>K1%:Q..[2-X$HJU,7@23*)T,8[FD['S+:;@S:-9 M.@^>'[0!#$XQGT?391PL)]%L-@G2931)TB">3J/)-#EIL603,E@5P%JBR0+& MF*71=+8(%LM9E(['01R-9_-H/)T$G.;"%ZJ&A74DT7(^#J91$D^B^70<+)?P M-RPFC98P9 J+?*L,M!(D\$T2C9-Y\%Z+)(BP<&J6 MI\R,:6CQPY$3Z!?&.=@L3^*3R'K)0(ACJKD8) YR9]>RR*%[VG#:]T"CXQY= MGBA+]$W,Z,=Y$D^F41K/:#M/ ,3C)$JF240R("($X.2]T8Q=&XJFJ$7I9D?9 MJ4H\S7@TCGD.^&OJ#L\DE$@U(C]LW;X!3L4S$VT\N6Y=FNT[79\E>W70!*]( M*.?\&UCQ@4>!,A^Q3"'_YGGK2CNDIE%WD,91G$[X?-)X'BV7D\PP^\OZU2"TA.O:8)VE*W-19)_.(/OR,D:5Z9RUP07+7,&5%J$: M^V<;G8)WFFD$/\-J I=%XE<8\,0<"06^M<2N,<_T%K^@$T%*E2"=2HD7 LV, MTLD2_@9"OU@ I5L@60;"!@ ";&DR#=X=LS+Y>44*O&L23Y&D+H&QC<=(/=^= MJ*#[6$4,-'4QAF_@>":TRG>G*LH^/@$\]E/4/L_K:] MA_T02 1M ?E#M=FSZH#V7<5$=(2!/DB?<\DOQ&I&I,P-RD(96=H1!],5:J8A MW^* E9%=LM<<&DU:@@10;S"@W;*;ZU-A,Q? /SJ9T2NW$:T4T5%%3JZ(_GR ML\6@[14H#M46EW6_Z_BD_M7K;",5L\Y53 ]%@L-W91B/OZ'#JCI\BP-?M2U. M10-9P2I%K5VW#K]CQD$<#=Y%0%)6JMX )MUL(2?8GP2GXGQDP17_D&G M6/#7^O;#+UGV4"IP?\ MCX+7[7C*JH2_5V+>><7I0;"J*9]%UKB^M/UNG2DCLXJYXH!(7#V+=/T6CI-J.3KM=E]PI(QO%;/RMUSC M'T4W%*T.%R$O[[9 PG);84B<'2V"UA0A)8+P"G]ERAL4]1H5 ]M@VH\.(C-T M/.>J7AQFT(CYE[X44RF+EQRARYY=#%'OK0<)6<&)'14M6!V %8HJ$3 4;*WB M(CF:JU"2@'(9JEID*ACP6N?:9C=HZ=,2$D@9(H :GV4WDE R]A26.4.K) 8R M5RI#49VW *):WB3_,YJW6-_IDE4\ANX;VN0HE79^W M5JP!,G^V'0*,%_E''3L,+ZVT7;6$'S2\8-BQ!8W"9?KQ.&I";1]<(_X(P\_U M0?(<<'!Z C)3D]$N,Z&T:D&E7G(O[KAB>R/H+/NZP[CQ8D#JQ-P7S'?E?$#S ML,)_'L?D2MC[9CBDM7%I+@[=D?%R.X54S((1$FUSE2A]=$- ERV*G./;;YF MZX3V".RR7X90]JYCB8S-OI^H9M\&G:I>N\YD5!$?-URKD"*S#>AIUSZ!W)(V M:H/+P U2,#SE!JY9D')PS,$+3E?CTS-H[*2>S")-LH]0;+XLLK1J:DU!\968 M]S.ZTT*7]F!',WOOVZS86#_)PE"-*$F.;-KSHL3H]!K^JO;*!BWLH%Y;[XH) M'IWG-2OS36L9<=&Q0CR=,JQ'X4^>;Q$N7:-_DU.8'H=B:5\&>28IY[4B)P+, M=BW9NE&XR1LGBG"'"L6*"\]PNC-;&A#E*9(3Q>$*-"013%2N7L9T[;V#C$5C M<0 ZHYUUQWPX"%T69'TNJH9LS!Z62>Z]H1PVM74Q@AYAOZ&U%X4%75HYB J2 M_S=,JM8%A_@-4RN?IG02]7IE0FY,R/M#L"-"<0.M5TK'*F\I[ 4]:Q*]QJ7? MI"X*+X,"=PF!R,=DJATPQ[0\'M9/%L<4PQ'7;)+IS'ZE' &%,NDO[2)UU[G% MMJVH#$HQHV61#V EM5(EKZ7>NNDJ-(TZ?3<;1T# D]8EM-AW.9%V(XJ$8?$+ M%;"SJ<2YQR0%4TY9W[*<4E8TE_*>*VC?"U^4M^1H)"'%@7R]2ME!=^U$,4.=P^9'BIER+HE'1#IUME2!;SP M^%SG+>LT(KP*K;,.@77[0@5+=VH<99T7S1D8.Y!C7$'IG:FIM1ED=/E&A_ J M[D&47<_L8L) J+V]$U.!_7>T4$JVR6GDE\#+5U"H'"E6HDHCHRC9\PL"",B@&9SB3! M0P7>D6@J^<=J8K("ZE)AZDL.+4;Q%>LL M8!41H$\4(%,=G%9&U7FB*!CI1##*GOZJ(2]7A :JXK4&4?1"&.(O[RBPM<&CV;D_%3 M(2;.P)HWF:)UV2F'I>L0"JV%J6@D)9*@*:1M5'A*5P&T]9EMMLXE%6LEN5&E MBJ:1.^2ED]9@KUMHF-(:C#F@9[DG/K-3-86HO@*>*Q+)M83E#2K2RQ&;S"C- M]2&T M"B+F[N>=W$P5T.208S4$#)M(ETFM./>13# _AERRYD!P+B.'?YFK/] MS2N:+-K9H.J*UOFY&D2# \X@PY!1%*6BNV(768D3M(6-*AHJ^B1J-?AB;N?T M:@)@J^:<@W9,HXZR\O^G-9Y'P+S/&E!)00UMKM#%U%%U M (@ZV^W;IX*?0K!6' $ HF"MQ'$5@(>I$5PA */4$2&N6T?BYE(<7.^*PO%1 M1"?XMT,WBYK?O$.=7!(G"&%QS1\I3+7-=QT&Q EUM!OE3!!5NF+/3WE &F@V+ND M4O(J+W:JRX8#**HPF"V"TA,WZ$']O/!PFD.L"P\1DU"7 M $Y&O>4JAO_K%7NE(9BL#.NW@L M4&-;$%,_(=/F?Q80+*^6L\2B_%!M/C"Q!7+*0*).@WP C:29YGQ(:MC/3?T> M!^VC\%(PUW(F-7VHH.@H[7?EI#@;S+]"=A^R"2!J=HXS,.1K+F:DBA=Y@>*Q MX*PLS J>)??T"B3>,*$/\?>.69VC#53X0R?/I&LE+IC+^ZQ=. X&0]#YXGD6 M->NX4NY/T7R03C"!J22!!9.E3&$H.2@37$&&_%QJ@FE,!&IP790B#[WB\&H^ M'Q738@"60G+<_:DZA(<62_4-L":H.L:NL=RP^7V)Y7A0W*$"&%E=WYO<]J/( MC6 SM!#V_CP$^],O+?M\)I1V\#D9_U;Q^9 )6D>=J]OKF9X_$PLB=@BWH3"Y M*)7)=H5I=F7'&Z=0G/595Y\PX52N%X]3CKO>0SMR% ZVQ?VZJ3<$Q:=JJ8&5 FU\MBUKQC^&9WMB?KU+> MHZ4\!8N1Q)!C/)D%.\T \+BJ]NDXUMQA&1,-N7:O&B6]*W., M6>&VCR+U9(ET(]?(53!H-5'!F2J(-5\;Y]T'$_U<N"4'5LAEV(V(3 ]N++K& S;Y9Q(P0= -7J_!LQ"69EM M[J4R;JKS%!":0W+">:Z.B"#KK/> (L-QP!0KGZ_P36_&U?F%*BWYT:HF" M_E_9N*]MLT.QL:1;\RE9M<@?^Y- K%:&ST]:/$ M$.R/>CV(7U/C!]7Z[H<*3^F29??PYU+0L- MJ(I-3W>6::\#V!:7.E6YN2R.P@)&4V?QN)U8?=/+S6T/S4%[==I$J7Z Y]=Y M)AU@4.;(UZ7D-#^QMA_A%QS&_B09S?6J,&=X+5&D&"98ROF(^26[;E3=5ZDI M2,$PRA^KS)Y2"04'XN"DK-=3D0K-Y-)Y $:_V-7%AG*/&$[??+K!,&YIUA6^ M?GVITX6L1R]YU)>Z>SB:>B3"'XD!;#G1>].EPE ]U/T?U6EYNI]W.[ 4WN P MT\K@EOH*85#Z-F(=%->^,>8T#]/L#B#="T( M/P!4B^ JG#A1A(^"^P94A;;_1:;#TGA?Z0-L#'=P^Z)S*.Z MH+%TBM20+U' 99XLH\5\''*+L?QPMVVW([JJP2CU$<,ZPP(\5@@9D*<]B,G9 M-8;T^_Q3*M*3:N!(# DEX=T251$#@R;X6 F;X%>W 42+GK:4V!2]>4 /!\K9 M8YE&W'!VG/+)PWCZ/9#)4@<&V>#EIK3T]_S -A22A:&K\I>]HEF2^<8.$R!B M5'A)BD6RK*#C$=&:A26ZKDV_U+YWSQBJ18/6E7OZS]J685UA6XI#Z!8,>E%8 MO)EG[G07.0PEH_#/.D+22D"RI0J62*W>9KS"1B5[FOH5_J2J>TH#O2MR+#6\ MJZN;HK4/J1>.5[3]U"7B)C8KT=),A4PVS\R]C,(_6/:2H991*D2FJ8!^2",_ M9+($CKI=@=LHE>37?K-4,MGU>L#WWK1[I)[2.?+@U,C4F)R:^M$4(FNUEK*2 M*0^=P+X9W+ZO22Y=L_9"XDX))RMVF7(!=;._0CZX] ME$*)%=7HY9LK#Z01GLC[@2& J@.IZ7.[(Z%P-C9BL%4:6TE15+;#;NS"RK^* MJNV1D_WUIEAA[ FG E&>'U4=>+*8&77C0CVHEW5*UP]G[S;%[)YC*/E&%0/# M5 4SP0M(.EM_U1%=!E_W<->T%SDV!KE_4F4HGTQ'$RU+&[%N E+=E:GNIR/_ MJT;OD:PW:M.=]965V1\U"51M,H7*Y(!C?[\G?& M)6YL=ZN\-ER+C/&@2:1CJK'$Q970XDD-K8H:R4%$H7$QBJJZ$P9GKAUVY MTYM%)3EC8O0A+*RZ_9:B[C7PY>LN')YB69\15):62NF"RBNI':G4K1T%MN?8 MEG4EO9D>BG^F#D># M&=T%/-PK_DH%E_0<7YXC> A))A50/R)KQ?M4Q7U#]I._ ;V9G5;DB/V]>M+6MW+?-.R#*G?D(Z2C9D=PP'*C#I'HN$=D_F/ M$BR]NO0+<+?4,BP^EKM%1V=96#S*[E,D"SVL,7GYH\KSZTQD&[Z.8?D#43P> MQ:=Q0G5?S W?6G>5#<*T@>F\W&9EP+QT#CNL\>&7U.#]@Z!E0RP;2'^PK49JHF$I&X<]J M/\8)!XJ:[9+6[4*4G7@MOTSP%[U['ZE-L:ZX8H8;I0AR/([D#'/ MM9]HCC/$7L21:6E<52U6%A7UU0]4ACFP&KNKY+?YZJ[$OM98^W"%906H)@'5 M2V7K#*E"YK;I]%1O]K+BSFI!HV#]3NYD2EC1GG2;/ML.D0S\]-),P_Z+985ZG8M4O]VBO4*X4]T?5DXF= M$I)>UI&O'2V;?!,SBTQ6#VIGB?9B>FHR%J<;12DJ.?#P[D9X7C]A.W8\+ZU+ MVL>%A3/+EI.1I,&?SKHY.OI7B\H_@T7%$2BHNAZ6W?I@Z9(A=;SO2Q+L0)P- MR[AT0G\878["/\/Z05Z]O6O#_Y-M=]_#$R/!(6*&]K$.BRX\87ID0C+URAC8 MT)0RL=&>32)R6V%/=H_*$$=8,SU.XX?@WZ :X4?U&%3K231+YM8<)UDMAF"\ M91IVS1[$'ER!_#H>6'<%NXK$&(RN2R.Z'^K+7K+1P6-#]F5K]&;OL!V\0:2:TC M*NZR8GU.>7),UW4GPB&]I(2"$^^88AO"C\(M*TN># MDIDELW]!*#D!W?X16ASOT*)WT_D<:-[BB]*[Z60:S2?IYX(&T8HHW8?D=JL! MB9;7N\+JC:NM6;$4DZ>CKH#Y$D'J3P12/YH:; >>>FY%FPW+K=-1Z!^Y ]P] MB#X0I],/$['@?6VRH&@X)9E2:)(I<:D*]*BB^*&6TQ3 Y7C1"LFY>R*L2D"]VR)/]:ZM^^K*[1#TVLYC5U$9S M2[L]&@;>D,KI/]=&XN \]M NA ]8IEEF/8'N %Q.8HMU^KJ/>I'&9VEWT$," M?OL6"6JEQL#O8X96@-HCZ9P4@'4:PRE8>0:"X2_G5ZN["A4Q2<;%=.QJ#==C M*L3I*"&K%.!WP17K"XC4V(=F%$^"%XZL0=_.QO#M3C7]HT;IZ_">JG./0:8) MO@F>"\02Z)U?5Q(E ,M!K.)'XU$Z@4?U2)OB)@_/8)ZB0\_'0!E_N6:QSP%V]NK$+Q5R8X;9@;S4:A=Q5TY@9O=3<-I8&Z M%?/6_-)W;H,83_>#EP6&Z%]0Y%KP(P9EE'G=">RAGE2+9 G@OJ0>:=B *5XL M@Y?[NJ1 %\Z$1,-5;KT63R?PVAS^743I AN1;($YY'4G9*BI;MJ/6,1_GHRC MV3()4E!I\%R60>31=3:9QV0^>B$CVY#,;0V5"@\6BV@YG0;S132938-+Y1XWA5AUW7_\ 9\;+V++LX-RW'= M)Y^CG#XZ)!Z^4?'@(A].?X4G9PK@NR11Q77-DRU@M;?SI ^L:" F M?13^K+0JN)3ZGJVSQX+4'6]$YA8/QO:I^/LFE\!Y'3&/S9^1UM)Y?W\[)NC!JEZHH0] M*G]*QLDNB&[4+FUO/037;R4)P+[[9VL5^#^D26"0@,I MCC"4O[#:9"K(DB1[TS!4RTBV%T>5M91>[5+/T"J9N<80A]Q="M^%OIK3=GI- M)BFMMY!W)%0=*U"Z "B"/U6O@CK'1> VSHJGX6*4SKY! >*L@$_DPMR3M?TL MXX_4+T@L\3^/KD;AZU?/WKSC@3EQ/=?E=?Z,X'#5ULA*_Z,"+H?34K\A761C MG=TWIJVA#9?*E.8 9Q3N-OLF/+O&E2[B;[H'='3O,"!MT0T4[2+7-OLE-WDR MU/C#Q..6[I)"E08AHK X97@"VR?ZX&N\Y18SR/8D98+IQUH=BU5"L[-8:;5" MR$YWY>S KG^H\_$XQP4GHGJJKC="78Y@"-.4ALCBAUS/X"2*&"&+O)&^!3X* MO+>)A!*KFTZ')5;U=U<4M-4'0,SS"&.G[1AC,H>Z"025,5E<7JGH;& MI]EH]HT.25)KL(Y:.R)= $*(QP21"ZZ8R_F"[LHPK8%R/_A6;+ RXRO9M3=! M@>FFU89[O7 V!Q5!<'PPF4S 'BGF(3%MAY0X7CL]4JS)K^9T&COD@RRM>N-' M.:@DG)HWS&6XX/@@'"4#O04NO'%,53U, -*OX,U$!GVW^I^_2<],1XVH[+PJ4D^6U.-%*!*_J M ;=4AT-*X6HHACI-I3:UG99!"R M**B2:]3P5M]03 .\E?UX#FM@,T@0ZD*"C"I3WH_PG@EMC+:1=ZIZ6]%V^$"H*N,\V"[@1/8D'HG:3Y' M0)88FX9;C"IC;? M+.BP'/\KU\O+T'W70U.RL'!/F[RCNDD7966+;BVYH^$>'7!_4P3$Q CJ!U4W M$A7X:.FM=N@CFT/X&LERNR_-Q&:E>!Z+930=X'MB%0:3T;+Q3>X)"K<>,*Z1OYB,'PB9I-&2+0UG"?I<@YX MD4B-E0C>A8-*&<9/):-V7VZG@E'.4-7=Q()FX_)?SIGZ(H79O?-2Q2WWG&@J MKHI\/.$;2_48-JECUS#/T(Y!3-HAZ;A,DS)OG$ZB&B#VW8H_KJ=5*'^AU1W* MJC.5-=9P.CA;1)B;GC\*[3/:+\29/EF(FT1I JM\Z48OB#JJ-D\M-(]>RRR*<^,WSUF M]?GP'!H1P4Z4&*P&S16TN'F2\H=?L31G.8K0/7A9R<*L:I;0WRISX4"7>K?1 M_9=/E\X"=;;BPY;WT@8T4_*3@!)!ZTD\GT4S&, B,@>G6O09]#"* M&87Z8XXXA,^S7G:,MG=;RWBF4 0]7GY#VX<_%\MO'@5FNN9D)\0**0 G2]IV M%!L;:VZCKJU_=$*P:,F]GHPZ\0#-ZBY?[T%#IPN!RU4*B^8DD@*JJB2QS<

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end XML 68 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 239 310 1 false 76 0 false 8 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.biocept.com/20170630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Balance Sheets Sheet http://www.biocept.com/20170630/taxonomy/role/StatementCondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.biocept.com/20170630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.biocept.com/20170630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://www.biocept.com/20170630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Statements of Cash Flows (Unaudited) (Parenthetical) Sheet http://www.biocept.com/20170630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnauditedParenthetical Condensed Statements of Cash Flows (Unaudited) (Parenthetical) Statements 6 false false R7.htm 100060 - Disclosure - The Company, Business Activities and Basis of Presentation Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentation The Company, Business Activities and Basis of Presentation Notes 7 false false R8.htm 100070 - Disclosure - Liquidity and Going Concern Uncertainty Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureLiquidityAndGoingConcernUncertainty Liquidity and Going Concern Uncertainty Notes 8 false false R9.htm 100080 - Disclosure - Sales of Equity Securities Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureSalesOfEquitySecurities Sales of Equity Securities Notes 9 false false R10.htm 100090 - Disclosure - Fair Value Measurement Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureFairValueMeasurement Fair Value Measurement Notes 10 false false R11.htm 100100 - Disclosure - Balance Sheet Details Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureBalanceSheetDetails Balance Sheet Details Notes 11 false false R12.htm 100110 - Disclosure - April 2014 Credit Facility Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureApril2014CreditFacility April 2014 Credit Facility Notes 12 false false R13.htm 100120 - Disclosure - Equipment Financings Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureEquipmentFinancings Equipment Financings Notes 13 false false R14.htm 100130 - Disclosure - Stock-Based Compensation Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 14 false false R15.htm 100140 - Disclosure - Common Stock Warrants Outstanding Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureCommonStockWarrantsOutstanding Common Stock Warrants Outstanding Notes 15 false false R16.htm 100150 - Disclosure - Net Loss per Common Share Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureNetLossPerCommonShare Net Loss per Common Share Notes 16 false false R17.htm 100160 - Disclosure - Commitments and Contingencies Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 100170 - Disclosure - Related Party Transactions Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 100180 - Disclosure - Subsequent Events Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 19 false false R20.htm 100190 - Disclosure - The Company, Business Activities and Basis of Presentation (Policies) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentationPolicies The Company, Business Activities and Basis of Presentation (Policies) Policies 20 false false R21.htm 100200 - Disclosure - The Company, Business Activities and Basis of Presentation (Tables) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentationTables The Company, Business Activities and Basis of Presentation (Tables) Tables http://www.biocept.com/20170630/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentation 21 false false R22.htm 100210 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureFairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.biocept.com/20170630/taxonomy/role/DisclosureFairValueMeasurement 22 false false R23.htm 100220 - Disclosure - Balance Sheet Details (Tables) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureBalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://www.biocept.com/20170630/taxonomy/role/DisclosureBalanceSheetDetails 23 false false R24.htm 100230 - Disclosure - Equipment Financings (Tables) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureEquipmentFinancingsTables Equipment Financings (Tables) Tables http://www.biocept.com/20170630/taxonomy/role/DisclosureEquipmentFinancings 24 false false R25.htm 100240 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.biocept.com/20170630/taxonomy/role/DisclosureStockBasedCompensation 25 false false R26.htm 100250 - Disclosure - Common Stock Warrants Outstanding (Tables) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureCommonStockWarrantsOutstandingTables Common Stock Warrants Outstanding (Tables) Tables http://www.biocept.com/20170630/taxonomy/role/DisclosureCommonStockWarrantsOutstanding 26 false false R27.htm 100260 - Disclosure - Net Loss per Common Share (Tables) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureNetLossPerCommonShareTables Net Loss per Common Share (Tables) Tables http://www.biocept.com/20170630/taxonomy/role/DisclosureNetLossPerCommonShare 27 false false R28.htm 100270 - Disclosure - Subsequent Events (Tables) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureSubsequentEventsTables Subsequent Events (Tables) Tables http://www.biocept.com/20170630/taxonomy/role/DisclosureSubsequentEvents 28 false false R29.htm 100280 - Disclosure - The Company, Business Activities and Basis of Presentation - Additional Information (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentationAdditionalInformationDetail The Company, Business Activities and Basis of Presentation - Additional Information (Detail) Details 29 false false R30.htm 100290 - Disclosure - The Company, Business Activities and Basis of Presentation - Composition of Gross and Net Revenues Recognized (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentationCompositionOfGrossAndNetRevenuesRecognizedDetail The Company, Business Activities and Basis of Presentation - Composition of Gross and Net Revenues Recognized (Detail) Details 30 false false R31.htm 100300 - Disclosure - The Company, Business Activities and Basis of Presentation - Summary of Activity in Gross and Net Accounts Receivable Balances and Reserves (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentationSummaryOfActivityInGrossAndNetAccountsReceivableBalancesAndReservesDetail The Company, Business Activities and Basis of Presentation - Summary of Activity in Gross and Net Accounts Receivable Balances and Reserves (Detail) Details 31 false false R32.htm 100310 - Disclosure - The Company, Business Activities and Basis of Presentation - Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentationSummaryOfThirdPartyPayersThatRepresentMoreThan10OfTotalNetRevenuesAndTotalNetAccountsReceivableAndTheirRelatedPercentageDetail The Company, Business Activities and Basis of Presentation - Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage (Detail) Details 32 false false R33.htm 100320 - Disclosure - Liquidity and Going Concern Uncertainty- Additional Information (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureLiquidityAndGoingConcernUncertaintyAdditionalInformationDetail Liquidity and Going Concern Uncertainty- Additional Information (Detail) Details 33 false false R34.htm 100330 - Disclosure - Sales of Equity Securities - Additional Information (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureSalesOfEquitySecuritiesAdditionalInformationDetail Sales of Equity Securities - Additional Information (Detail) Details 34 false false R35.htm 100340 - Disclosure - Fair Value Measurement - Additional Information (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetail Fair Value Measurement - Additional Information (Detail) Details 35 false false R36.htm 100350 - Disclosure - Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureFairValueMeasurementAssumptionsUsedForDeterminingFairValuesOfCommonStockWarrantsDetail Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) Details 36 false false R37.htm 100360 - Disclosure - Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfFixedAssetsAndAccruedLiabilitiesDetail Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) Details 37 false false R38.htm 100370 - Disclosure - April 2014 Credit Facility - Additional Information (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureApril2014CreditFacilityAdditionalInformationDetail April 2014 Credit Facility - Additional Information (Detail) Details 38 false false R39.htm 100380 - Disclosure - Equipment Financings - Additional Information (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureEquipmentFinancingsAdditionalInformationDetail Equipment Financings - Additional Information (Detail) Details 39 false false R40.htm 100390 - Disclosure - Equipment Financings - Schedule of Remaining Future Minimum Lease Payments for Financed Equipment Obligations (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureEquipmentFinancingsScheduleOfRemainingFutureMinimumLeasePaymentsForFinancedEquipmentObligationsDetail Equipment Financings - Schedule of Remaining Future Minimum Lease Payments for Financed Equipment Obligations (Detail) Details 40 false false R41.htm 100400 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 41 false false R42.htm 100410 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail Stock-Based Compensation - Summary of Stock Option Activity (Detail) Details 42 false false R43.htm 100420 - Disclosure - Stock-Based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForDeterminingFairValueOfStockOptionsUnderBlackScholesPricingModelDetail Stock-Based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail) Details 43 false false R44.htm 100430 - Disclosure - Stock-Based Compensation - Schedule of Percentage Of Overall Performance Grant Subject To Vesting (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfPercentageOfOverallPerformanceGrantSubjectToVestingDetail Stock-Based Compensation - Schedule of Percentage Of Overall Performance Grant Subject To Vesting (Detail) Details 44 false false R45.htm 100440 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetail Stock-Based Compensation - Summary of RSU Activity (Detail) Details 45 false false R46.htm 100450 - Disclosure - Stock-Based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureStockBasedCompensationEffectsOfStockBasedCompensationRelatedToEquityAwardsToEmployeesAndNonemployeesOnCondensedStatementOfOperationsAndComprehensiveLossDetail Stock-Based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) Details 46 false false R47.htm 100460 - Disclosure - Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureCommonStockWarrantsOutstandingSummaryOfEquityClassifiedCommonStockWarrantActivityDetail Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) Details 47 false false R48.htm 100470 - Disclosure - Common Stock Warrants Outstanding - Additional Information (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureCommonStockWarrantsOutstandingAdditionalInformationDetail Common Stock Warrants Outstanding - Additional Information (Detail) Details 48 false false R49.htm 100480 - Disclosure - Net Loss per Common Share - Additional Information (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetail Net Loss per Common Share - Additional Information (Detail) Details 49 false false R50.htm 100490 - Disclosure - Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntiDilutiveSecuritiesExcludedFromComputationsOfDilutedWeightedAverageSharesDetail Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) Details 50 false false R51.htm 100500 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 51 false false R52.htm 100510 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 52 false false R53.htm 100520 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) Details 53 false false R54.htm 100530 - Disclosure - Subsequent Events - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) Sheet http://www.biocept.com/20170630/taxonomy/role/DisclosureSubsequentEventsAssumptionsUsedForDeterminingFairValuesOfCommonStockWarrantsDetail Subsequent Events - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) Details 54 false false All Reports Book All Reports bioc-20170630.xml bioc-20170630.xsd bioc-20170630_cal.xml bioc-20170630_def.xml bioc-20170630_lab.xml bioc-20170630_pre.xml true true ZIP 73 0001564590-17-017529-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-17-017529-xbrl.zip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�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�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�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end